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2D    two dimensional 
ADP    adenosine 5’-diphosphate 
ATP    adenosine 5’-triphosphate 
BN    blue native 
bp    base pair 
BSA    bovine serum albumin 
cDNA        complementary DNA 
CoA     coenzyme A 
CoQ    coenzyme Q10 
COX    cytochrome c oxidase 
CS    citrate synthase 
Cyt    cytochrome 
DDM    n-dodecyl-β-D-maltoside 
DNA    deoxyribo nucleic acid 
Δψ    membrane potential 
dNTP     deoxyribonucleoside triphospate 
ECL    enhanced chemiluminescence 
FADH2/FAD
+ flavin adenine dinucleotide-reduced/oxidized 
FeS    iron-sulfur 
FMN    flavin mononucleotide 
GFP    green fluorescent protein 
KO    Knock-Out 
IGA    in-gel-activity 
kDa    kilo Dalton 
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Introduction 
Every breath we take and every move we make requires energy. Energy is 
necessary for all processes in any living organism, like for instance growth, 
development and reproduction. Therefore, the ability to extract energy from 
the environment is fundamental for life. Humans obtain energy from the 
intake and breakdown of food, such as sugars. The degradation of sugars 
occurs through a series of specialized processes, which results eventually in 
the generation of adenosine triphosphate (ATP), the suitable energy-form 
used by cells. Complex sugars are degraded to glucose, which is further 
converted to pyruvate in the cytosol by a process called glycolysis. Pyruvate 
goes into the mitochondria where it is transformed to acetyl coenzyme A 
(Acetyl CoA). Acetyl CoA enters the Krebs cycle, which generates the 
reduced electron carriers NADH and succinate. These are the substrates for 
the oxidative phosphorylation (OXPHOS) system which is responsible for 
the main ATP production (Fig.1).  
 
Mitochondria and OXPHOS 
Mitochondria are the key players in the energy production of the cells and 
are, therefore, also called the “powerhouses” of the cell. According to the 
current model they are evolutionary derived from an endosymbiotic event 
involving the encapsulation of a α-proteobacterium. This can explain why 
mitochondria still contain their own copies of circular double-stranded DNA 
(mtDNA) surrounded by two membranes, namely the outer-membrane, 
derived from the host, and the inner-membrane, derived from the symbiont 
(1). This double membrane divides the mitochondria in several 
compartments. The outer-membrane separates the mitochondria from the 
cytosol and is a semi-permeable membrane that allows the communication 
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between these compartments. The space divided by the outer and inner-
membrane is called inter-membrane space. The inner-space of the 
mitochondria surrounded by the inner-membrane is called matrix. During 
the course of evolution, the mtDNA, originating from the α-
proteobacterium, has significantly reduced its size by the transfer of genes to 
the chromosomal DNA in the nucleus. The present mammalian mtDNA 
encodes for only 13 structural proteins of the OXPHOS system, 22 tRNAs 
and 2 rRNAs (2). The other proteins necessary for the mitochondrial 
functions, such as protein translation, mtDNA replication and the other 
subunits of the OXPHOS are encoded by nuclear DNA (nDNA), translated 
in the cytosol and imported into the mitochondria. 
The OXPHOS system contains five multi-subunit complexes embedded in 
the mitochondrial inner-membrane and two mobile electron carriers, 
coenzyme Q and cytochrome c. The reduced substrates generated by the 
Krebs cycle, NADH and succinate are oxidized by the first complex, NADH 
ubiquinone oxidoreductase (complex I, CI), and by succinate ubiquinone 
oxidoreductase (complex II, CII), respectively. The electrons, derived from 
these oxidation reactions, are transported, via ubiquinone, to ubiquinone 
cytochrome c reductase (complex III, CIII) and subsequently, via 
cytochrome c to cytochrome c oxidase (complex IV, CIV), from where they 
are delivered to the final electron acceptor molecular oxygen, reducing it to 
water. The energy coming from this electron transfer is coupled, by CI-CIII-
CIV, to the proton translocation from the matrix towards the inter-
membrane space, creating a proton gradient, which is the driving force used 
by ATP synthase (complex V, CV) to generate ATP (Fig.1). 
15
 
 
 
F
ig
ur
e 
1.
 T
he
 g
lu
co
se
 “
tri
p”
 fr
om
 fo
od
 to
 e
ne
rg
y.
 G
lu
co
se
 (
lig
ht
 g
re
en
 re
ct
an
gu
la
r)
 is
 tr
an
sp
or
te
d 
to
 t
he
 c
el
ls
 v
ia
 b
lo
od
 v
es
se
ls
. I
n 
th
e 
ce
ll,
 
th
e 
gl
uc
os
e 
is
 tr
an
sf
or
m
ed
, b
y 
gl
yc
ol
ys
is
, i
nt
o 
py
ru
va
te
 (
vi
ol
et
 r
ec
ta
ng
ul
ar
),
 th
at
 c
an
 b
e 
tr
an
sf
or
m
ed
 in
to
 la
ct
at
e 
(r
ed
 r
ec
ta
ng
ul
ar
) 
ex
pe
lle
d 
by
 
ce
lls
 a
nd
 p
ou
re
d 
ba
ck
 in
to
 th
e 
bl
oo
d 
ve
ss
el
s.
 O
th
er
w
is
e,
 p
yr
uv
at
e 
ca
n 
be
 tr
an
sp
or
te
d 
in
to
 th
e 
m
ito
ch
on
dr
ia
 a
nd
 d
eg
ra
de
d 
to
 A
ce
ty
l C
oA
 (
da
rk
 
gr
ee
n 
re
ct
an
gu
la
r)
. 
E
nt
er
in
g 
in
to
 t
he
 K
re
bs
 c
yc
le
 (
ci
rc
le
 i
n 
re
d)
 i
t 
is
 p
ro
ce
ss
ed
 t
o 
N
A
D
H
 a
nd
 s
uc
ci
na
te
, 
w
hi
ch
 i
s 
us
ed
 b
y 
th
e 
O
X
PH
O
S 
sy
st
em
 t
o 
ge
ne
ra
te
 A
T
P 
by
 t
he
 A
T
Pa
se
. I
n 
bl
ue
 c
om
pl
ex
 I
; 
in
 o
ra
ng
e 
co
m
pl
ex
 I
I;
 i
n 
re
d 
co
m
pl
ex
 I
II
, i
n 
gr
ee
n 
co
m
pl
ex
 I
V
 a
nd
 i
n 
lig
ht
 b
lu
e 
co
m
pl
ex
 V
; p
in
k 
st
ar
 c
yt
oc
hr
om
e 
c,
 g
ra
y 
st
ar
 u
bi
qu
in
on
e.
 
16 
 
Complex I 
This thesis focuses on the first enzyme of the OXPHOS system, CI 
(EC.1.6.5.3). It is the largest and least understood component of this system 
(3, 4). CI has an L-shaped structure with a hydrophobic arm embedded in 
the mitochondrial inner-membrane and a peripheral hydrophilic arm that 
protrudes into the matrix (5-7). Human CI is composed of 45 subunits (8). 
Seven subunits are encoded by the mtDNA and are located in the 
hydrophobic arm of the complex. The remaining 38 subunits are encoded by 
nDNA and are present in both the hydrophilic and hydrophobic arms. 
Fourteen proteins, all mtDNA- and seven nDNA-encoded, are 
evolutionarily conserved from bacteria to mammals and are called “core” 
subunits. In bacteria, these core subunits are sufficient to perform the proton 
translocation coupled the NADH reduction. The remaining proteins are 
termed “accessory” or “ancillary” subunits (9), and they may stabilize CI, 
prevent the generation of reactive-oxygen species (ROS), regulate the 
enzymatic activity or protect the complex from oxidative damage (9-11). 
However, their function remains largely unknown.  
The biogenesis of CI is a puzzling issue, the analysis is complicated by the 
size of the enzyme and its dual genetic origin. In mitochondria, newly 
imported subunits encoded by nDNA must assemble with the highly 
hydrophobic subunits encoded by mtDNA. This dynamic and coordinated 
process is regulated by the signalling between mitochondria and nucleus 
(12, 13). Besides nuclear and mitochondrial subunits, CI also contains 
prosthetic groups, being iron sulphur clusters and flavin-mononucleotide 
(FMN). The coordinated assembly of all these components requires specific 
assembly factors, called chaperones. These chaperones are necessary during 
the CI assembly pathway, but they are not part of the holo-complex (14-16). 
17 
 
How CI and the other respiratory complexes are organized in the 
mitochondrial inner-membrane was under debate for more than 50 years 
(17, 18). It now generally accepted that CI is not a single entity in the inner-
membrane, but it physically and functionally interacts with other respiratory 
enzymes, namely CIII and CIV, to form several different supramolecular 
structures, called supercomplexes. It was proposed that the role of these 
supercomplexes is to facilitate the electron transfer, to reduce the escape of 
toxic side products and to stabilize the individual complexes (19-21). Thus, 
these supercomplexes do have an important physiological role and might 
even be the main active respiratory unit.  
 
Complex I and disease 
CI is the most frequently encountered enzyme defect of the OXPHOS 
system. Mutations have been reported in all the seven mtDNA-encoded 
subunits, in 16 nuclear structural subunits and also in nine CI-assembly 
chaperones (16, 22-46). Disorders caused by CI deficiency, are usually 
progressive, multi-systemic, have a poor prognosis and often lead to early 
death of the patients (4, 47, 48). CI deficiency results in a broad spectrum of 
clinical signs and symptoms involving energy demanding tissues, like brain 
and muscle, but also other organ systems can be affected. However, there is 
no correlation between mutations and clinical outcomes (49) and an 
explanation for these differences in clinical phenotypes is still an open 
question.  
The majority of children harboring nDNA mutations (~26%) present Leigh 
disease which is a devastating neurodegenerative disease [OMIM 256000; 
(50)]. Clinical signs and symptoms include muscular hypotonia, dystonia, 
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developmental delay, abnormal eye movements, seizures, respiratory 
irregularities, failure to thrive and lactic acidemia (51, 52). Death usually 
occurs within the first years of life as a consequence of respiratory failure, 
caused by ongoing brainstem dysfunction, which can be accompanied by 
increasing muscle weakness (52). The syndromes of fatal infantile lactic 
acidosis (FILA), neonatal cardiomyopathy with lactic acidosis, 
leucodystrophy with macrocephaly and hepatopathy with renal tubulopathy 
have been described as additional clinical phenotypes in patients bearing 
mutation in genes encoded nuclear CI-subunits (50,53).  
The most of mutations in mitochondrial encoded CI-subunits lead to Leber’s 
Hereditary Optic Neuropathy (LHON) characterized by degeneration of 
retinal ganglion cells and their axons causing an acute or subacute loss of 
central vision; this affects predominantly young adult males. In addition, 
some other mutations of mtDNA encoded CI-subunits show complex 
multisystem syndromes (54, 55) such as the MELAS (Mitochondrial 
Encephalomyopathy Lactic Acidosis and Stroke like episodes). MELAS is a 
condition that affects particularly the brain, nervous system and muscles. In 
most cases, the clinical signs and symptoms of this disorder appear in 
childhood following a period of normal development. Early symptoms may 
include muscle weakness and pain, recurrent headaches, loss of appetite, 
vomiting, and seizures. Most affected individuals experience stroke-like 
episodes beginning before the age of 40. These episodes often involve 
temporary muscle weakness on one side of the body (hemiparesis), altered 
consciousness, vision abnormalities, seizures, and severe headaches 
resembling migraines. Repeated stroke-like episodes can progressively 
damage the brain, leading to vision loss, problems with movement, and a 
loss of intellectual function (dementia) (56).  
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Biochemical consequences of complex I dysfunction 
As we already described in the previous paragraph, CI couples NADH 
oxidation to proton translocation, thus, in this way it is responsible for the 
maintenance of the NAD+/NADH ratio, of the membrane potential (Δψ) and 
of ATP production (57). Moreover, it is now generally accepted that CI is 
the major source of reactive oxygen species (ROS) production in the 
mitochondria. During the NADH oxidation or ubiquinone reduction 
electrons can escape leading to ROS generation (58-61). These ROS are 
dangerous for the cell, since they can damage mtDNA, proteins and lipids. 
Therefore, CI deficiency may affect many mitochondrial functions and 
cellular homeostasis. This can result in widespread effects including 
activation of apoptosis or autophagy, which, in turn, are the bases of the 
pathogenic mechanisms leading to neuro-muscular disorders. 
A common feature in CI-deficient cell lines is the reduction of CI-driven 
ATP synthesis, which correlates with data derived from 31P-MRS (Magnetic 
Resonance Spectroscopy) in brain and muscle from patients (62-65). This 
reduction of ATP production by OXPHOS, pushes the cells towards an 
alternative way to generate energy, such as glycolysis. Many authors 
reported that different mutant cell lines acidified the culture medium more 
rapidly than control cell lines, suggesting an increased aerobic glycolysis 
(66). Furthermore, the decreased CI redox activity in mutant cells was 
correlated with an accumulation of NADH (67), that consequently leads to 
an accumulation of pyruvate, due to the unbalanced TCA cycle. The 
increasing amount of pyruvate in the cytosol, that it is not imported in 
mitochondria becomes the substrate of cytoplasmic lactate dehydrogenase 
(LDH) and it is used by LDH to produce lactate, which, in turn, is 
eliminated from cells causing medium acidification (66). The same 
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mechanism is reported in patients who present metabolic alterations and 
showed an abnormal accumulation of lactate in the plasma after exercise 
and also in resting conditions. This phenomenon is considered as one of the 
main criteria for the diagnosis of a mitochondrial disorder (68, 69).  
 
Aim, objective and outline of the thesis  
Since the discovery of the first mitochondrial (70) and nuclear (37) 
pathogenic mutations associated with genes encoding CI subunits an 
enormous progression has been made. To date, all structural components of 
CI are known and its structure has been resolved in lower organisms, like 
Thermus thermophilus and Yarrowia lypolytica (3, 6). Although this 
knowledge has led to the finding of many mutations in different genes 
encoding CI-subunits that can only explain less than 50% of the cases. The 
discovery of assembly factors leading to CI isolated deficiency has revealed 
a new class of proteins, which has paved the way to find the remaining 
pathogenic mutations. Despite these advances, many important questions 
still remain. What is the genotype-phenotype correlation? In other words 
how can we explain the huge diversity in clinical symptoms associated with 
CI deficiencies? Can we find a therapy to cure or alleviate the disastrous 
effects of CI deficiency in patients? In order to answer these questions it is 
essential to understand the detailed molecular mechanisms caused by CI 
deficiency in a whole organism.  
The main aim of this thesis is to obtain insight into the molecular 
mechanisms of CI defects leading to disease in order to be able to provide a 
rationale for therapeutic approaches. To this end our main objective was to 
elucidate the CI biogenesis/function and the role of the supercomplexes in 
health and disease. To properly address this problem it is essential to use a 
21 
 
whole organism as a model which mimics the patient situation. Thus, in this 
study we used a mouse model, in which a NDUFS4-CI subunit was 
disrupted, that resembled the situation encountered in patient bearing 
mutation in NDUFS4 gene.  
In Chapter II we provide the essential background on what is known about 
CI assembly in bacteria, fungi and humans. We describe the CI subunits, 
assembly alteration caused by mutations in genes encoding CI subunits and 
chaperones. Finally, we summarize the literature of the supercomplex 
organization. 
The central part of this thesis is the analysis of the molecular consequence in 
a mouse model. However, since our department had modest experience in 
studying CI in mice, at the beginning of this thesis study, the methods that 
were planned to be used had to be verified and adjusted. This included 
mitochondria isolation from different mouse tissues, genotyping of the mice 
and testing antibodies suitable for the mouse samples. An essential 
technique to study CI assembly and supercomplex formation is the blue 
native polyacrylamide gel electrophoresis (BN-PAGE) and two dimensional 
BN/SDS-PAGE (2D BN/SDS-PAGE). Chapter III provides a hand on 
description of how this method can be used to investigate the assembly of 
OXPHOS complexes and especially how this is altered in patients. The 
importance and the practical application of these techniques are shown in 
Chapter IV, in which a family harboring a novel mutation in mitochondrial 
tRNAHIS was studied. This family also nicely illustrates the complexity of 
the relation of mutation and clinical outcome. 
In Chapter V and in Chapter VI we studied the molecular consequences of 
the disruption of CI accessory subunit in mice. These NDUFS4 Knock-Out 
(KO) mice were, despite the lack of an essential CI-subunit, viable, 
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suggesting that, possibly, reduced amounts and activity of CI should be 
present. Moreover, a transgenetic mouse with a brain specific NDUFS4 
disruption had a similar clinical appearance compared to the systemic 
NDUFS4 KO mice that we studied. This suggests that NDUFS4 disruption 
in peripheral tissues is less detrimental for CI function and activity 
compared with brain. To answer this question we studied CI assembly and 
function in a number of tissues in these mice. Understanding why certain 
tissues are more affected provides a better insight in the development of the 
disease. Interestingly, the assembly profiles of CI subassemblies in the 
NDUFS4 KO mice indicated that a cofactor containing part of CI missed 
from the complex. Based on these findings, we proposed a rationale for 
therapy: increasing the co-factor might stabilize CI and lead to an enhanced 
amount of CI present in the KO mice (patient) cells. This hypothesis was 
tested in chapter VI. 
Chapter VII summarizes our established findings and provides a scientific 
context in order to address the conceptual advances of this study and 
addresses possible future implications of my findings. I focused on the 
important role of CI assembly, the supercomplex organization and possible 
future therapy. 
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Abstract 
Human mitochondrial complex I is one of the biggest membrane bound 
enzymes found in man. Its assembly is a complicated process and requires 
the combination of forty-five subunits, encoded by the nuclear and 
mitochondrial genomes. It has become clear that the assembly of complex I 
takes place in different steps in which some parts are assembled separately 
and connected to form a functional enzyme. Remarkably this stepwise 
process follows the assembly of the distinct functional and evolutionary 
conserved modules, the hydrogenase part, the membrane transporter part 
and the NADH dehydrogenase part. Assembly of these parts and further 
combination of these modules requires the help of specialized proteins 
called chaperones. A number of these chaperones have been identified and 
they play a role in the different stages of the assembly. Although the precise 
molecular mechanisms concerning complex I assembly are still unknown, 
the overall picture of this process is getting shape as discussed in this 
chapter.     
 
  
36 
 
1. Introduction 
Mitochondrial complex I, NADH:ubiquinone oxidoreductase (EC1.6.5.3) is 
a central enzyme in the regulation of cell metabolism. As major entry point 
of electrons to the respiratory chain it couples the transfer of electrons from 
NADH to ubiquinone with the translocation of protons across the 
mitochondrial inner membrane (1). In this fashion it contributes to the 
generation of a membrane potential which is used by complex V to generate 
ATP. Thus by controlling cellular NADH, ATP levels and the mitochondrial 
membrane potential, complex I is an important regulator of metabolic 
pathways. Beside its function in oxidative phosphorylation, complex I has 
been implied to be the main generator of reactive oxygen species (ROS) (2, 
3). These ROS are known to be toxic for the cell by damaging proteins, 
membranes and DNA, but also function as molecular signaling molecules 
(4). Moreover dysfunction of complex I is believed to play an important role 
in mitochondrial triggered programmed cell death (5). With such a crucial 
biochemical role it is expected that defects in this enzyme give rise to a 
large number of clinical heterogeneous mitochondrial disorders.  
 
To understand how complex I activities influence the function of a cell it is 
important to know how this complex is assembled and how this assembly is 
regulated. Although in recent years excellent progression has been made in 
revealing the structure (6, 7, 8), the evolution and function of complex I (9), 
the molecular mechanisms involved in its biogenesis are still poorly 
understood. This might not come as a surprise when one realizes that 
complex I is one of the largest membrane bound complexes in the cell, its 
components are encoded by mitochondrial and nuclear genes, it contains a 
large number of prosthetic groups, it is part of respiratory supercomplexes 
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and its assembly requires specialized proteins, called assembly chaperones. 
In this chapter we will describe our current knowledge on how this large 
membrane bound complex is assembled. Firstly, to know how complex I 
assembly takes place it is essential to know what the components are and 
where they are located in the complex. Secondly, because complex I is 
believed to originate from different enzymes which have been combined 
into one complex, the assembly of complex I might be reflected by its 
evolutionary route. Our understanding of the 45 subunit-containing 
mammalian complex I assembly will therefore benefit from the studies 
which were performed to investigate how simpler forms of complex I 
assemble in lower organisms, like in Escherichia coli and Neurospora 
crassa. Thirdly, it is not difficult to imagine that the assembly and 
regulation of complex I assembly requires additional factors. These factors, 
the so-called assembly chaperones, facilitate certain steps in the assembly, 
however they are not part of the holo-complex. Finally, because the 
mitochondrial respiratory chain is believed to be organized in 
supercomplexes it is very well possible that the assembly of complex I does 
not stand alone but also depends  on the coordinate assembly of the other 
members of the respiratory chain.  
 
2. Subunits  
To understand complex I assembly one should first have knowledge of its 
components. Most complete experimental subunit determination of 
mammalian complex I has been performed by the group of Walker who 
studied the composition of complex I in bovine heart. This study identified 
45 different subunits (10). Based on sequence comparison and experimental 
data, the complex I subunit content of many other organisms, including 
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Homo sapiens, has been established (see table 1).  
When comparing the complex I subunit content of the different species there 
are quite some differences. Beside a basic set of subunits which are 
conserved throughout all organisms from bacteria to man, also several 
subunits were acquired later in evolution and these are specific for different 
species (9). The minimal set of subunits required to fulfill the enzymatic 
function of complex I are the 14 subunits found in most bacteria (two of 
them are fused in E.coli (11), which are considered to be the core subunits. 
These subunits include the seven mitochondrial encoded subunits (ND1-
ND6, ND4L), subunits which contain prosthetic groups (NDUFV1, 
NDUFV2, NDUFS1, NDUFS7 and NDUFS8) and a subunit involved in 
ubiquinone binding (NDUFS2). These subunits are distributed over three 
evolutionary conserved modules, the membrane arm (ND1-ND6, ND4L), 
the hydrogenase part (NDUFS2, NDUFS3, NDUFS7 and NDUFS8) and the 
NADH-dehydrogenase part (NDUFS1, NDUFV1 and NDUFV2). These 
evolutionary modules will be discussed below. 
Beside these 14 core subunits, mammalian complex I has gained another 31 
subunits, which are called accessory or supernumerary subunits (table 1). 
Why human complex I has acquired these accessory subunits, which are not 
required for its basic enzymatic function, is not known. They might play a 
role in the regulation of the enzyme as suggested by the fact that some of 
these subunits can be phosphorylated (12, 13, 14, 15). 
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Table 1. Complex I subunit nomenclature in different organisms.  
Escherichia coli Thermus 
thermophilus 
(NDH-1) 
Neurospora 
crassa 
Yarrowia 
lypolitica 
Chlamydomonas 
reinhardtii 
Bos 
taurus 
Homo sapiens 
NuoH NQO8 ND1 NU1M ND1 ND1 ND1 
NuoN NQO14 ND2 NU2M ND2 ND2 ND2 
NuoA NQO7 ND3 NU3M NUO3 ND3 ND3 
NuoM NQO13 ND4 NU4M ND4 ND4 ND4 
NuoK NQO11 ND4L NULM NUO11 ND4L ND4L 
NuoL NQO12 ND5 NU5M ND5 ND5 ND5 
NuoJ NQO10 ND6 NU6M ND6 ND6 ND6 
NuoF NQO1 51 kDa NUBM NUO6 51 kDa NDUFV1 
NuoE NQO2 24 kDa NUHM NUO5 24 kDa NDUFV2 
-  - - - 10 kDa NDUFV3 
NuoG NQO3 78 kDa NUAM NUOS1 75 kDa NDUFS1 
NuoD (together with 
NuoC) 
NQO4 49 kDa NUCM NUO7 49 kDa NDUFS2 
NuoC (together with 
NuoD) 
NQO5 30.4 kDa NUGM NUO9 30 kDa NDUFS3 
-  21 kDa NUYM NUOS4 18 kDa 
(AQDQ) 
NDUFS4 
-  11,5 kDa NIPM 15 kDa 15 kDa 
(PFFD) 
NDUFS5 
-  28.7 kDa NUMM NUOS6 13 kDa NDUFS6 
NuoB NQO6 19.3 kDa NUKM NUO10 PSST NDUFS7 
NuoI NQO9 21.3c kDa NUIM NUO8 TYKY NDUFS8 
-  9.8 kDa NIMM 7.5 kDa MWFE NDUFA1 
-  10.5 kDa NI8M NUOB8 B8 NDUFA2 
-  9.3 kDa NI9M - B9 NDUFA3 
-  - - - MLRQ NDUFA4 
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-  29.9 kDa NUFM NUOB13 B13 NDUFA5 
-  14.8 kDa NB4M NUOB14 B14 NDUFA6 
-  - - - B14.5a NDUFA7 
-  20.8 kDa NUPM NUO8A PGIV NDUFA8 
-  40 kDa NUEM NUOA9 39 kDa NDUFA9 
-  - - - 42 kDa NDUFA10 
-  21.3b kDa NUJM 23 kDa B14.7 NDUFA11 
-  13.4 kDa N7BM NUO13 B17.2 NDUFA12 
-  13,5 kDa NB6M NUOB16 B16.6 NDUFA13/Grim-
19 
-  - - - MNLL NDUFB1 
-  - - - AGGG NDUFB2 
-  - NB2M 6.5 kDa B12 NDUFB3 
-  7 kDa NUVM NUO2P B15 NDUFB4 
-  - - - SGHD NDUFB5 
-  - - - B17 NDUFB6 
-  89.7 kDa NB8M NUOB18 B18 NDUFB7 
-  19 kDa NIAM - ASHI NDUFB8 
-  18.3 kDa NI2M NUOB22 B22 NDUFB9 
-  12.3 kDa NIDM NUOB10 PDSW NDUFB10 
-  11,7 NUWM NUO17 ESSS NDUFB11 
-  9.6 kDa 
ACP 
ACPM ACP1 SDAP NDUFAB1 
-  - - - KFYI NDUFC1 
-  - - - B14.5b NDUFC2 
  21.3 kDa     
  21.3a kDa NUZM - - - 
  20.9 kDa NUXM NUO21   
  17.8 kDa - - - - 
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 NQO15      
    NUOP1   
    NUOP3   
    FBP1   
    FBP2   
    CAH9   
    NUOP4   
    NUOP5   
    NUOP6   
       
 
These accessory subunits can be associated with other enzymatic functions 
as is suggested by the fact that: NDUFA13 (Grim 19), has been shown to 
play a role in apoptosis (16); NDUFAB1 (SDAP), is proposed to play a role 
in lipoic acid biosynthesis (17, 18) and NDUFS9 which contains a NADPH 
binding site (19, 20). They might also play a role in the regulation of the 
assembly. Suggestive for such a role in regulating assembly of complex I is 
the fact that some subunits are homologous to proteins which are involved 
in the mitochondrial biogenesis like for instance: NDUFA2 and NDUFA10, 
which are homologues of mitochondrial ribosomal proteins L43 and S25; 
NDUFA11, which has homology with Tim17/22 family of proteins involved 
in mitochondrial protein import and NDUFA12, which is paralogue of 
assembly factor NDUFAF2 (9). In addition it has been proposed that these 
accessory subunits might be involved in the stability and protection against 
ROS or proteolytic degradation. Nevertheless, experimental evidence for 
any of such functions is still lacking.  
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3. Topology and evolution 
The subunit topology will put constrains on the complex I assembly. Recent 
crystal structures of complex I of Thermus thermophilus (7), Escherichia 
coli (6), and Yarrowia lypolytica (8) have given much insight into the 
structure and how subunits are arranged within these complexes. In higher 
eukaryotes the most detailed topological structure of subunits within 
complex I is obtained from experiments using mild chaiotropic salts to 
break up complex I into subcomplexes. First studies performed by Hatefi 
and colleagues enabled to fractionate complex I into a flavoprotein part, a 
hydrogenase part and a membrane part (21). This approach was later refined 
by the group of Walker which was able to define Iα, Iβ, Iλ, Iγ fragments and 
resolve the subunit content of these parts by mass spectrometry (22, 23). 
This has led to a crude topological view of where the subunits are localized 
in complex I (Fig. 1). 
Given the fact that complex I has evolved from a 14 subunit enzyme into a 
45 subunit complex, evolution might provide some insights into how this 
increasing complexity has developed and how this is reflected in its 
assembly. Of particular interest is the modular evolution of complex I 
proposed by Friedrich and Weiss (24). Based on homologies with bacterial 
enzymes, this theory postulates that complex I originates from fusion of 
distinct pre-existing protein assemblies, which have combined their 
activities in one complex. The hydrogenase has evolved from the small and 
large subunit of the bacterial nickel-Hydrogenase which are conserved in 
subunit NDUFS7 and NDUFS2 respectively (25). This hydrogenase has 
acquired a ferredoxin (NDUFS8), a membrane bound quinone reduction site 
(ND1), a transport protein (ND4) and a protein of unknown function 
(NDUFS3). Further upon evolution the transporter module has expanded by 
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the recruitment of ND5, a gene duplication of ND4 to form ND2 and the 
incorporation of ND3, ND6 and ND4L (26). This enzyme was equipped 
with the NDUFS1, NDUFV1-V2 NADH-dehydrogenase module. Further 
gain of (accessory) subunits in the evolutionary lineage has occurred in all 
stages and in all fractions of the complex (9).  
 
 
Figure 1. A model for the topology of the subunits of mammalian complex I. 
With mildly chaotropic detergents, intact bovine complex I has been resolved into various 
subcomplexes that have subsequently been subjected to extensive analysis (22). 
Subcomplex IO represents the peripheral arm of the complex, subcomplex ID consists of 
subcomplex IO plus part of the membrane arm and subcomplex IE forms the major part of 
the membrane arm. Subunits that do not associate with the ID or IE subcomplexes are 
grouped as the IJ ‘subcomplex’, a fraction for which it is not clear whether it represents a 
true fragment of complex I. Some subunits associate with two subcomplexes (ID/IE), for 
others it is not exactly clear which subcomplex they associate with (IO/ID). The nuclear 
DNA-encoded subunits are named according to the human nomenclature and preceded by 
the prefix ‘NDUF’. 
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4.Complex I assembly 
4.1. Complex I assembly in E. Coli 
The 14 subunit containing bacterial NDH-1 complex is considered to be the 
structural minimal form of complex I (11, 27). Because all NDH-1 subunits 
are homologues to human complex I subunits (see table 1), assembly of 
complex I in this organism might serve as an example for the assembly of 
the core of human complex I. The genes encoding the E. coli complex I 
subunits are called nuoA to nuoN, including nuoC and nuoD which have 
been fused to one gene (28) (see table 1). Six of these genes code for the 
seven subunits (NuoB-G and NuoI) of the peripheral hydrophilic part 
including the subunits harboring the flavin-mononucleotide (FMN), iron 
sulfur (Fe-S) cluster, the site binding NADH (NuoF) (29), and the site 
binding quinone (NuoB and NuoD) (30). The other seven subunits (NuoA, 
H, J-N) are mostly hydrophobic proteins which are incorporated into the 
membrane. Recently, Sazanov and colleagues have isolated and crystallized 
the membrane domain of complex I from Escherichia coli. In the crystal 
structure NuoL (ND5) is localized at the distal part of the complex followed 
by NuoM (ND4), NuoN (ND2) and closer to the peripheral arm of complex 
I NuoA (ND3), J (ND6) and K (ND4) (6) are positioned, whereas NuoH 
(ND1) is not present in the crystal structure since is it readily dissociated 
from the complex.  
Thanks to the availability of E. coli strains with disruption of each of the 
complex I genes (31) a systematic investigation to the effect caused by the 
lack of each subunit on complex I assembly could be performed (32). In all 
mutants the specific NADH oxidase activity was absent indicating that all 
complex I genes are required for proper complex I function. Further 
investigations revealed most mutants still form partially assembled or 
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degraded subassemblies. In deletion mutants for NuoA-CD (ND3, 
NDUFS7, NDUFS3 and NDUFS2) and NuoH-N (ND1-ND6, NDUFS8) 
interestingly a subassembly containing NuoEFG (NDUFV1, NDUFV2, 
NDUFS1) including Fe-S clusters N1a and N1b could be recovered from the 
cytoplasm. Consistent with the presence of iron sulfur clusters this 
subassembly still had activity for NADH oxidation (32). This NuoEFG 
subassembly forms the NADH dehydrogenase module and it was proposed 
to be an assembly intermediate of complex I which is in line with the 
modular evolution scheme. In fact, it seems that the NADH dehydrogenase 
module is the most recent acquisition of the precursor of complex I. 
However, joint overexpression of the genes encoding the subunits NuoE, F, 
G leads to the overproduction of these subunits which are not assembled 
into any subcomplex (33). This could be possibly due to a lack of cofactors 
involved in this part or to the absence of a stabilizing complex I 
preassembly. In mutant nuoL (ND5) a membrane-bound complex I 
fragment, which only lacks this subunit, without a detectable NADH 
oxidase activity was found (32). In mutant nuoH (ND1) the membrane arm 
is severely disturbed (34). Disruption of nuoJ (ND6) gene did not result in 
hampering of assembly, which suggests that this membrane subunit is added 
to the complex at a final stage in assembly (35). NuoL (ND5) and nuoM 
(ND4) are localized in the distal part so it is supposed that these subunits are 
added at later stages in the assembly (36, 37).  
In summary, the hydrogenase part, containing the nuoCD-B-I (NDUFS3, 
NDUFS2, NDUFS7, NDUFS8), is added to NuoEFG (dehydrogenase part) 
(NDUFV2, NDUFV1, NDUFS1) and part of the membrane arm (NouK, J, 
A and N; ND4L, ND6, ND3 and ND2). At a later stage Nuo M-L (ND4 and 
ND5) are added to this subassembly, this corresponds to the crystal structure 
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in which these subunits are localized at the end of the membrane domain. 
 
4.2 Complex I assembly in Neurospora crassa 
In eukaryotes the level of complexity of complex I and its assembly 
increases. Firstly, the number of subunits increases significantly from 14 up 
to 45 in man. Secondly, the complex has become under dual genetic control 
harboring subunits encoded by the nuclear DNA and mitochondrial DNA. 
The new nuclear-encoded subunits are assembled in coordination with the 
mitochondrially encoded ones and this intricate process requires regulated 
signaling between nucleus and mitochondrion (38). Thirdly, complex I is 
located in the mitochondria requiring coordinated transportation and import 
of the nuclear encoded subunits in this cellular compartment.  
The fungus Neurospora crassa has been used as one of the main model 
organisms to investigate complex I for different reasons: first the fungal and 
the mammalian enzymes are very similar; second, this fungus grows quite 
rapidly and can be easily genetically manipulated; and finally, since the 
genetics and biochemistry of this organism are well understood, it is 
possible to perform a wide range of experiments.  
At the end of the `80s, the group of Weiss described the presence of two 
different sub-assemblies in N. crassa that can be formed independently from 
each other. In fact, when mitochondrial protein synthesis was inhibited by 
using chloramphenicol, an accumulation of the peripheral arm of complex I 
constituted by nuclear encoded subunits with NADH:Q reductase activity 
could be observed (39); whereas in cells grown in medium lacking 
manganese, membrane arm accumulation was observed (40). The same 
group followed the flux of radioactivity in complex I polypeptides, which 
demonstrated that the peripheral arm and membrane arm of complex I 
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undergo independent assembly (41). 
The first gene inactivated in Neurospora crassa was 21,3b (NDUFA11) 
which encodes a subunit situated in the membrane arm. The authors found 
that complex I accumulated in two intermediates: a larger intermediate 
containing four mitochondrially encoded subunits and six nuclear encoded 
subunits; and a smaller intermediate containing two mitochondrially 
encoded and two nuclear-encoded subunits. The larger intermediate was 
found connected to two CIA-proteins (Complex I intermediate-associated): 
CIA30 and CIA84 (42, 43). These proteins are not part of the fully 
assembled complex I and have been shown to cycle between bound and 
unbound state (42). Subsequently, other subunits of the membrane arm were 
disrupted leading to the accumulation of the peripheral arm and the 
formation of two membrane intermediates  or to the formation of an 
incomplete membrane arm like in mutants nuo20,9  (44), 
nuo12,3(NDUFB10) (45, 44), nuo14 (NDUFA13) (47) and nuo20,8 
(NDUFA8) (46). In mutant nuo9,8 (NDUFA1) (48) both membrane and 
peripheral arm fail to assemble. Instead, when the 11,5 kDa subunit 
(NDUFS5) was disrupted the peripheral arm was not detected, nevertheless 
the accumulation of two membrane arm intermediates was observed. 
Moreover, besides disruption, this gene was mutated in four conserved 
cysteines, and for all the four mutants a complete and inactive complex I 
was detected and an accumulation of the peripheral arm with a molecular 
weight of ~500 kDa was observed, suggesting that the peripheral arm 
accumulated due to the inhibited assembly of the membrane part (49).  
So far, just one mutant, the E35 stopper mutant, was described to cause 
depletion in mtDNA subunits (ND2/ND3), in this mutant only a structure 
resembling the peripheral arm was formed (50). Different subunits of the 
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peripheral arm were disrupted and in some cases an almost complete 
complex I was found such as in mutants nuo21 (NDUFS4) (51), nuo51 
(NDUFV1)(45, 52), nuo21,3a (53), nuo24 (NDUFV2) (54) and nuo40 
(NDUFA9) (19). In other cases, the absence of one subunit of the peripheral 
arm led to an accumulation of the membrane arm with the absence of 
assembly of the peripheral part like in nuo19,3 (NDUFS7) (55, 45), nuo29,9 
(NDUFA5) (56), nuo49 (NDUFS2) (44), nuo21.3c  (NDUFS8) (57, 45), 
nuo30,4 (NDUFS3) (58) and nuo78 (NDUFS1). An exception was in the 
mutant for ACP (NDUFAB1) protein (acyl-carrier protein) which was not 
only unable to assemble the peripheral arm but it also failed to assemble the 
membrane part.  
To put all these findings together, complex I assembly in Neurospora crassa 
is a process divided in different steps in which the different modules are 
assembled independently from each other. Subsequently, they are joined 
together to form holo-complex I. Mutations in subunits of the peripheral 
arm lead to the accumulation of the membrane part and vice versa. Further, 
none of the manipulated mutations in subunits of the NADH dehydrogenase 
module cause a disturbance of the peripheral arm meaning that this module 
is added at a later stage of Complex I assembly. In total four different 
intermediates were described in Complex I assembly in Neurospora crassa: 
a small and a large membrane arm intermediate, the complete membrane 
arm, and a peripheral arm. First the small and large membrane parts are 
joined together with the formation of the membrane arm intermediate then 
also the peripheral arm is connected to the membrane part to form a 
complete complex I. 
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4.3 Mammalian complex I assembly 
The most complicated structure of NADH:oxidoreductase is the 45 subunit-
containing mammalian complex I. Since isolated complex I deficiency is the 
most common form of defective oxidative phosphorylation, complex I 
function and assembly has been frequently studied using samples of patients 
with mutations in one of the subunits or assembly chaperones (59). 
Complex I assembly will be stalled if one of the structural subunits or 
assembly factors is mutated. However, examining patient fibroblasts does 
not always reveal the same level of deficiency as for instance muscle 
material but if it is displaying the same level of deficiency, complex I 
assembly can be checked by two dimensional blue native/SDS 
electrophoresis (2D-BN/SDS-PAGE) to determine where the assembly is 
disturbed. Hereafter we will discuss experimental data gathered by in vitro 
systems and by analysis of patient material harboring mutations in subunits 
and assembly factors to show where these subunits are required in the 
assembly pathway. These mutations will be discussed in the context of the 
earlier introduced evolutionary modules.   
 
4.3.1 Assembly of membrane arm (proton translocating unit) 
The membrane arm is known to contain the mitochondrially encoded 
subunits. Over the years many mutations in mitochondrially encoded 
subunits have been described. In general, such mutations lead to a defective 
enzyme activity, and more precisely to a disturbed membrane arm assembly. 
An important step forward was the development of cybrid cell line 
technology: cell lines depleted of mitochondrial DNA can be repopulated 
with mutant DNA allowing researchers to study specific mutations in a 
control background. In an early study it was discovered that in the cybrid 
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cell line lacking the ND4 subunit, the membrane arm was not assembled 
(60). Moreover, it was found that some of the nuclear subunits were still 
assembled as suggested by presence of NADH:Fe(CN)6 activity. Further 
investigations demonstrated that the absence of either ND4 or ND5 led to a 
loss of the NADH:ubiquinone oxidoreductase and the NADH:NTB activity, 
and to the formation of a subassembly formed by NDUFS2, NDUFS3 and 
NDUFS8 (61). These three subunits are supposed to be part of the 
connective complex I module between the membrane arm and the peripheral 
arm (61).  ND5 was shown to be more important for the complex I stability 
rather than for the assembly (62, 63). By tagging NDUFS3 with GFP in 
combination with 2D-BN/SDS-PAGE it was shown that the assembly of 
different peripheral arm subcomplexes occurred prior to the incorporation of 
membrane subunit ND1(64). 
Recently, Enriquez and colleagues exploited their collection of ND mutated 
cybrids to perform a thorough investigation of the assembly of membrane 
arm ND subunits (65). The authors indentified five entry points of ND 
subunits in the CI assembly process. The first entry point was for ND1 that 
anchors peripheral arm subunits to the inner mitochondrial membrane, 
forming an intermediate of ~400 kDa. The second entry point was the 
assembly an ND2, ND3 and ND4L containing intermediate of ~460, which 
was independent from the ND1 intermediate. The third entry point was the 
incorporation of ND4. The incorporation of ND6 defined the fourth entry 
point and seems to facilitate bringing together the two subcomplexes 
containing ND1 and ND2. ND5 is incorporated at a later stage and it is the 
last entry point of the mitochondrially encoded subunits (65). ND5 does not 
seem to be essential for complex I assembly, supported by the fact that in 
mutant ND5 cybrids all mitochondrially encoded subunits, except ND5, 
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could be detected. Studies on patient cell lines harbouring mutations in 
either ND1 or ND6 showed that these subunits are important for the 
assembly of complex I (66, 67). The lack of ND2 resulted in an impairment 
of assembly displayed by an accumulation of all NDUFS3 containing 
subcomplexes (68, 69).  
In summary, ND1 assembles to a preassembled complex which contains 
nuclear encoded subunits. This part is added to a separate ND2 containing 
subassembly which has acquired also subunits ND4L, ND3 and ND6. In a 
next stage transporter module ND4 is possibly added followed by the 
incorporation of ND5 (Fig. 2A).  
 
4.3.2 Assembly of the hydrogenase part 
In the recent years several models for the assembly have been proposed (68, 
70, 15, 64). Although the models show some differences, almost all agree 
that the hydrogenase part is made independently, including NDUFS3 as an 
essential component. Vogel and colleagues have shown that the assembly of 
the hydrogenase module starts at least with the association of NDUFS3 and 
NDUFS2 (64). These subunits are part of three subassemblies of which the 
last two are associated with the mitochondrial inner membrane (Fig 2b). 
Further studies using blue native electrophoresis in combination with mass 
spectrometry revealed that the membrane bound subassemblies contained 
the subunits NDUFS2, 3, 7, and 8 (71). This suggests that the hydrogenase 
part preassembles and binds to the membrane prior to the incorporation of 
subunit ND1. Consistent with this finding is the fact that patients with 
mutations in the subunits NDUFS2, NDUFS7 or NDUFS8 lack the 
occurrence of these subcomplexes whereas mutations in other subunits 
which enter the assembly pathway at a later stage, such as NDUFS4, still 
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allow assembly of the hydrogenase part (72). 
In brief, the hydrogenase part is assembled by the association of NDUFS3 
and NDUFS2, of note these are the subunits which are fused in E. coli. This 
matrix assembly of NDUFS3 and NDUFS2, binds to NDUFS7 and 
NDUFS8 and this subassembly tethers to the membrane. This basically 
completes the assembly of the hydrogenase part which goes further in the 
assembly pathway by acquiring amongst others ND1 (Fig. 2B). 
 
4.3.3 Assembly of the NADH dehydrogenase part 
The NADH dehydrogenase part contains at least NDUFV1, NDUFV2, 
NDUFV3 and NDUFS1. Mutations in NDUFV1 do allow complex I 
assembly to proceed to a subassembly of about 830 kDa (73, 74). This 
subassembly does not show any NADH reactivity anymore and lacks at 
least subunits NDUFV1 and NDUFS4 (73). This suggests that the 830 kDa 
subassembly seems to lack the NADH-dehydrogenase part, indicating that 
this part is assembled independently and added at a later stage. In line with 
this idea is the finding of similar subassembly of 830 kDa in patients with 
mutations in the NADH dehydrogenase subunit NDUFS1 (75). 
Furthermore, this 830 kDa subassembly is found in patients with mutations 
in NDUFS4 (73, 74) and NDUFS6 (67), meaning that this is a more 
frequently impaired stage of assembly and that the subunits NDUFS4 and 
NDUFS6 are involved in the addition of the NADH dehydrogenase part to 
an almost finished complex I subassembly. In an in vitro assembly study, 
the import and incorporation into complex I subcomplexes of radiolabeled 
subunits in isolated mitochondria was studied. This method showed that in 
mitochondria isolated from patient cells containing an NDUFS4 mutation, 
subunits NDUFS2, NDUFS7, NDUFA9 and NDUFA10 were incorporated 
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in an 830 kDa subassembly. By contrast, the subunits NDUFV1, NDUFV2 
and NDUFS1 were incorporated only in lower but similar molecular weight 
subcomplexes, possibly suggesting the preassembly of the NADH 
dehydrogenase part (70).  
These findings suggest that the NADH dehydrogenase part preassembles 
and enters the complex I assembly at a late stage to complete complex I (Fig 
2C). Nevertheless, whether this NADH-dehydrogenase part is assembled 
independently as shown in E. coli (see above) or if it requires other complex 
I subassemblies still remains to be established.  
 
4.3.4 ssembly of accessory subunits 
Most mammalian complex I subunits are not homologous to components of 
E. coli complex I, the so-called core subunits. The extra subunits are 
referred to as the accessory subunits. Although these subunits are not 
supposed to be required for complex I activity, mutations in these subunits 
causing complex I deficiency have been found. These subunits enter the 
assembly pathway at different stages and probably play a role in the 
assembly or stabilization of assembly intermediates. 
NDUFS4 is the subunit which is most frequently mutated in isolated 
complex I deficiencies. NDUFS4 mutations cause an accumulation of 
NDUFS3 containing subcomplexes and subunits NDUFS5 and NDUFA9 
accumulate just before entering into the holocomplex (15). In three patients 
with homozygous NDUFS4 mutations an accumulation of NDUFA5 in a 
subcomplex of approximately 800 kDa was observed (76). These data are 
consistent with the previously mentioned findings of Lazarou and coworkers 
who showed that in an NDUFS4 patient NDUFV1, NDUFV2, NDUFV3, 
NDUFS1 and NDUFS6 could not assemble into complex I, while subunits 
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NDUFS2, NDUFS7, NDUFA9 and NDUFA10 could integrate into 
intermediates of complex I. (70). 
NDUFA1 mutations can cause a decrease of NDUFA9 and NDUFS3 
containing subcomplexes (77). The mutated NDUFA1 is still expressed 
albeit at a lower level, probably the lower expression level causes the 
decrease of present subcomplexes, and any NDUFA1 that is still expressed 
is immediately incorporated in fully assembled complex I. Another 
NDUFA1 deficient patient harboring a missense mutation (78) shows a 
decreased expression level of NDUFS2, 6, NDUFA13, NDUFB8, all 
located in different modules of complex I. In the mouse cell lines used to 
demonstrate the entry points of the mitochondrially encoded ND subunits it 
was shown using antibodies against membrane subunits NDUFB6 and 
NDUFB8, that NDUFB6 already assembles in an ND2 containing 
subcomplex whereas for NDUFB8 integration occurred at a late stage when 
almost all ND subunits where assembled (65).  
The mutation causing the exon skipping in NDUFA2, causes a mild 
accumulation of NDUFS3 containing subcomplex, though no accumulation 
of NDUFB6 in any subcomplex (79). Mutations in NDUFA11 have been 
reported, though its effect on the assembly is unclear (80). These data 
indicate that the accessory subunits enter the assembly at different stages 
and mutations cause a decrease in amount of fully assembled complex I 
accompanied with the accumulation of subassemblies. Based on the 
accumulation of different subassemblies it can be deduced where in the 
assembly pathway some of these subunits might come into play (Fig. 2). 
Nevertheless it remains an intriguing question what the exact role of these 
subunits in assembly is.    
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Figure 2. Schematic overview of the assembly of the different modules of complex I. A. 
Represents the assembly of the membrane arm, B. represents the assembly of the 
hydrogenase part and C. represents the assembly of the NADH dehydrogenase part. For 
clarity the core subunits are represented by colored symbols. Accessory subunits (blue text) 
and assembly factors (red text) are indicated.  
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5. Complex I chaperones 
Beside all the nuclear and mitochondrially encoded subunits and prosthetic 
groups, complex I requires additional proteins to assemble. These proteins, 
called assembly chaperones, aid the assembly of complex I but they are not 
part of the holocomplex. To date, a number of these chaperones have been 
described. The firstly discovered mammalian chaperone was found by a 
homology search of the known assembly factor in Neurospora crassa, 
CIA30 (NDUFAF1) (81, 82).  The second assembly chaperone, NDUFAF2, 
to be found was a protein which appeared to be a paralogue of complex I 
subunit NDUFA12 (73). In the last three years several approaches like; 
homozygosity mapping, comparative genomic screens and co-purifications 
of subassemblies or other assembly chaperones, have led to the finding of 
new assembly chaperones. These methods showed that NDUFAF3, 
C7ORF20, C8ORF38, Ecsit, ACAD9, NDUFAF4 and Ind1 are involved in 
complex I biogenesis and further analysis showed their requirement for 
complex I assembly (73, 83, 84, 85, 86, 87, 88). The molecular working 
mechanism of the assembly chaperones is still unclear. In analogy of the 
better known complex IV assembly proteins they are suggested to be 
involved in the incorporation and maturation of prosthetic groups, the 
insertion of hydrophobic mitochondrial membrane proteins and assembly or 
stabilisation of subcomplexes.  
Despite our lack of knowledge on the precise working mechanisms of the 
assembly chaperones, however, it is possible to pinpoint in what stage of the 
assembly process some of these chaperones play a role (89).  
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5.1 Chaperones for the membrane unit 
The assembly of the membrane unit involves translation and coordinated 
insertion of the mitochondrial encoded subunits. From the assembly of 
complex IV it is known that similar steps in the biogenesis of this complex 
involve chaperones which aid this process. In complex I assembly the 
chaperone C20orf7 is a likely candidate to play a role in the ND1 insertion 
into the already preassembled hydrogenase core. In patients with mutations 
in C20orf7, subunit ND1 was absent, suggesting a decreased translation or 
an increased instability due to the lack of assembly (86). Two other 
assembly chaperones, NDUFAF3 and NDUFAF4, were both associated 
with a number of assembly intermediates starting with the hydrogenase 
subassembly prior to the incorporation of ND1 (85). This suggests that they 
might be involved in the insertion of mitochondrially translated subunits. 
Both proteins were found to bind to the mitochondrial inner membrane and 
knock down of either of these chaperones by RNA interference shows that 
their stability is interdependent. Remarkably after inhibition of 
mitochondrial translation, NDUFAF4 stays bound to NDUFS3 containing 
subcomplex, which solely consists of nuclear encoded subunits, whereas 
NDUFAF3 interactions seem to disappear under these conditions. This 
suggests that dynamic interactions of these proteins play a role in the 
regulation of this assembly step. Gene order conservation analysis of 
NDUFAF3 shows significant conservation with the SecF/SecD/YajC gene 
cluster, indicative of a function in membrane protein insertion (85). This 
correlates with the observed association of NDUFAF3 with higher 
molecular weight complexes in the presence of mitochondrial DNA encoded 
subunits, so these subunits are probably helped by NDUFAF3 to enter the 
subcomplexes. Interestingly, assembly chaperone C3orf38 was also shown 
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in the gene order conservation analysis to be associated with NDUFAF3. 
This might suggest that this chaperone is also involved in this stage of the 
complex I assembly process, however up till now no further experimental 
data exist which support this.  
Also for the incorporation of ND2 in a membrane subcomplex, which is a 
different subassembly to the ND1-containing, the involvement of 
chaperones is suggested. In a patient with a mutation in chaperone 
NDUFAF1 it appears that the ND2 translation is impaired or that the 
stability of ND2 is decreased (90). The NDUFAF1 protein has been shown 
to associate with at least two other proteins, Ecsit (87) and ACAD9 (88). 
Down regulation of any of these proteins leads to a destabilisation of the 
other chaperones, suggesting that their stability depends on each other. Also 
knock down of any of these proteins still allows assembly of the ND1 
subcomplexes to proceed to the stage where the incorporation of ND2 takes 
place, consistent with the fact that they play a role in this stage of the 
assembly. Remarkably, the heterogeneity of these proteins is large; Ecsit 
was already proposed to play a role in the toll-like pathway and the bone 
morphogenetic pathway, both essential processes which take place in the 
cytosol. ACAD9 moreover, structurally appears to be a mitochondrial fatty 
acid oxidation enzyme, nevertheless it is, combined with Ecsit and 
NDUFAF1, required for complex I assembly. Although the three proteins 
are co-dependent and co-migrate on two-dimensional scale, no associations 
of ACAD9 and Ecsit with complex I subunits have been found (88). 
 
5.2 Chaperones for the core hydrogenase part 
An important step in the assembly of the core hydrogenase part is the 
incorporation of iron-sulfur clusters, as two subunits of this part contain 
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these prosthetic groups (NDUFS7 and NDUFS8). Although maturation of 
iron-sulfur clusters depends on many proteins and a general defect in iron-
sulfur cluster maturation would also affect a number of other proteins, it is 
quite conceivable that the specific transfer of iron-sulfur clusters in complex 
I might require specific proteins. Recently Ind1 has been shown to bind an 
Fe/S cluster via a conserved CXXC motive and knock down of this protein 
led to a strong complex I decrease (91). Analysis of the complex I subunit 
and subcomplex content in HeLa cells lacking Ind1 demonstrated a 
significant decrease of peripheral arm subunits NDUFS1, NDUFS3 and 
NDUFA13, and an accumulation of a 450 kDa membrane arm subcomplex. 
The decrease of hydrogenase subunit NDUFS3 indicates that this subunit is 
broken-down rapidly most likely because the subunit cannot continue its 
assembly route. This is consistent with the idea that Ind1 might play a role 
in the incorporation of Fe/S clusters in NDUFS7 and NDUFS8 and co-
ordinately leading to the prevention of assembly of this hydrogenase core.  
The previously mentioned chaperones NDUFAF3 and NDUFAF4 associate 
with this subassembly and might play a role in the membrane tethering or 
stabilisation of this part of complex I prior to the incorporation of ND1 (85). 
Interestingly a recently described putative methyl transferase MidA (also 
called C2orf56 or PRO1853) was shown to play a role in complex I 
assembly (92). Because of its interaction with subunit NDUFS2 one could 
suggest that it plays a role in the assembly of this part of the complex.   
 
5.3 Chaperones for the NADH dehydrogenase part 
Because the NADH dehydrogenase part also contains subunits which 
contain Fe-S clusters it could be assumed that Ind1 might play a role in the 
assembly of this subcomplex. Indeed the observed severely reduced levels 
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of the Fe-S containing subunits NDUFV1 and NDUFS1 are in line with this 
assumption (91). Nevertheless, it is possible that the absence of the 
subassemblies containing the hydrogenase part may destabilize the 
assembly of the NADH dehydrogenase part therefore this observation might 
also be an indirect effect.  
The assembly of the NADH dehydrogenase part into the complex I core 
takes place at a late stage. In patients with a mutation in NDUFS4, 
NDUFV1 or NDUFS6, assembly can proceed up to an 830 kDa 
subassembly. Further analysis has shown that this subassembly specifically 
lacks the subunits NDUFV1-3 and NDUFS1, suggesting the absence of the 
NADH dehydrogenase part. Interestingly, this 830 kDa subassembly also 
contains assembly chaperone NDUFAF2, which indicates that this 
chaperone might specifically play a role in the acquisition of the NADH-
dehydrogenase part (73). The total lack of the NDUFAF2 protein leads to 
the accumulation of five NDUFS2 and NDUFS3 containing subcomplexes. 
ND1 accumulates at the same (85) weight level as the two largest NDUFS3 
containing subcomplex. This confirms that in the absence of this chaperone 
complex I assembly can proceed to the stage in which the NADH-
dehydrogenase part is incorporated.  
 
5.4 Other chaperones 
Pagliarini and co-workers searched for mitochondrial proteins without 
annotated function and essential for complex I (83). To accomplish this 
mitochondrial protein compendium they performed mass spectrometry 
analysis on mitochondria derived from 14 mouse organs and they used 
several verification methods, furthermore they analyzed whether the 
proteins are mitochondrially localized by tagging them with GFP. Some 
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candidates were also checked by means of RNA interference, and 19 
candidates survived the selection. To date four proteins of this list are 
established as genuine complex I assembly chaperones, C8orf38, C20orf 7, 
PRO1853 (C2orf56, MidA) and C3orf60 (NDUFAF3) (83, 85, 86, 92). In 
addition three proteins, FOXRED1, LYRM5 and LACT8, were shown to 
reduce complex I activity upon knock down of these proteins. Nevertheless, 
whether the role of these proteins can also be found in complex I assembly 
is unknown. The other proteins on the list also need to be confirmed.  
 
6. Complex I in supercomplexes 
Initially, the organization of the respiratory complexes was described as 
randomly dispersed enzymes functionally connected by diffusion of smaller 
redox components (Coenzyme Q and cytochrome c). Only recently, the 
supercomplex concept is considered as a physiological condition and not 
just an experimental artifact. By using mild extraction procedures, Schagger 
and coworkers demonstrated by native electrophoresis the existence of 
supercomplexes and the re-introduced the idea of a respirosome to define 
the supramolecular organization of the respiratory chain complexes (93, 94, 
95). The study about the position of complex I in the supercomplexes was 
performed  in bovine mitochondria and the authors suggested a model in 
which complex III- complex IV are both associated with the membrane arm 
of complex I (96). Based on this study, the positions of the coenzyme Q 
binding sites of complex I and III and the cytochrome c binding sites of 
complex III and IV, are in close proximity in the supercomplex structure. 
This supports the hypothesis that the supercomplex is a more efficient 
organization since the existence of supercomplexes reduces the diffusion 
distance of the substrates and improves the electron transfer. Another 
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possible role of the supercomplex organization is to decrease ROS 
formation. Although this is plausible, so far, no direct studies were 
performed to verify this hypothesis.  
Moreover, mutations in cytochrome b, causing a destabilization of complex 
III, cause a secondary complex I deficiency (96, 97); the same holds true for 
mutations in complex IV (98, 99). Interestingly, patient cell lines with 
complex III decreased activity but no disturbance in assembly, did not show 
any secondary complex I deficiency (97). These data imply that 
supercomplexes also have another role, namely to stabilize complex I by the 
physic presence of complex III or complex IV. Though in the model 
organism, N. Crassa, this is not the case, in fact disruption of complex III 
does not interfere with the stabilization of complex I or  complex IV, maybe 
because an alternative oxidase is present (100). Further, in patient cell line 
with a mutation in NDUFS4, a supercomplex  complex I-complex III was 
formed,  in which complex I is not the holocomplex but a subassembly of 
830 kDa, meaning that a supercomplex can be formed even if the complex I 
assembly process is not finished (73). This situation might represent a 
pathological condition which is not present in healthy cells, however it can 
be hypothesized that complex III assists complex I during the late stage of 
the assembly process.  
  
7. Concluding remarks 
Complex I assembly and its regulation are studied extensively nowadays, 
however, it seems like only the basic part of the assembly has been 
uncovered. Hitherto it has been shown that complex I assembles in 
functional modules and, for several subunits, in which stages they are 
incorporated. Another fact is that probably not all assembly factors for 
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complex I have been found: complex IV assembly requires the assistance of 
at least 15 assembly factors whereas the complex only contains 11 subunits. 
Very recently, new assembly factors of complex I have been discovered, 
also indicating that probably more are to be found in the near future. Even 
less is known about the actual function of the assembly factors, where and 
how they facilitate the process of assembly. Moreover, do they actually bind 
several subunits and bring them to the assembly intermediate or is there 
another mechanism to be found?  
Altogether it has to be concluded that complex I assembly is a very intricate 
process, as it requires the combination of 45 subunits encoded by 
mitochondrial and nuclear DNA. Moreover, it has been difficult to 
investigate the assembly since the model organism to study oxidative 
phosphorylation complex assembly, Saccharomyces cerivisiae, lacks 
complex I. New model organisms or other systems had to be sought and 
were found in Neurospora crassa, Yarrowia lypolitica and the use of human 
cell lines. Another difficulty can be found in the interpretation of assembly 
products in patient fibroblasts; it is not known if when complex I assembly 
is stalled, also complex I breakdown products appear. If that is the case, 
researchers might have looked at the breakdown products instead of 
assembly intermediates; therefore new systems including the tagging of 
subunits in non complex I affected cells might be helpful. With all the new 
systems introduced and the discovery of new assembly factors we are now 
approaching the real concept of the assembly. 
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Abstract 
Defects in mitochondrial oxidative phosphorylation (OXPHOS) are a 
frequent cause of severe inherited metabolic disorders and also contribute to 
aging. The OXPHOS system constitutes five multi-subunit complexes 
embedded in the mitochondrial inner membrane. Correct function of this 
system requires proper assembly of the ~80 proteins in the complexes, as 
well as numerous assembly factors. Blue native electrophoresis has become 
a crucial tool to investigate OXPHOS-related defects in mitochondrial 
disease patients. In addition, OXPHOS-assembly profiles can be obtained 
by two dimensional blue native/SDS gel electrophoresis, which provides 
additional information for identifying disease-causing mutations and insight 
in the role of specific proteins in the biogenesis of the OXPHOS system. 
Here we provide a practical guide on how to set up the basic technique to 
study OXPHOS defects in patient-derived cells and tissues.  
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1. Introduction 
Defects in the oxidative phosphorylation (OXPHOS) system give rise to 
numerous neuromuscular disorders (1, Bonilla and Tanji, this issue). The 
huge clinical differences in phenotype, which can vary from deafness to 
early infant death, make these mitochondrial disorders difficult to identify 
and characterize. Nonetheless, with an incidence of at least 1 in 5000 
individuals it is recognized as the most common group of inborn errors of 
metabolism (2). When a patient is clinically diagnosed, specialised enzyme 
assays are performed to find possible deficiencies of the OXPHOS 
complexes. This can results in a defect of a single OXPHOS complex 
(called isolated complex deficiency) or in a defect of more enzymes at the 
same time (multiple complex deficiencies). The next challenge is to identify 
the disease gene, which is very complicated because over two hundred 
genes from both mitochondrial and nuclear DNA can be involved (Aigar et 
al., this issue). Even when just a single enzyme is affected numerous genes 
remain to be sequenced. In this article we describe how electrophoresis 
techniques can aid the complicated task of finding the disease-causing 
mutation in these patients... 
The OXPHOS system is the main ATP generating system in our cells. It 
uses the energy released by the reduction of substrates to build up a proton 
gradient across the mitochondrial inner membrane, which on its turn is used 
by complex V to convert ADP into the high energy compound ATP 
(Marcinek et al., this issue). The five multi-subunit complexes consist of 
many subunits, which are encoded by either mitochondrial or nuclear DNA. 
Electrophoretic separation of these complexes is a complicated task for 
several reasons. Firstly, due to the fact that the OXPHOS complexes are 
integral membrane proteins, they are very hydrophobic and therefore require 
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the addition of detergents to keep them in solution. Secondly, because they 
are multi-subunit complexes there is risk of partial dissociation during the 
electrophoresis process. Thirdly, it is believed that the complexes are not 
single entities but are organised in higher order structures called 
supercomplexes (3). Therefore the concentration and type of detergent used 
are of crucial importance for the outcome of native electrophoresis 
experiments. Schagger and Von Jagow have found a good way to deal with 
these problems by introducing Blue Native electrophoresis (BN-PAGE) (4). 
This technique combines the mild properties of the detergent n-Dodecyl β-
D-maltoside (DDM) to dissolve the native protein complexes in 
combination with the use of the anionic dye Coomassie Brilliant Blue G250 
to introduce a charge shift required for the mobility of the protein complexes 
in the electric field. The sieving achieved by the correct gradient of a 
polyacrylamide matrix results in an optimal separation of the mitochondrial 
OXPHOS complexes in their native form. 
After its introduction, this method has been widely used and many 
variations and adaptations for specific research questions have been 
implemented. For instance, the use of the mild detergent digitonin instead of 
DDM has led to the identification and separation of OXPHOS 
supercomplexes (3). Also Clear Native electrophoresis (CN-PAGE) has 
been introduced for improvement of downstream applications such as mass 
spectrometry, in-gel-activity staining or fluorescence resonance energy 
transfer (5). Instead of being encyclopedic on all of the "ins and outs" of 
native electrophoresis, in this article we present the basic technique with a 
focus on elucidating defects in patients with OXPHOS deficiencies. More 
detailed reading on this subject is available (6-8).  
From patients with a suspected mitochondrial OXPHOS disorder, routinely 
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fibroblast or muscle biopsies are obtained to perform photo-spectrometric 
enzyme activity assays or metabolic assays. Small amounts of these tissues 
however can also be used for BN-PAGE analysis, which is good pre-
screening for possible defects in the OXPHOS system. This easily 
applicable technique can be performed using standard electrophoresis 
devices available in most laboratories. After a first dimension blue native 
gel in combination with in-gel activity assays and western blotting using 
antibodies against the OXPHOS complexesmany defects can be readily 
observed. To obtain further information on the assembly status of the 
affected complex, two dimensional blue native/SDS-PAGE can be 
performed. In many instances, this will also yield additional information 
about the nature of the deficiency and the specific subunit affected. 
 
2. Samples preparation 
The most commonly available patient materials are muscle biopsies or in 
vitro cultured skin fibroblasts. Therefore we describe the basic protocol 
using these as starting materials. The protocol we use for fibroblasts (9) or 
muscle biopsies (10) is a trade-off between the purity of the sample and the 
amount of tissue. Enriched mitochondrial fractions are of sufficient purity to 
obtain good BN-PAGE results and have the advantage that limited amounts 
of precious patient tissue can be used. 
 
2.1 Protocol for muscle biopsies 
Materials required: 
x Centrifuge (e.g. Sorvall RC5B with a Sorvan SM-24 rotor) 
x Teflon-glass Potter-Elvehjem homogenizer. 
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x MOPS sucrose buffer (440mM sucrose, 20 mM Mops, 1mM EDTA)  
x ACBT-buffer: 150 mM Bis-Tris, 1.5M aminocaproic acid, adjusted to 
pH7.0 with HCl at 4 °C 
x n-Dodecyl β-D-maltoside (DDM) (Sigma-Aldrich), 10% in water. 
x Blue Native sample buffer: 750 aminocaproic acid, 75 mM Bis-Tris/HCl 
pH7.0, 0.5 mM EDTA and 5%  Coomassie Brilliant Blue G250 (Serva 
blue G, Serva) 
 
Protocol:  
1. Mince 20 mg of muscle tissue using a Sorvall TC2 tissue chopper and 
further homogenize the tissue in ice-cold 250 μl MOPS sucrose buffer 
using a tight fitted Teflon-glass Potter-Elvehjem homogenizer. 
2. To obtain an enriched mitochondrial pellet centrifuge the homogenate at 
20,000g for 20 minutes at 4°C. This enriched mitochondrial pellet can be 
stored at -80°C for several months. 
3. Resuspend the mitochondria-containing pellet  in 40 μl ACBT-buffer by 
swirling it with a small spatula. 
4. Add 20 μl DDM (10% w/v in water) and leave the suspension for 10 
min. on ice. Note: these concentrations and amounts of proteins give 
good results in our hands, however it should be noted that amount of 
detergent per mg protein is important and this depends on the tissue and 
type of detergent.   
5. Centrifuge at 20,000g for 20 minutes at 4°C. Transfer the supernatant in 
a new tube and measure protein concentration (micro BCA protein assay 
kit, Pierce). 
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6. Add 10 μl Blue Native sample buffer and mix. The sample is ready to 
load on the gel. 
7. Load 10-40 μg of protein on the gel 
 
2.2 Protocol for fibroblasts 
Materials required: 
x Centrifuge (e.g. Eppendorf 5810R), Micro-Centrifuge (e.g Eppendorf 
5402 ) 
x Phosphate buffered saline, PBS (Gibco) 
x ACBT-buffer: 150 mM Bis-Tris, 1.5M aminocaproic acid, adjusted to 
pH7.0 with HCl at 4 °C 
x Digitonin stock, (Calbiochem), 4 mg/ml. To dissolve the digitonin, the 
solution should be heated to 70° C (it should become a transparent 
colorless solution). After dissolving the digitonin cool the solution on ice. 
x n-Dodecyl β-D-maltoside (DDM) (Sigma-Aldrich), 10% in water. 
x Blue Native sample buffer: 750 aminocaproic acid, 75 mM Bis-Tris/HCl 
pH7.0, 0.5 mM EDTA and 5%  Coomassie Brilliant Blue G250 (Serva 
blue G, Serva) 
 
Protocol: 
1. Harvest a minimum of one million cells using trypsin (approx. one 75 
cm2 flasks). 
2. Bring the cell-suspension to a 15 ml tube and centrifuge the cells at 
287g at 4°C for 5 min. 
3. Remove the supernatant, wash the pellet twice with cold PBS and 
centrifuge at 287g at 4°C for 5 min. 
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4. Remove the supernatant and resuspend the cell-pellet in a concentration 
of 106 cells/100 μl cold PBS.  
5. Transfer them into a 1.5 ml eppendorf tube and add 100 μl digitonin (4 
mg/ml in PBS) and leave the cell-suspension on ice for 10 min. Note: 
The optimal digitonin/protein ratio is 0.8-1.6. 
6.  Add 1 ml cold PBS (to dilute the digitonin). 
7. Spin 10 minutes at 4°C, at 10.000g/14000rpm. 
8. Remove the supernatant and wash the pellet twice with 1 ml cold PBS. 
Spin down again 5 minutes 4°C at 10.000g/14000rpm. 
9. Remove the supernatant and continue with the crude mitochondrial 
pellet or snap freeze it in liquid nitrogen and store in a –80°C-freezer 
(These pellets can be kept for several months without any adverse 
effects). 
10. The crude mitochondrial fraction is resuspended in 100 μl ACBT  
11. Add 20uL 10% E-docecyl maltoside and homogenize the pellet by 
pipetting it up and down. 
12. Leave the suspension on ice for 10 minutes. 
13. Centrifuge the cells at 10.000g at 4°C for 30 min. 
14. Put the supernatant in a new 1.5 ml eppendorf tube.  
15. Measure the protein amount first (micro BCA protein assay kit, Pierce) 
16. Add 10 μl of BN-Sample Buffer.  
17. Load 20-80 μg protein on the gel.  
 
3. Blue Native polyacrylamide gel electrophoresis 
We normally use a minigel system to perform the electrophoresis (Bio-Rad 
Mini-Protean 3). This size is sufficient for a good separation of the 
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OXPHOS complexes and has the advantage that it requires less reagents and 
less patient material. This becomes even more important considering 
downstream applications such as Western blotting and in-gel activity assays, 
which necessitate expensive chemicals and antibodies. The casting of a 
gradient gel is the most delicate part of this procedure. For good separation 
of the OXPHOS complexes, we standard use 5-15% gradient acrylamide 
gel, but other gradients to zoom in on a specific OXPHOS complex can also 
be used, for instance a 10-18% gradient was used to better resolve complex 
IV subcomplexes (11). 
NOTE: there are also commercial ready-to-use blue native gels available 
(Invitrogen, NativePAGE Novex Bis-Tris Gel system).  
 
3.1 Casting of a blue native gradient gel 
Materials required: 
x Equipment for two gels (Mini-Protean 3, Bio-Rad): 2 short glass plates, 2 
spacer glass plates (1.5mm), 2 glass-plate holders, manual casting stand. 
x Peristaltic pump p-1 (e.g. Watson Marlow 10/U/R) 
x Gradient mixer (e.g. Hoefer SG15) 
x Magnetic stirrer (e.g. VARIOMAG mono) 
x Needle (18-20 Gauge, 4 inch) 
x 40% acryl amide/bis solution (29:1) (Bio-Rad) 
x BN Gel buffer 3x (1.5M aminocaproic acid; 150 mM Bis-Tris; pH 7,0) 
x Glycerol (Sigma) 
x 10% Ammonium persulfate (Bio-Rad) 
x TEMED (Bio-Rad) 
x Protein markers: NativeMark™ Unstained Protein Standard (Invitrogen) 
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Protocol: 
1. Assemble the gel sandwich (Mini-PROTEAN 3, Bio-Rad); place it on 
the manual casting stand check for leakage using water. 
2. Prepare the following gel mixtures without TEMED and 10%APS 
according to table 1 and store them on ice. 
3. Rinse gradient mixer and fill the tube with water.  
4. Assemble gradient casting set-up (see Fig. 1). To reduce the dead 
volume in the system, use tubing with small diameter e.g. 0.8 or 1.6 
diameter.  
5. Insert needle of gradient mixer between the glass plates. Place the 
needle to the side of the gel sandwich. Leave a few millimeters space 
between the end of the needle and the bottom of the sandwich to avoid 
unnecessary turbulence. This can affect the quality of the gradient. A 
piece of adhesive tape can be used to fix the needle at the top of the 
glass-plates.   
6. Add 10%APS and TEMED according table 1 to the gel mix and 
immediately proceed with the casting of the gel.  
7. Close the connecting valve between the compartments A and B of the 
gradient mixer and remove the water. 
8. Fill compartment B (fig.1) with 3.5 ml with 5% gel mix and 
compartment A with 3.5 ml of the 15% gel mix. Store the remainder of 
the gel-mixes on ice; these can be used for a second gel.  
9. Start the stirrer (do not set it at a too high speed) and open the valve 
between the compartments. Start the peristaltic pump at a speed of 
approximately 0.7 ml/min. This way it will take about 10-12 min. to 
cast the gel. Note: Faster speed of the pump cause turbulence, slower 
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speed increases the risk of premature polymerization of the gels. 
Continue the casting of the gel until the tube (almost) does not contain 
gel mix anymore; however be careful not to let air bubbles enter the gel.  
10. When the gel is ready, stop the pump and very gently remove the needle 
without disturbing the gradient. 
11. Rinse the tubing immediately with water and repeat the procedure for 
the second gel.  
12. Let the gels polymerize at room temperature. Note: the water which was 
in the tubing will give a 2-4mm layer on top of the gel allowing a sharp 
boundary at the top of the gel.  
13. The polymerization of the gels takes approximately 1-2 hours. Tip: 
Leave the remainder of the gel-mixes on room temperature. This can be 
used to check whether the polymerization is completed.  
14. Remove the water from the top of the gel and proceed with the stacking 
gel. Note: the gels can be stored for a few weeks. To prevent them from 
drying out, add 1x gel buffer on top of the gel and store the gel wrapped 
in cling film at 4°C. 
15. Add 55 μl 10% APS and 5,5 μl TEMED to the 4% stacking gel mix and 
cast the stacking gel. 
16. Place a comb (10 wells) between the glass plate and use a 1ml pipette 
fill-up the stacking around the comb (take care to avoid air-bubbles 
trapped under the comb). 
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Table 1. Solutions for casting a blue native gradient gel 
 Stacking gel 
(4%) 
Gradient gel 
(5%) 
Gradient gel 
(15%) 
Acrylamide 
solution 
0.5 ml 1.25 ml 2.60 ml 
Gelbuffer (3X) 1.67 ml 3.33 ml 3.33 ml 
Glycerol - - 2.0 ml 
H2O 2.83 ml 5.42 ml 2.07 ml 
APS (10%) 55 Pl 60 Pl 30 Pl 
TEMED 5.5 Pl 6 Pl 3 Pl 
    
Total volume 5 ml 10 ml 10ml 
 
 
Figure 1. Basic setup for casting gradient gels.  
 
3.3 Running of the gel 
Materials: 
Electrophoresis system (Mini-PROTEAN 3, Bio-Rad) 
Power supply; powerpac 300 (Biorad) 
Anode Buffer: 50 mM Bis-Tris; pH 7.0 
Cathode Buffer A: 50 mM Tricine, 15 mM Bis-Tris, 0.02% Serva Blue G; 
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pH 7.0 
Cathode Buffer B: 50 mM Tricine, 15 mM Bis-Tris; pH 7.0 
 
Protocol: 
1. Remove the comb from the stacking and rinse the wells with cathode 
buffer A (to remove unpolymerized acrylamide). Fill the wells with 
cathode buffer A and gently load the samples (usually 20-40ug of 
protein). Because of the higher density the sample will settle in the well 
(this way possible carry-over between the wells will be minimized). 
2. Assemble the electrophoresis system and fill the inner compartment 
with cathode buffer A and the outer compartment with Anode Buffer. 
3. Run electrophoresis for approximately 30 min. at 30 V then raise the 
voltage up to 80 V. 
4. When the front has reached at the middle of the separating gel replace 
cathode buffer A by cathode buffer B. 
5. Electrophoresis continues at 80V until the blue dye front reaches the 
end to the gel. 
6. Total running time is approximately 4 hours. 
 
3.4 Detection of OXHOS complexes 
Because of the blue color, protein bands from muscle tissue can be observed 
immediately in the gels as they run (Fig.2A). However, the amount and 
purity of the fibroblast mitochondrial fraction is not sufficient to identify the 
OXPHOS complexes at this stage.  Therefore in-gel activity (IGA) (12) 
assays or Western-blotting can be performed in this case. In-gel-activity 
assays entail the incubation of the gels in complex specific-solutions which 
contain substrates and color reagents which stain upon the acceptance of 
93 
 
electrons or phosphate. Because the OXPHOS complexes are native they 
still have enzymatic activity. The combination of the appearing stained band 
and its molecular weight allows good and quantitative identification of the 
complexes (Fig. 2A). Complex IV assay works well in muscle tissue 
samples but not in fibroblast samples in our hands (For further reading 13).     
 
3.4.1 In-Gel Activity assay 
Protocol: 
Gels are incubated at room temperature with the following solutions: 
x Complex I: 5 mM Tris-HCl, pH7.4, 0.1 mg/ml NADH, and 2.5 mg/ml 
NTB (NitroTetrazolium Blue, Sigma)  
x Complex II: 5 mM Tris-HCl, pH7.4, 0.2 mM phenazine methasulfate, 20 
mM succinic acid and 2.5 mg/ml NTB.  
x Complex IV: 50 mM sodium phosphate buffer pH 7.2, 05 mg 3.3’-
diamidobenzidine tetrahydrochloride (DAB, Sigma-Aldrich) 0.5 mM 
cytochrome c (horse heart <95% purity, Sigma). 
x Complex V: 35 mM Tris -270 mM Glycine pH 8.3, 14 mM MgSO4, 
0.2% Pb(NO3)2 and 8 mM ATP. 
Good signals are usually obtained after 2 hours for complex I and II and 
after overnight staining for the other complexes. After completion of the 
staining reaction, the gels are washed in water and immediately 
photographed or scanned. Hereafter the incubation with the specific colour 
reagent can be extended if desired or additional Coomassie staining can be 
performed.  
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3.4.2. Western blotting of BN-PAGE. 
Western blotting of blue native gels can essentially performed according 
standard procedures. It should be noted that since the native gradient gels 
are thicker than the standard SDS gels (1.5 mm instead of 0.75) blotting 
times should be extended. It takes at least 2-3 hours (or overnight in a 
cooled device) to assure complete transfer of the hydrophobic complexes. 
 
 
 
Figure 2. A. Blue Native gel from human heart mitochondria. CI: complex I at 1000 kDa, 
CV: complex V at 780 kDa, CIII: complex III (dimer) at 600 kDa, CIV, complex IV 
(monomer) at 250 kDa. B. Blue Native gel from human fibroblasts stained with CI in-gel 
activity reagent. CI: complex I, also an unspecific band is indicated. B. Scheme for casting 
a second dimension gel. A first dimension gel strip is squeezed in between the second 
dimension glass plate sandwich. Next the separation gel is casted via the side of the 
sandwich (1). After polymerization of the separation gel, a stacking gel is poured around 
the first dimension strip (2). For details see text. C. Drawing of the principle of two 
dimensional blue native/ SDS gels  Schematic pictures of possible subassemblies which can 
be observed from 2D BN/SDS western blots probed with complex specific antibodies. 
Complex I subunit NDUFS3 antibody (top right panel), complex V subunit α-ATPase 
antibody (bottom left panel), complex IV subunit COXI antibody (bottom right panel). 
Arrows indicate the direction of the first dimension BN and second dimension SDS. 
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For antibody detection of the complexes it should be noted that some 
subunits give a poor detection, possibly due to the lack of epitope 
availability in the native complexes. Standard commercially available 
antibodies which yield quantitative results on blue native blots for the 
different complexes are: for complex I, α-NDUFA9, α-NDUFS3; complex 
II, α-70kDa Fp; complex III, α-core 2, α-FeS subunit; complex IV, α-COXI 
, α-COXII, α-COXIV; complex V, α-ATPase subunit (Invitrogen, 
Mitosciences). Good results are obtained using peroxidase-conjugated anti-
mouse immunoglobulins (Invitrogen) as secondary antibodies and ECL1 
plus reagents (GE Healthcare) for signal detection. 
 
4. Two dimensional blue native/SDS electrophoresis. 
As the first dimension blue native PAGE separates intact OXPHOS 
complexes, subsequent denaturing electrophoresis resolves the individual 
subunits of the respective complexes. This way the content and distribution 
of the individual subunits can be displayed, allowing the detection of 
possible subassemblies. Such subassemblies can in some cases be indicative 
for the presence of a specific gene defect (see section 5). Another advantage 
of a second dimension gel in combination with western blotting is that the 
signals are usually much stronger. This is probably due to increased epitope 
availability and reduced disturbance of the Coomassie dye.  
 
Materials: 
x Gel system (Mini-PROTEAN 3, Bio-Rad).  4 small glass plates and 4 
spacer glass plates (0.75mm) 
x 1% SDS  w/v and 1% E-mercaptoethanol v/v in water  
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x 40% acryl amide/bis solution (29:1) (Bio-Rad) 
x SDS Gel buffer 3x (3,0 M Tris-HCl, 0,3% SDS; pH 8,45) 
x Glycerol (Sigma; art. nr. G8773) 
x 10% Ammonium persulfate (Bio-Rad)  
x TEMED (Bio-Rad) 
x Cathode buffer: (0,1 M Tris, 0,1 M Tricine, 0,1 % SDS; pH 8,2) 
x Anode buffer: (0,2 M Tris-HCl; pH 8,9) 
 
Protocol: 
1. A lane is cut out of the first dimension gel with a razorblade and placed 
on a small glass plate. 
2. The lane is incubated with a dissociating solution (1% SDS and 1% E-
mercaptoethanol) for one hour at room temperature. Excess dissociating 
solution is drained away using a filter paper (Careful removal of 
dissociating solution is essential as E-mercaptoethanol inhibits gel 
polymerization). 
3. The gel strip is placed at the top of the glass plate (see Fig. 2B) and the 
gel sandwich is further assembled.  Because the first dimension gel is 
thicker than the second dimension gels (1.5 mm versus 0.75 mm), the 
gel is squeezed between at the top of the glass plates.    
4. Prepare the following gel mixes for four gels: 
4% stacking gel: 0.75 ml acryl amide/bis solution, 1.85 ml SDS-
gelbuffer, 4.9 ml water 
10% separation gel: 5 ml acryl amide/bis solution, 6.65 ml SDS-gel 
buffer, 4.2 ml 50% Glycerol, 4.15 ml water. 
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5. Add 125 μl 10% APS and 10 μl TEMED to the separation gel-mix and 
pipette the gel-mix via the available space beside the fixed gel strip and 
overlay the gel with water (see Fig. 2B). After polymerization the water 
is removed. 
6. Add 75 μl 10% APS and 7.5 μl TEMED to the stacking gel. The 
stacking gel is poured around the first dimension strip (see Fig.2B). 
7. After polymerization electrophoresis is started at 30 V for 30 min. 
Electrophoresis is continued at 80 V (2 –4 hours) or at 20 V (overnight 
run 10-12 hours). 
8. Stop the gel when the blue dye front reaches the end to the gel. 
 
4.1 Staining and or blotting of a two dimensional gel. 
Two dimensional blue native/SDS gels can be stained with Coomassie or 
silver according to standard protocols. However depending on the purity of 
the sample this is difficult to interpret. For analysis of the assembly status of 
these gels western blotting using an appropriate antibody will be better (see 
3.4.2). Since the second dimension gel is an SDS gel, standard western 
blotting protocols for SDS gels can be applied.  
 
5. Interpretation of results 
The cartoon in Figure 2C shows the principle of a 2D BN/SDS gel. When 
performing a Western blot using a complex-subunit specific antibody, the 
most intense spot occurs at the place where in the first dimension the 
complex has ran. However such a subunit can also appear at lower 
molecular weights (from the first dimension). This way several spots from 
the same antibody occur on the same horizontal line (Fig. 2C).  
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Figure 3. A. Left panel blue native western blot of complex I deficient patients fibroblasts, 
incubated with an anti-NDUFS9 antibody.  Patient (1-5) show a severe decreased amount 
of fully assembled complex I compared to control cells (C). Patient 5 demonstrates an 830 
kDa complex I subassembly characteristic for patients with mutations in NDUFS4 (for 
details see text). Right panel 2D BN/SDS western blots of complex I deficient fibroblasts 
incubated with an anti-NDUFS3 antibody showing typical subassemblies (1-6). Con, 
control cells; Pat1, a patient with a NDUFS2 mutation; Pat 2, a patient with a NDUFS4 
mutation. B. 2D BN/SDS western blots incubated with a complex IV subunit anti- COXI 
antibody, of Surf1 patient fibroblasts (pat) showing an increase of subcomplex S1 and S2 
compared to the control (con). C. Blue native western blot (left panel) and  2D BN/SDS 
western blots (right panel) from cells of a patient harboring a complex V- APT6 mutation, 
incubated with an anti- α-ATPase antibody. In the patient (P) there are beside fully 
assembled complex V also subassemblies F1 and V* present. For details see text and table 
2. 
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These lower molecular weight signals indicate that not all of this subunit is 
present in fully assembled complexes, suggesting an assembly intermediate 
or a breakdown product. Mutations in mitochondrial or nuclear genes lead 
to a specific decrease of one or more OXPHOS enzymes and in addition can 
result in an accumulation of subcomplexes of either partially assembled or 
breakdown products. Therefore gene-defects can result in a specific 
composition of complexes and subcomplexes of the OXPHOS system. In 
the cartoon in Figure 2C the most clear and frequently observed 
subcomplexes are displayed. When using an complex I-NDUFS3 antibody 
in addition to fully assembled complex I and monomeric NDUFS3, also six 
subcomplexes (1-6) can be seen, which can be indicative for complex I 
breakdown products or assembly intermediates (14). Similarly, when 
complex V- α subunit (or β subunit) antibody is used unassembled F1-
ATPase can be observed (15) and when complex IV-subunit I antibody is 
used, complex IV subcomplexes S1-S4 can be observed (16,17).  
How specific assembly profiles can indicate a possible gene defect is 
summarised in table 2 and below some illustrative examples are discussed. 
Complex I deficiency so far always resulted in a decrease of the complex I 
band in a BN gel (Fig. 3A). Moreover, in some cases a lower molecular 
weight band can be observed (last lane, Fig. 3A). This observation is most 
predominant in patients with NDUFS4 mutations, but can also occur in 
some other cases (see table 2). Typical subcomplexes for complex I can be 
observed in a 2D BN/SDS western blot incubated with a NDUFS3 antibody 
(Fig. 3A). In patients there can be a change in relative distribution of these 
subcomplexes, for instance a relative accumulation of subcomplex 1-3 is 
observed in patients with NDUFS4 mutations (patient 2 in Fig. 3A) or 
accumulation of unassembled subunit NDUFS3 in a patient with a NDUFS2 
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mutation (patient 1 in Fig. 3A). Complex IV deficiency is most frequently 
caused by mutations in Surf1. These patients give an accumulation of 
subcomplexes S1 and S2 on a 2D BN/SDS western blot incubated with an 
anti-COXI antibody (Fig. 3B). In most of the cases of patients with a 
complex V defect, increased subassemblies representing F1-ATPase and 
assembly intermediate V* can be observed in both BN and 2D BN/SDS 
western blots incubated with an antibody against α-ATPase subunit (Fig. 
3C). These subassemblies are illustrative for a defect in the mitochondrial 
DNA. This defect can be caused by a mutation in the mitochondrial ATPase 
subunits A6 or A8, but also in more general genes such as: mitochondrial 
tRNA mutations, mitochondrial DNA deletions, depletion or defects in 
mitochondrial DNA maintenance.   
 
6. Concluding remarks 
Almost 17 years after its inception, BN-PAGE been a widely used technique 
in the mitochondrial field as illustrated by the fact that the first article by 
Schagger and Von Jagow has been cited to date over 725 times (4). Since 
then Schagger and others have continued to refine the method and explored 
new applications. Several excellent reviews about this method have been 
published, which are recommended for background information (6, 26-29). 
This article is a hands-on description of the method specifically for 
investigating patients with a mitochondrial OXPHOS deficiency. The use of 
crude mitochondrial preparations and small gel devices allow investigation 
of often limited amounts patient material. By analysing the differences in 
assembly status in patients, this technique can be very informative on the 
possible deficiency causing mutations.  
 
103 
 
Reference List 
 
1.  Smeitink,J., van den Heuvel,H.L., DiMauro,S. (2001) The genetics and 
pathology of oxidative phosphorylation. Nat Rev Genet, 2,342-52. 
2. Thorburn,D.R. (2004) Diverse powerhouses.Nat Genet, 36,13-14. 
3. Schagger,H.,Pfeiffer,K. (2000) Supercomplexes in the respiratory 
chains of yeast and mammalian mitochondria. EMBO J, 19,1777-83. 
4. Schagger,H., von Jagow,G. (1991) Blue native electrophoresis for 
isolation of membrane protein complexes in enzymatically active form. 
Anal Biochem, 199,223-31. 
5. Wittig,I., Schagger,H. (2005) Advantages and limitations of clear-
native PAGE. Proteomics, 5,4338-46. 
6. Krause,F., Seelert,H. (2008) Detection and analysis of protein-protein 
interactions of organellar and prokaryotic proteomes by blue native and 
colorless native gel electrophoresis. Curr Protoc Protein Sci, Chapter 
14, Unit14.11 
7. Wittig,I., Braun,H.P., Schagger,H. (2006) Blue native PAGE. Nat 
Protoc, 1,418-8. 
8. Wittig,I., Carrozzo,R., Santorelli,F.M., Schagger,H. (2007) Functional 
assays in high-resolution clear native gels to quantify mitochondrial 
complexes in human biopsies and cell lines. Electrophoresis, 28,3811-
3820. 
9. Klement,P., Nijtmans,L.G., Van den Bogert,B.C., Houstek,J. (1995) 
Analysis of oxidative phosphorylation complexes in cultured human 
fibroblasts and amniocytes by blue-native-electrophoresis using 
mitoplasts isolated with the help of digitonin. Anal Biochem 231,218-
24. 
10. Nijtmans,L.G., Henderson,N.S., Holt,I.J. (2002) Blue Native 
electrophoresis to study mitochondrial and other protein complexes. 
Methods 26,327-34. 
104 
 
11. Nijtmans,L.G., Taanman,J-W., Muijsers,A.O., Speijer,D.,Van den 
Bogert,C. (1998) Assembly of cytochrome-c oxidase in cultured human 
cells. Eur J Biochem 254,389-94. 
12. Zerbetto,E.,Vergani,L., Dabbeni-Sala,F. (1997) Quantification of 
muscle mitochondrial oxidative phosphorylation enzymes via 
histochemical staining of blue native polyacrylamide gels.  
Electrophoresis, 18,2059-64. 
13. Wittig,I., Karas,M., Schagger,H. (2007) High resolution clear native 
electrophoresis for in-gel functional assays and fluorescence studies of 
membrane protein complexes. Mol Cell Proteomics, 6,1215-25. 
14. Vogel,R.O., Dieteren,C.E., van den Heuvel,L.P., Willems,P.H., 
Smeitink,J.A., Koopman,W.J., Nijtmans, L.G. (2007) Identification of 
mitochondrial complex I assembly intermediates by tracing tagged 
NDUFS3 demonstrates the entry point of mitochondrial subunits. J Biol 
Chem, 282,7582-90. 
15. Nijtmans,L.G., Henderson,N.S., Attardi,G., Holt,I.J. (2001) Impaired 
ATP synthase assembly associated with a mutation in the human ATP 
synthase subunit 6 gene. J Biol Chem, 276,6755-62. 
16. Tiranti,V., Galimberti,C., Nijtmans,L., Bovolenta,S., Perini,M.P., 
Zeviani, M. (1999) Characterization of SURF-1 expression and Surf-1p 
function in normal and disease conditions. Hum Mol Genet, 8,2533-40. 
17. Williams,S.L., Valnot,I. Rustin,P., Taanman,J.W. (2004) Cytochrome c 
oxidase subassemblies in fibroblast cultures from patients carrying 
mutations in COX10, SCO1, or SURF1. J Biol Chem, 279,7462-9. 
18. Ogilvie,I., Kennaway,N.G., Shoubridge,E.A. (2005) A molecular 
chaperone for mitochondrial complex I assembly is mutated in a 
progressive encephalopathy. J Clin Invest, 115,2784-92.  
19. Ugalde,C., Janssen,R.J., van den Heuvel,L.P., Smeitink,J.A., 
Nijtmans,L.G. (2004) Differences in assembly or stability of complex I 
and other mitochondrial OXPHOS complexes in inherited complex I 
deficiency. Hum Mol Genet, 13,659-67.  
20. Hoefs,S.J., Dieteren,C.E., Distelmaier,F., Janssen,R.J., Epplen,A., 
105 
 
Swarts,H.G., Forkink,M., Rodenburg,R.J., Nijtmans,L.G., Willems, 
P.H., Smeitink,J.A., van den Heuvel,L.P. (2008) NDUFA2 complex I 
mutation leads to Leigh disease. Am J Hum Genet, 82,1306-15. 
21. Fernandez-Vizarra,E., Bugiani,M., Goffrini,P. Carrara,F., Farina, L., 
Procopio,E., Donati,A., Uziel,G., Ferrero,I., Zeviani,M. (2007) 
Impaired complex III assembly associated with BCS1L gene mutations 
in isolated mitochondrial encephalopathy. Hum Mol Genet, 16,1241-52.  
22. Acín-Pérez,R., Bayona-Bafaluy,M.P., Fernández-Silva,P., Moreno-
Loshuertos,R., Pérez-Martos,A., Bruno,C., Moraes,C.T., Enríquez,J.A. 
(2004) Respiratory complex III is required to maintain complex I in 
mammalian mitochondria. Mol Cell, 13,805-15. 
23. Barel,O., Shorer,Z., Flusser,H., Ofir,R., Narkis,G., Finer, G., Shalev,H., 
Nasasra,A., Saada,A., Birk,O.S. (2008) Mitochondrial complex III 
deficiency associated with a homozygous mutation in UQCRQ. Am J 
Hum Genet, 82,1211-6. 
24. Tiranti,V., Corona,P., Greco,M., Taanman,J.W., Carrara,F., 
Lamantea,E., Nijtmans,L., Uziel,G., Zeviani,M. (2000) A novel 
frameshift mutation of the mtDNA COIII gene leads to impaired 
assembly of cytochrome c oxidase in a patient affected by Leigh-like 
syndrome. Hum Mol Genet 9,2733-42. 
25. De Meirleir,L., Seneca,S., Lissens,W., De Clercq,I., Eyskens,F., 
Gerlo,E., Smet,J., Van Coster,R. (2004) Respiratory chain complex V 
deficiency due to a mutation in the assembly gene ATP12. J Med 
Genet, 41,120-4. 
26. Wittig,I., Braun,H.P., Schagger,H. (2006) Blue native PAGE. Nat 
Protoc, 1,418-28. 
27. Wittig,I., Carrozzo,R., Santorelli,F.M., Schagger,H. (2007) Functional 
assays in high-resolution clear native gels to quantify mitochondrial 
complexes in human biopsies and cell lines. Electrophoresis, 28,3811-
20. 
28. Schagger,H. (2001) Blue-native gels to isolate protein complexes from 
mitochondria. Methods Cell Biol, 65,231-44. 
106 
 
29. Sunderhaus, S., Eubel,H., Braun,H.P (2007) Two-dimensional blue 
native/blue native polyacrylamide gel electrophoresis for the 
characterization of mitochondrial protein complexes and 
supercomplexes. Methods Mol Biol, 372,315-24. 
 
   
 
 
  
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
Chapter IV 
 
 
New mitochondrial tRNAHIS 
mutation in patients with lactic 
acidosis and stroke-like episodes 
(MELAS) 
 
Calvaruso M. A.a, Willems M.b, Rodenburg R.a, van de 
Brandt M.a, Smeitink J.a, Nijtmans L.a 
 
aNijmegen Center for Mitochondrial Disorders at the Department 
of Pediatrics, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands 
bDepartment of Pediatric Neurology, Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands 
 
Mitochondrion 2011, Volume 11, Number 5, Page 778-782 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
Abstract 
We report a new mutation in m.12146 A>G in the mt-tRNAHis  in a family 
with a remarkable clinical history having different degrees of lactic acidosis 
and stroke-like episodes. Biochemical measurements of a muscle biopsy 
established an isolated complex IV deficiency, while similar analysis of 
fibroblasts showed a combined complex I,III and IV deficiency.  
Transmitochondrial cybrid analysis proved that this tRNAHis mutation 
causes the enzymatic deficiency. This family illustrates the complexity of 
the clinical, biochemical and genetic characteristics of a novel mtDNA 
encoded disorder, as well as the challenge to prove its pathogenicity.  
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1. Introduction 
To date, over 250 mutations associated with human disease have been 
identified within the mitochondrial DNA (mtDNA)(1). More than half of 
these disease-related mutations are located within tRNA genes, which 
represent only a small part of mtDNA. Mitochondrial encephalomyopathy, 
lactic acidosis and stroke like episodes (MELAS) is a frequently occurring 
phenotype associated with these mutations (2). Nevertheless, these disorders 
are still difficult to diagnose due to their highly variable course and severity, 
as well as variability in the tissues involved (3). This clinical heterogeneity 
is partly explained by the percentage of mutated mtDNA molecules per cell 
(heteroplasmy), among other individual genetic or environmental factors.  
Numerous mtDNA polymorphisms have been described, and pathogenicity 
of novel mtDNA variants remains difficult to prove. The pathogenity of a 
mtDNA point mutation may be inferred from its absence in healthy subjects 
and by the phylogenetic conservation of the mutated nucleotide (4). 
Nevertheless cybrid technology is essential for firm conclusions on this 
matter, as it allows the mtDNA defect to be investigated in the absence of 
the influence of nuclear DNA-encoded factors.  
In this study, we present a patient with MELAS-like phenotype due to a 
novel mutation in tRNAHis resulting in OXPHOS complex deficiencies.  
 
2. Material and methods 
2.1 Case report  
The index patient (II-1) is the first of three children of a non-
consanguineous Dutch couple. At the age of 12 years this boy presented 
with headache, left-sided visual field defect and ipsilateral partial seizures. 
Within two days his clinical condition deteriorated due to progressive rise of 
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intracranial pressure with subsequent loss of consciousness, and the 
development of secondary generalized status epilepticus. Cerebral computed 
tomography showed a large hypodense lesion in the right parieto-occipital 
region. Cerebrospinal fluid (CSF) analysis was normal with regard to cells, 
protein and glucose, but revealed elevated concentrations for lactate (3350 
(reference 1380-1900) micromol/l) and pyruvate (180 (reference 96-145) 
micromol/l). Lactate levels in blood were slightly elevated (2.5 – 3.5 
(reference < 2.0) mmol/l) in the acute phase but also during follow-up. The 
clinical diagnosis was mitochondrial encephalomyelopathy with lactic 
acidosis and stroke-like episodes (MELAS). Blood amino acids levels and 
urinary excretion of amino acids and organic acids was unremarkable. The 
boy recovered slowly and was left with a left-sided visual field defect and 
mild spastic hemiplegia. At the age of 15 years, he suffered from another 
stroke-like episode at the contra-lateral side, presenting with acute loss of 
vision and – later that same day – right-sided status epilepticus. Cerebral 
imaging showed extensive bilateral occipital defects (Figure 1A). He was 
left with central blindness, (mild) bilateral spastic paraplegia, and occipital 
lobe epilepsy. In the chronic phase his MRI showed bilateral cystic 
degeneration of the parieto-occipital regions (Figure 1B). Profylactic 
treatment with L-arginine (1000 mg per day) was prescribed from the age of 
20 years. 
In the early nineties, the mother (patient I-2) from patient II-1 suffered from 
a large ‘stroke’ at the age of 34 years, in those days considered “young 
stroke in the left hemisphere of unknown origin”. In retrospect she had 
similar signs and symptoms (acute, progressive encephalopathy with 
increased intracranial pressure, visual field defects, and status epilepticus) as 
well as imaging abnormalities compared to her son. Blood lactate levels, 
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and urinary excretion of amino acids and organic acids were normal. CSF 
analysis also revealed only normal results, especially for lactate and 
pyruvate. She never recovered fully, and at the age of 36 years a second 
episode occurred with a similar but even more severe and fatal course. Post-
mortem examination of the brain was performed but did not lead to an 
etiologic diagnosis. 
Figure 1. Cerebral imaging of patient  II-1. A. CT of the brain showing an acute left-sided 
hypodense lesion with swelling, while the right hemisphere already shows the remnants of 
the previous stoke-like episode. B. T1-weighted MR-image, showing bilateral parieto-
occipital cystic degeneration with subsequent widening of the ventricular system. 
 
The younger brother (II-2) of the index patient was considered fully healthy 
until the age of 18 years, when he suffered from a stroke-like episode 
located in the right parieto-occipital region. He presented with status 
epilepticus which could be treated relatively easily and recovered fully with 
the exception of a small left-sided visual field defect. In the acute phase 
cerebral MRI showed the typical stroke-like lesion. Blood lactate levels 
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were slightly elevated (2.5 – 3.5 (reference < 2.0) mmol/l) in the acute phase 
and during follow-up. 
The father (I-1) and the youngest daughter (II-3) are healthy.   
 
2.1 Biochemical and genetic analysis 
Skin fibroblasts were cultured in M199 medium supplemented with 10% 
fetal calf serum (FCS) and antibiotics. Transmitochondrial cybrid cell lines 
were made according to the protocol of King and Attardi (5). The mtDNA 
was extracted from mucle tissue, fibroblasts and cybrids. The entire mtDNA 
coding region was analyzed, sequences and percentage of heteroplasmy was 
determined in muscle, blood, fibroblasts and cybrids as described previously 
(6).  
The complex I , II, III, IV, V and CS activities were measured 
spectrophometrically in mithocondria isolated from frozen pellets of patient 
and control cybrids as described and expressed relative to the succinate 
oxidoreductase and the citrate synthase (CS) activity (7). For blue native 
PAGE analysis, 5–15 % gradient gels were loaded with 40 μg of digitonin-
isolated mitochondria. After electrophoresis, the gels were further processed 
for In-gel-activity assays, Western Blottings as  
described in (8). The  Western blots were incubated using antibodies against 
complex I (39 kDa), complex II (70 kDa), complex III (Core2), complex IV 
(COXII) and complex V (α-ATPase) (MitoSchiences, Eugene, OR, USA). 
In vitro pulse labeling of mitochondrial translation was performed as 
described elsewhere (6).  
 
3. Results 
Biochemical analysis of the index patient’s (II-1) muscle biopsy 
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demonstrated an isolated complex IV deficiency, whereas fibroblasts 
revealed a combined complex I, IV and mild III deficiency (Table 1). In line 
with the biochemical data we observed a mild complex I and IV deficiency 
but no significant decrease in complex II, III and V in BN-PAGE (2A).  
Sequencing of the mtDNA indicated an alteration in of a adenine into a 
guanine at place 12146 located in  the transfer RNA histidine (tRNAHis) 
gene (Figure 2B). This mutation was heteroplasmic in blood (60%) but 
homoplasmic in muscle tissue and fibroblasts of the patient. His less 
affected brother (II-2) carried this mutation (30% in blood), whereas his 
unaffected sister (II-3) and mother (I-2), who deceased before diagnosis was 
made, were not analyzed. A direct effect of  this tRNAHis mutation on  
mitochondrial translation was observed in the patients fibroblasts, which 
showed a decrease of COXI-III translation products compared with control 
fibroblasts (data not shown). To further confirm that this tRNAHis mutation 
causes the biochemical defect, transmitochondrial cybrids of the patient 
fibroblasts were created. Sequence analysis showed that the obtained 
cybrids contained the m.12146A> G mutation at homoplasmic level. 
Biochemical analysis of these cells demonstrated a severe complex I, IV and 
V deficiency, whereas complex II and III where normal (Table 2). 
In line with these enzymatic data, BN-PAGE demonstrated a decrease in 
amount of complex I, IV and V (Figure 2D). Consistent with these data, in 
vitro translation of mitochondrial gene products revealed a severe decrease 
of mitochondrial translation in the cybrids obtained from the patients 
fibroblasts (Figure 2E).  
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Figure 2. Characterization of novel transfer RNAHis mutation. A. BN- PAGE of fibroblasts 
from patient (PII.1) and controls (C) were blotted and incubated with antibodies against 
complex specific subunits. Complex II was used as loading control. B. Electropherogram 
demonstrating the homoplasmic 12146 A>G mutation. C. Pedigree of the family. The 
black, gray and open symbols show clinically affected, mildly affected and unaffected 
members respectively; squares male members circles female members; slash, deceased. D. 
BN-PAGE of independent cybid clones. E. In vitro labeling of mitochondrial translation 
products in cybrids. Cc1 and Cc2, independent cybrid clones containig control 
mitochondrial DNA (Cc1, Cc2) and Cp1 and Cp2 represent cybrid clones containing 
mutated mtDNA (Cp1, Cp2). 
 
4. Discussion 
In this study we show a patient with a MELAS-like phenotype due to a 
mutation in tRNAHis, which causes OXPHOS complex deficiencies. This 
alteration has not been reported before, is conserved in mammals (Figure 
3A)and is not represented as a polymorphism in two large databases of 
human mtDNA sequences (1, 9). The mutation is localized between the 
acceptor and D stem (position 12146 in mtDNA and position 9 in tRNAHis , 
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see Figure 3B).  
 
Figure 3. Effect of mutation. A. Phylogenetic conservation of mutation containing region 
of the tRNAHis sequence. B. Schematic representation of the mt-tRNAHis cloverleaf 
structure, showing the mutation.  
 
Computer based predictions using MFOLD (http://mfold.rna.albany.edu/) 
reveals that the change in the mutant tRNAHis is likely to perturb the 
secondary structure. Moreover this mutation may also affect the tertiary 
structure of mt- tRNAHis which is based on long-range interactions between 
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residues: 8-14-21;9-23-12;15-48;25-10-45;13-22-46;26-44 (10). So far, only 
two other pathologic mutations have been reported in this tRNA (11, 12, 
13), which both are also associated with the MELAS/MERF phenotype 
Interestingly two of these reports involve a transition of G12147A, which is 
adjacent to the base where we found the mutation (12, 13).   
In retrospect this patient and his family represent a classical case of a 
mitochondrial deficiency caused by a novel mutation in tRNAHis. 
Nevertheless it clearly illustrates the difficulties which are encountered in 
both the biochemical and clinical diagnosis. This is exemplified by the fact 
that the mother was only properly diagnosed in retrospect, after recognition 
of the MELAS phenotype in one of her children.  
Concerning the biochemical analysis, there was a discrepancy in the 
enzymatic defects found in the different tissues and cell types from the 
index patient. Biochemical analysis of the patients muscle biopsy  revealed 
an isolated complex IV deficiency, whereas analysis of  fibroblasts showed 
a combined complex I, III and IV deficiency and the patient cybrids 
demonstrated the most pronounced deficiency of complex I, IV and V. 
These differences cannot be explained by variations in heteroplasmy levels 
because all these tissues were homoplasmic for the mutation. This indicates 
that other tissue specific factors play a role in the expression of the 
enzymatic defects. 
Firm establishment of pathogenicity of a mtDNA mutation requires the 
construction of cybrid cells, as illustrated in this family. While it is clear that 
this tRNA mutation is associated with a respiratory chain defect, the exact 
molecular mechanism through which this occurs is unknown. The tRNAHIS 
mutation, may directly influence the mitochondrial tRNA function in 
translation by (i) affecting recognition of the tRNA by the histidine-tRNA 
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synthetase, which may lead to mischarging or noncharging of the tRNA, or 
(ii) inhibiting the correct recognition of the tRNA by the ribosome. In this 
context it was remarkable that  complex III showed on  Western blot and 
spectrophotometric assay normal expression and activity respectively. 
Because complex III also entails a mitochondrial encoded subunit, 
cytochrome b, and the aminoacid sequence of this subunit includes several 
histidines, we expect that, if this aminoacid is noncharging or mischarging, 
the functionality of the complex III should also be compromised. Illustrating 
that there are other aspects in translation or translation regulation that play a 
role.  
In conclusion, we present a novel tRNAHis mutation leading to a MELAS-
like phenotype. Despite the fact that we were clearly able to prove its 
pathogenic effect, more studies seem necessary to gain full insight into how 
the mutation affects the function of the respiratory chain.  
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Abstract 
Mitochondrial complex I (CI) is a multi-subunit enzyme that forms the 
major entry point of NADH electrons into the respiratory chain. Mutations 
in the NDUFS4 gene, encoding an accessory subunit of this complex, cause 
a Leigh-like phenotype in humans. To study the nature and penetrance of 
the CI defect in different tissues, we investigated the role of NDUFS4 in 
mice with fatal mitochondrial encephalomyopathy, caused by a systemic 
inactivation of the Ndufs4 gene. We report that the absence of NDUFS4 in 
different mouse tissues results in decreased activity and stability of CI. This 
CI instability leads to an increased disconnection of electron influx of the 
NADH dehydrogenase module from the holo-complex. However, the 
formation of respiratory supercomplexes, still allows formation of active CI 
in these Ndufs4 knock out mice. These results reveal the importance of these 
supramolecular interactions not only for stabilization but also for the 
assembly of CI, which becomes especially relevant in pathological 
conditions. 
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Introduction 
Mitochondrial complex I (CI) deficiency is the most widespread enzyme 
defect in oxidative phosphorylation, leading to a clinically heterogeneous 
class of metabolic disorders. The enzyme is a large multi-subunit complex, 
which serves as the electron influx part of the respiratory chain. The energy 
released from the transfer of two electrons from NADH to ubiquinone is 
used to translocate four protons from the mitochondrial matrix to the inter-
membrane space, contributing to build-up a proton gradient across the 
mitochondrial inner-membrane, which is utilize to generate ATP.  
Mammalian CI is an L-shaped molecule embedded in the mitochondrial 
inner membrane with a size of approximately 1 MDa. The complex is 
formed by 45 protein subunits and it is believed to be organized in three 
functional modules: 1) an NADH dehydrogenase part, which catalyzes 
electron influx by oxidizing NADH; 2) a hydrogenase part, which conducts 
the electrons to ubiquinone, its final electron acceptor; and 3) a membrane-
bound part, which acts as a conformation-driven proton pump (1). The 
assembly of CI is a multi-step process, in which several subunits are first 
combined into smaller intermediates of the three functional modules, and 
then these preassembled parts, with additional subunits, are joined to form 
the holo-enzyme. This process is aided by specific proteins, the so-called 
assembly chaperones (2). In addition, different studies showed that CI is not 
independently dispersed in the mitochondrial membrane, but it forms 
together, with complex III and IV, supramolecular structures called 
supercomplexes. The supercomplexes might serve to reduce the diffusion 
distance of the substrates, to improve electron transfer, to decrease the ROS 
formation and to stabilize the individual complexes (3, 4). 
Previous studies have identified numerous disease causing mutations in the 
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intrinsic subunits (5) and more recently in the assembly chaperones (6). 
These mutations give rise to large diversity of clinical presentations 
including Leigh or Leigh-like syndrome, cardiomyopathy, leukodystrophy 
and hepatopathy. The molecular basis of this variety of disorders is still 
poorly understood. The NDUFS4 subunit is a small protein of 18 kDa (7), 
which is thought to be important in CI assembly and function. Mutational 
analyses of CI-deficient patients have revealed several loss-of-function 
mutations in NDUFS4 gene (8-11). CI assembly studies of patient 
fibroblasts showed that the NDUFS4 subunit is inserted in the complex at 
late stage of assembly process (12-14)  and that the absence of NDUFS4 
leads to the formation of a partially assembled 830 kDa subcomplex and 
lack of fully assembled CI (9, 14, 15). Despite this absence of fully 
assembled CI in blue native gels (BN-PAGE) in NDUFS4 patient samples, 
some CI activity could still be measured by spectrophotometric analysis (8-
11, 16). So far, no explanation could be given for this discrepancy between 
the BN-PAGE findings and the spectrophotometric assay. 
Mice in which the Ndufs4 gene was disrupted develop a neurological 
phenotype similar to Leigh (like) syndrome patients with mutations in this 
gene (17, 18). The symptoms included encephalomyopathy, growth 
retardation, lethargy, loss of motor skills, blindness and elevated serum 
lactate levels (18). Remarkably, a mouse with a brain-specific disruption of 
this gene has a clinical phenotype which is basically identical to the 
systemic inactivation of the Ndufs4 gene (19). This rises the question 
whether in the systemic Ndufs4 knock out (KO) mice disruption in the 
peripheral tissues is less detrimental for CI activity compared to brain. We 
therefore investigated the biochemical and molecular defects in various 
tissues of the Ndufs4 KO mice. Our data show that loss of NDUFS4 affects 
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CI in all tissues, although there are differences in residual CI-activities. We 
demonstrate that this CI defect is due to instability of the complex leading to 
the loss of the NADH dehydrogenase electron influx part from the enzyme. 
CI in NDUFS4 deficient mice is stabilized by the formation of the 
supercomplex that includes complex III (CIII). 
 
Results 
CI activity is decreased but not abolished in the absence of NDUFS4 in 
different tissues 
Inactivation of CI-subunit gene Ndufs4 in mice leads to viable offspring 
which develop encephalomyopathy and die within ~50 days after birth (18). 
To investigate whether this neurological phenotype is due to tissue-specific 
CI defects, we measured the activity of CI and OXPHOS complexes II-V in 
various tissues of wild-type (Wt), heterozygous (Het) and knock-out (KO) 
mice (Table 1). All investigated tissues of the KO mice showed a significant 
decrease in CI activity compared to the control values. Nevertheless, there 
were remarkable differences in the residual activities in the different KO 
tissues. In heart tissue there was a residual activity of 44% of the control 
values; whereas muscle, brain, and kidney had a residual activity of 29, 26 
and 25%, respectively; while pancreas, liver and lung showed residual 
activities of 17, 19 and 9%, respectively.  No significant differences in 
complexes II, III, IV, and V activities were found in the KO samples 
compared to the Wt and Het (data not shown). 
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Table 1. Spectrophotometric activities in different mouse tissues 
Tissues Wt Het KO 
    
Pancreas 100 ± 32   (9) 120 ± 30 (7) 17 ± 10   (6) 
Kidney 100 ± 32   (9) 118 ± 38 (7) 25 ± 11   (6) 
Liver 100 ± 39   (9)   94 ± 30 (7) 19 ±  9   (6) 
Lung 100 ± 30   (9)   82 ± 28 (7)   9 ±  6   (6) 
Brain 100 ± 32 (13) 144 ± 54 (7) 26 ±   6 (10) 
Heart 100 ± 28   (8) 115 ± 39 (7) 44 ±  16  (9) 
Muscle 100 ± 27 (13) 128 ± 46 (7) 29 ±   9 (10) 
Complex I activities are normalized to complex IV (mU C.I/U C.IV) and expressed as 
percentage of the wild type mice ± SD (n). Assays were performed in duplicated for each 
samples, p=0,001 by Student`s t-test. 
 
The absence of NDUFS4 affects CI assembly and/or stability  
To further investigate whether these differences in residual activities in the 
different KO tissues were due to variation in assembly or stability of CI we 
studied the OXPHOS complexes using blue native gel electrophoresis (BN-
PAGE). Western blot analysis of BN-PAGE using complex-specific 
antibodies revealed that fully assembled CI was absent in all investigated 
tissues in the KO mice, in contrast to WT and Het mice (Fig. 1A). 
Complexes II, III, IV and V remained normal in all tissues of the KO and 
Het compared to the Wt mice (Fig. 1A). In the KO mouse tissues a lower 
molecular weight  
CI-subcomplex of about 830 kDa was observed, resembling the 
subassembly also observed in NDUFS4 patient fibroblasts (9, 15, 20). Note 
that the amount of this subassembly was markedly less in the KO tissues 
compared to the amount of fully assembled CI in the corresponding Het and 
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Wt tissues. This suggests that this large subassembly does not accumulate in 
similar amounts as CI itself.  
In fibroblasts, the 830 kDa subassembly contained the CI-assembly protein 
NDUFAF2 (15). To verify whether the mouse 830 kDa CI-subassembly was 
also associated with this chaperone, we performed a two dimensional blue 
native SDS-PAGE (2D BN/SDS-PAGE) from kidney and brain. Western 
blots of these gels indicated a specific co-localization of NDUFAF2 with the 
830 kDa mouse CI-subcomplex in the KO mouse tissues, whereas it was 
absent in the Het tissues, which lack the 830 kDa subassembly (Fig.1B). 
 
 
Figure 1. BN-PAGE and 2D BN/SDS-PAGE analysis of mitochondrial complexes in 
different mouse tissues. Mitochondrial complexes were isolated as described in Materials 
and Methods and 20-60 μg protein were loaded on 1D BN-PAGE and 2D BN/SDS-PAGE, 
respectively. A. Western Blots for mouse tissues were incubated with different antibodies 
against Complex I subunit (NDUFA9), Complex II subunit (SDHA), Complex III 
(CORE2), Complex IV subunit (COXVA) and Complex V subunit (α-ATPase). The levels 
of expression of complex II-V are normal in Wt, Het and KO tissues. Complex I is normal 
in Wt and Het tissues however it is absent in the KO samples, but it shows an accumulation 
of an 830 kDa subassembly. B. The 2D BN/SDS-PAGE blots were incubated with an 
antibody against NDUFAF2, which shows the accumulation of the chaperone in KO tissues 
at 830 kDa, and its absence in the control tissue. 
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Figure 2. Presence of 200 kDa subassembly in KO mouse  tissues. A. BN-PAGE processed 
for CI-In Gel Activity (CI-IGA) of different mouse tissues. The 830 kDa subassembly in 
the KO tissues is inactive in Brain, Heart and Muscle KO tissues an “extra” CI-IGA band, 
of approximate 200 kDa, is visible (indicated with arrow). B. BN-PAGE Western Blot 
incubated with NDUFV2 to verify that the “extra” IGA band in KO tissues is an 
accumulation of NADH dehydrogenase part of CI. 
 
Ndufs4 KO mitochondria contain a loose NADH dehydrogenase module 
NADH oxidation of CI and CI-subassemblies was measured by an in-gel 
activity assay (IGA) using the artificial electron acceptor nitrotetrazolium 
blue. Wt and Het tissues displayed a single IGA-positive band at the height 
of fully assembled CI, whereas the corresponding KO tissues failed to show 
a positive signal at CI position or at 830 kDa subassembly (Fig. 2A). The 
latter result shows that the 830 kDa subassembly completely lacked IGA. 
Remarkably, in some of the KO mouse tissues (kidney, brain, heart and 
muscle) an additional low molecular weight band of approximately 200 kDa 
was found (indicated by arrows in Fig. 2A). Because this 200 kDa band 
gives NADH oxidation, we reasoned that it is likely the NADH 
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dehydrogenase module. This module contains at least CI-subunits 
NDUFV1-3 and represents the NADH-binding part of the complex. To test 
this possibility, we incubated the BN-PAGE Western blot with an antibody 
against NDUFV2, one of the subunits present in this part. The signal 
obtained with the NDUFV2 antibody corresponded exactly with the 
accumulation of the 200 kDa CI subassembly as observed in the IGA for 
KO mouse tissues (Fig. 2B). Moreover, because of the high sensitivity of 
antibody detection the 200 kDa CI-subassembly could also be observed in 
liver and lung. 
NDUFS4-lacking but fully assembled CI is present in a supercomplex 
with CIII 
To investigate how the disturbed CI assembly/stability affects the formation 
of respiratory supercomplexes in the NDUFS4 KO mice, we performed BN-
PAGE using the detergent digitonin instead of n-dodecylmaltoside. This 
milder extraction condition allows loose interactions to remain intact. BN-
PAGE gels were loaded with mitochondrial samples from muscle and 
further processed for IGA and Western Blot. In the Wt and Het 
mitochondria, CI was present in the monomeric form and in various 
supercomplex forms, CI+CIII2 and CI+CIII2+CIV1-4 (Fig. 3A). Interestingly, 
IGA of complexes from the KO mouse showed NADH oxidation activity in 
CI+CIII2, but not in free CI (Fig. 3A indicated with CI). In the Western Blot 
analyses of KO samples a double CI band at the supercomplex position was 
observed when we incubated with anti-NDUFA9 (Fig. 3A). The upper band 
likely represents a CI-CIII2 supercomplex, since this gives NADH oxidase 
activity (as showed in IGA, Fig.3) and has a comparable molecular size as 
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in Wt and Het tissues (Fig. 3A); whereas the lower band likely represents a 
supercomplex containing CIII and the 830 kDa CI-subcomplex  
The large supercomplexes (CI+CIII2+CIV1-4) were almost absent in the KO 
samples, possibly reflecting the decreased stability of these supercomplexes 
in the KO samples. Notably, also a tiny band co migrating with the 
830+CIII2 complex was observed the Wt and Het samples. This band reacts 
with both the complex I (Fig. 3A) and complex III antibody (not shown) and 
has no in-gel activity, suggesting that it represents indeed the 830+CIII2 
supercomplex. No loose 830 kDa subassembly was observed in these 
samples.  Moreover, only the 830 kDa CI-subassembly, but not the intact 
free CI, was detected in the KO mouse samples.  
To investigate whether the 830+CIII2 still contains assembly factor 
NDUFAF2 we incubated an additional supercomplex gel Western blot using 
antibodies against the chaperone and CI subunit NDUFA9 (Fig. 3B). We 
observed clear NDUFAF2 signals in the KO samples, which had similar 
intensities and co-localizes with the NDUFA9 bands representing the 830 
kDa subassembly and the 830+CIII2 supercomplex. In addition, faint 
NDUFAF2-bands in the CI+CIII2 supercomplex were visible in the Wt and 
Het samples, which did not correspond with the intensity of this complex, as 
seen in the NDUFA9 blot. No NDUFAF2 signal was seen at the height of 
CI. 
These data suggest that under mild extraction conditions, likely representing 
a more physiological situation, the NADH dehydrogenase module can 
attach to the 830 kDa sub-complex to give fully assembled CI, thus NADH 
dehydrogenase activity. However, this association only occurs when CI is 
part of a supercomplex containing CIII. 
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Figure 3. Supercomplex formation in muscle. The supercomplexes formation was analyzed 
in Wt, Het and KO samples of muscle, as described in Materials and Methods. A. The BN-
PAGE was processed for IGA and Western Blot. The IGA shows in the KO tissues the 
presence of holo-CI in the supercomplexes organization. The Western Blot incubated with 
NDUFA9 antibody shows the co-presence of CI+CIII2 and 830kDa+CIII2 in KO tissues. B. 
Western blot analysis of Wt, Het, and KO samples of muscle incubated with an antibody 
against assembly factor NDUFAF2 (left panel) and against complex I subunit NDUFA9 
(right panel). 
 
Discussion 
In the present study, we performed molecular analysis to determine the 
nature and penetrance of CI deficiency in different tissues in mice lacking 
the Ndufs4 gene that lead to a fatal encephalomyopahty. We observed a 
decrease in spectrophotometric CI activity in all investigated NDUFS4 KO 
mouse tissues, which is consistent with the fact that CI is ubiquitously 
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expressed and all investigated tissues require NDUFS4 for proper CI 
function. Nevertheless, significant residual activities were found, explaining 
the viable phenotype of the KO mice, since complete inactive CI is likely to 
lead to embryonic lethality. In the original article, describing these mice, no 
spectrophotometric CI activity was measured in liver, in contrast to our data 
which exhibit 20% of residual activity in this tissue. This diversity can be 
explained, as also suggested by the authors, by variances in sample 
preparation leading to different amounts of functional enzyme due to the CI 
instability, caused by the absence of NDUFS4 (18). 
Although, the published BN-PAGE analysis showed a decrease of intact CI 
in brain and liver tissues in KO mice, our high resolution poly-acrylamide 
gradient gels show absence of holo-CI (18), and a partially assembled 830 
kDa CI-subcomplex in the KO mouse tissues. This 830 kDa CI-subassembly 
cannot represent a breakdown product caused by the isolation procedure, 
because it contains assembly chaperone NDUFAF2, which is absent in the 
fully assembled CI (15). Studies on NDUFS4 patient fibroblasts revealed 
that this 830 kDa subassembly was unable to incorporate radioactive 
labelled subunits: NDUFS6, NDUFS4 and NDUFV1-V3 (12). Moreover, 
this 830 kDa subassembly is also observed in patient fibroblasts with 
mutations in subunits NDUFS6 and NDUFV1 (15, 21). These data suggest 
that the 830 kDa CI-subassembly lacks the tip of CI representing the NADH 
dehydrogenase module. Interestingly, we found a 200 kDa subassembly 
exclusively in some of the KO tissues. Since this band had NADH oxidation 
activity and contains at least the subunits NDUFV1 and V2, we deduce that 
this is likely the NADH dehydrogenase module lacking from the 830 kDa 
CI-subassembly. Although the finding of a separate NADH module has not 
been reported before, studies show import of radiolabeled NDUFV1 and V2 
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subunits in mitochondria isolated from NDUFS4 patient fibroblasts into a 
200-300 kDa CI subassembly resembling the NADH module we observe 
here (12).  
There is a discrepancy between the residual enzyme activity measured by 
the spectrophotometric assays and the lack activity of the 830 kDa 
subassembly from KO mice. The spectrophotometric assay is based on 
measuring the rotenone-sensitive DCIP reduction by electrons accepted 
from decylubiquinone. Because the electrons for the oxidation of 
decylubiquinone come from NADH in this assay, this would not be possible 
for the 830 kDa subassembly which lacks the NADH dehydrogenase 
module. In addition, a separate NADH dehydrogenase module would not be 
able to donate its electrons to decylubiquinone, since it lacks the 
ubiquinone-binding site. This suggests that binding of the NADH 
dehydrogenase module to the 830 kDa subassembly is necessary for 
spectrophotometric activity. Evidence of a loose binding of the NADH 
dehydrogenase module to the 830 KDa subassembly comes from the 
investigation of supercomplexes in the muscle tissue. Mild extraction 
conditions allowed detection of active fully assembled CI in the KO mouse 
sample, but only in association with CIII. This finding provides evidence 
that CIII helps CI stabilization. In NDUFS4 deficient patient fibroblasts, the 
amount of 830 kDa subassembly correlates with the residual CI activity in 
these cells (22). Similarly, both the amount of 830 kDa CI subassembly and 
the amount of 200 kDa subcomplex found in the mouse tissues also crudely 
correlates with spectrophotomeric residual activity observed in the different 
tissues. This suggests that all of the present 830 kDa and 200 kDa contribute 
to the formation of an instable but active CI. The instable CI likely leads to 
an increased degradation resulting in CI deficiency in the investigated 
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tissues. 
It was noteworthy that the 830-CIII2 supercomplex was also observed in 
WT and Het muscle samples. This suggests that the association of the 
NADH dehydrogenase module to the 830 kDa subassembly might occur 
after the formation of an 830 kDa-CIII2 supercomplex or that the NADH 
dehydrogenase module was lost after supercomplex formation. The presence 
of the assembly factor NDUFAF2 in the 830-CIII2 supercomplex indicates 
that this supercomplex is likely a physiological entity and not an artifact of 
the procedure. Interestingly, the presence of tiny amount of NDUFAF2 in 
CI+CIII2 supercomplexes might indicate that this assembly factor is released 
after the addition of the NADH dehydrogenase module. However, more 
research is needed to understand the precise mechanism of supercomplex 
formation. The disconnection of the electron input module from the NADH 
dehydrogenase module might represent a general mechanism of unplugging 
a possibly crippled complex from its electron influx. Reassembly of this 
module or exchange of a newly synthesized module might occur as 
suggested by Lazarou and colleagues (12), allowing a restoration of the 
complex. 
Currently, besides supportive care, no cure for mitochondrial CI deficiency 
exists. Understanding the effects of the single mutations might give clues 
for therapeutic interventions. In this case, it is clear that NDUFS4 subunit 
stabilizes the connection between the NADH hydrogenase and rest of the 
enzyme, which is aided by the formation of supercomplexes. Aside from 
providing NDUFS4 to the cells, enhancing supercomplex formation or 
increasing the amount of the NADH dehydrogenase module to further 
stabilize the complex are possible strategies to ameliorate disease due to CI 
deficiency. 
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Materials and Methods 
Animal experiments 
All animal experiments were performed with the approval of the Animal 
Care and Use Committee of the University of Nijmegen. Previously 
described mice (18) were fed with a standard animal diet (Ssniff GmbH, 
Soest, 76. Germany. V1534-300 R/M-H) and water available ad libitum in 
standard vivarium conditions with 12 hour light dark cycle at 22°C. 
 
Isolation of mitochondria from mouse tissues 
After sacrificing the animals, tissues were prepared and put on ice in 
mitochondrial isolation buffer [100 mM sucrose, 50 mM KCl, 20 mM TES 
(pH=7.2), 1 mM EDTA] with 0.2 % BSA. The tissues were minced with a 
Sorvall TC2 tissue chopper, homogenized using a glass/Teflon Potter-
Elvehjem homogenizer (1800 rpm in melting ice), in mitochondrial isolation 
buffer with 0.2% BSA and nagarse (1 mg per 1 g of tissue). Next they were 
centrifuged at 14000g for 10 minutes at 4 °C. The resulting supernatant, 
with floating fat and nagarse, was discarded and the pellet was resuspended 
in mitochondrial isolation buffer with 0.2% BSA, by hand homogenization. 
The homogenates were freed from cells debris and nuclei by centrifugation 
at 600g for 10 minutes at 4 °C. The resulting supernatant was centrifuged at 
14000g for 10 minutes at 4 °C. The pellet was resuspended in mitochondrial 
isolation buffer with 1mM mix inhibitor (GE Healthcare), 1 mM 
Phenymethanesulfonyl (Sigma) and re-centrifuged at 14000g for 10 minutes 
at 4°C. The resulting pellet was resuspended in 100-200 μl mito buffer with 
mix inhibitor and divided in different aliquots of 10-25 μl each for further 
analysis and stored at -80°C. The protein amount was measured using micro 
BCA protein assay kit, (Pierce). 
141 
 
Spectrophotometric assay 
The complex I, II, III, IV, and V activities was measured 
spectrophotometrically in mitochondria isolated from fresh mouse tissues as 
described (23). 
 
Blue native PAGE and two dimensional electrophoresis 
Blue Native electrophoresis (BN-PAGE), 2D gel electrophoresis, complex I 
In-Gel-Activity assays and Western blotting were performed as previously 
described (24). 
 
Supercomplexes analysis 
The frozen mitochondria pellet isolated form tissues were solubilized in 
digitonin by resuspending in 30 mM HEPES, pH=7.4, 150 mM K-acetate, 
10% (w/v) glycerol, 1 mM PMSF, 1% (w/v) digitonin and incubated on ice 
for 30 minutes. The samples were centrifugated for 2 min at 600g. Before 
loading sample buffer (5% Serva G Blue in 750 mM 6 Aminocaproic acid) 
were added in ratio 1:20 to the samples (4, 25).  
 
Immunodetection and Antibodies 
Protein immunodetection was performed using the following primary 
antibodies: NDUFAF2 (B17.2L) (gift from Professor M. Tsuneoka, 
Kurume, Japan), SDHA, COXVA, alpha-ATPase (Mito Sciences), 
NDUFS4, NDUFA9, NDUFS3, CORE 2 (Invitrogen), NDUFV2 (Sigma 
Aldrich). The secondary antibodies used were: peroxidase conjugated anti-
mouse or anti-rabbit IgGs (Invitrogen). The signal was generated using 
ECL® plus (Amersham Biosciences). 
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Abstract 
NADH:ubiquinone oxidoreductase or complex I (CI) is the most frequently 
affected enzyme causing a mitochondrial disorder. CI is a key player in the 
oxidative phosphorylation system, as it is involved in the regulation of the 
cellular redox state and ATP production. Defects in CI have severe cellular 
consequences. Currently, for patients harboring mitochondrial disorders, 
including CI isolated deficiency, no treatment, besides supportive care, can 
be offered.  
In this study, we analyzed Mouse Embryonic Fibroblasts (MEFs) isolated 
from NDUFS4 Knock-Out and Wild-Type mice. Defect in this accessory 
protein causes CI instability leading to the release of NADH dehydrogenase 
module from the enzyme. Here we show that supplementation with the 
flavinmononucleotide (FMN) precursor, riboflavin, increases the stability of 
the NADH dehydrogenase module, that in turn, enhances CI activity in the 
NDUFS4-depleted cells. These results provide a rationale for possible 
therapeutic approaches for CI deficiency caused by NADH dehydrogenase 
module alterations.  
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Introduction 
Defects in mitochondrial complex I (CI) are the most widespread cause for 
inherited mitochondrial disorders. They are usually progressive, multi-
systemic and often lead to early death. Most commonly, tissues with a high 
energy demand are affected such as brain and skeletal muscle. To date there 
is no cure available.  
CI is the first and largest enzyme of the respiratory chain. It contains 45 
subunits, 7 of which are encoded by the mitochondrial genome and the 
remaining by the nuclear DNA. Fourteen subunits are called core subunits, 
conserved during the evolution, and necessary for the catalytic activity of 
CI, namely to couple the electron transfer to proton translocation across the 
mitochondrial inner membrane. The remaining 31 proteins are called 
accessory or ancillary subunits, which have unknown functions and are not 
directly involved in the enzymatic activity. It has been suggested that these 
subunits are necessary to stabilize CI, to prevent the reactive-oxygen species 
(ROS) generation, to regulate the enzyme activity or to protect the complex 
from oxidative damage. Nevertheless, it is clear that the accessory subunits 
are fundamental for the correct CI assembly and function (1-4).  
The assembly of CI is an intricate processes that it is complicated by the 
size of the enzyme, the dual genomic control and the incorporation of 
different prosthetic groups. Moreover, several proteins, which are not part of 
the holo-complex, are required to assist CI during its assembly pathway, 
called assembly chaperones. It is currently accepted that CI assembly occurs 
through several steps, in which different subcomplexes are assembled 
independently to each other and then they are joined together to form the 
holo-complex (5-8).  
In the mitochondrial inner membrane, CI is not independently dispersed but 
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it interacts physically with other respiratory complexes, namely complex III 
(CIII) and complex IV (CIV), to form a supramolecular organization, called 
supercomplexes. Supercomplexes are considered the “real functional 
respiratory unit” (9-11). They may reduce the distance between the electron 
transfer units thus increasing electron transfer and proton translocation. 
Moreover, in such organization the ROS overproduction might be limited. 
Finally, it is now clear that, besides their functional role, supercomplexes 
have a structural role, as in the absence of CIII or CIV, CI is less stable (12, 
13).  
Pathogenic mutations have been found in mitochondrial and nuclear 
encoded structural subunits as well as CI assembly factors (14, 15). 
Different mutantions have been found in the gene encoding accessory 
NDUFS4 protein (4, 16-25). Patients bearing mutations in this gene show a 
severe clinical phenotype, and death often occurs in the first two years after 
birth. In 2008, Kruse and co-workers generated a NDUFS4 Knock-Out 
(KO) mouse, resembling the clinical phenotype of the patients (26). CI-
analysis in NDUFS4 KO-mouse tissues showed that the enzyme was 
unstable, resulting in a dissociation of the part representing the NADH-
dehydrogenase module. However, holo-CI could be partially stabilized by 
the association of CIII (27). The NADH-dehydrogenase module is 
responsible for the NADH oxidation by the prostetic group 
flavinmononucleotide (FMN). FMN is an essential cofactor for many 
dehydrogenases and its binding increases the stability of the protein. In CI, 
FMN is bound to subunit NDUFV1, forming, together with NDUFV2 and 
NDUFV3 subunits, the NADH dehydrogenase module.  
We anticipated that increasing the amount of this cofactor, might have a 
stabilizing effect on the NDUFV1 subunit and in turn on the NADH 
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dehydrogenase module, which, at the end, could enhance the binding of this 
part to CI and therefore increase its activity. Given that a deletion of the 
NDUFS4 subunit does not completely abolish the CI enzyme activity, this 
suggests that the fully assembled active enzyme can still be made. 
Increasing the CI-activity might be sufficient to reduce the clinical 
symptoms of the patients.   
To test this hypothesis we derived Mouse-Embryonic-Fibroblasts (MEFs) 
from the KO and Wild-type (Wt) mice and treated these cell lines with 
riboflavin (vitamin B2), precursor of FMN. We observed that the CI activity 
in the KO-MEFs increased significantly and this was accompanied by a 
raised stability of the NADH-dehydrogenase module. Since many years, the 
deficiency of a flavoenzyme is treated with administration of riboflavin; 
however, so far, the positive effect of this treatment is limited to the 
description of the clinic benefits in patients (28-42). Our results provide a 
rationale for therapy and might explain why this therapy might work only in 
a restricted set of CI deficiencies.  
 
Results 
The complex I assembly defect in MEFKO resembles the defect in KO 
mouse tissues 
To explore therapeutic approaches we generated MEFs from Wt (MEFWt) 
and NDUFS4 KO (MEFKO) mouse embryos. These cell lines allow to 
modulate culture conditions, permit genetic manipulations and facilitate 
biochemical analysis to address therapeutic approaches. 
Spectrophotometric analysis of complex II, III, IV and V  (CII, CIII. CIV 
and CV) enzymatic activities showed similar values in the MEFKO 
compared with the MEFWT; in contrast, CI enzymatic activity in MEFKO 
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showed a decrease of 77% compare to the control (Table 1). These values 
are within the range observed in mouse tissues (27).  
Table 1. Spectrophotometric activities 
   
  Wt KO 
NADH-ubiquinone oxidoreductase (CI)a 94,5 ± 8 25,3 ± 18 
NADH-ubiquinone oxidoreductase (CI)b 50,4 ± 4 11,5 ± 8 
Succinate dehydrogenase (CII)b 122,9 ± 15 92,1 ± 18 
Ubiquinol-cytochrome c oxidoreductase (CIII)b 408,9 ± 30 315,8 ± 35 
Cytochrome c oxidase (CIV)b 533,1 ± 3 467,5 ± 93 
ATP synthase (CV)b 80,7 ± 6 99,5 ± 59 
a mU/U CIV 
b mU/mg protein 
 
To investigate how CI assembly is impaired in the MEFKO cells, we 
performed blue native gel electrophoresis (BN-PAGE) combined with 
western blotting or CI-In-Gel-Activity (IGA) assay. In the MEFKO the 
absence of holo-CI and accumulation of 830kDa sub-complex were 
observed (Fig. 1A). Normal expression levels in both MEFKO and MEFWT 
cells were detected for complex II, complex III, complex IV and complex V 
(Fig 1A), which is consistent with their measured enzymatic activities and 
comparable with the data obtained for mouse tissues (27). 
BN-PAGE was processed for IGA (Fig. 1B) showing the absence of CI-
activity band (CI-IGA) in the MEFKO sample. An “extra” band of ~200kDa 
was present in the MEFKO and absent in the MEFWt (Fig. 1B, indicated with 
an arrow). In order to verify that this band corresponds to the NADH 
dehydrogenase module, as shown previously (27), we performed western 
blot analysis using an NDUFV1 antibody, a component of NADH 
dehydrogenase module. The immunoreactivity for NDUFV1 antibody was 
present in the MEFWt at ~1MDa (holo-CI), whereas, in the MEFKO it was 
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present at ~200kDa (Fig. 1C). The “extra” band appearing in IGA and 
detected with anti-NDUFV1 incubation shows the same molecular weight. 
To investigate whether the loose NADH dehydrogenase module could be 
stabilized in the supercomplexes organization (CI+CIII2), as observed in 
mouse tissues, we performed supercomplex analysis on these cells, as 
shown in Fig. 1D-E-F. 
The cell pellets were treated with a high concentration of the mild detergent 
digitonin, in order to preserve the supercomplex interactions. The samples 
were run under native condition and the gels were further processed for IGA 
and western blot (Fig. 1D and 1E). The IGA shows for MEFWt a band 
corresponding to monomeric CI (indicated with I) and a band corresponding 
to CI-CIII2 (indicated with I-III). The MEF
KO sample did not show any 
NADH oxidation activity. A duplicate gel was processed for western blot 
and incubated with CI-NDUFA9 and CIII-CORE2 antibodies (Fig. 1E). In 
the MEFWt the band at the bottom corresponds to CIII2 (indicated with III), 
above this band monomeric CI (indicated with I) and supercomplex CI-CIII2 
(indicated with I-III) could be detected. In the MEFKO, signals representing 
a CI-subcomplex of 830kDa (indicated with 830), an 830kDa CI-CIII2 
supercomplex and a supercomplex formed by CI-CIII2 (indicated with 830-
III and I-III, respectively) were observed. In order to further confirm that in 
the MEFKO a fully assembled CI is present upon interaction with CIII2, we 
performed a second dimension BN/SDS-PAGE (2D BN/SDS-PAGE) 
analysis.  
The blot was incubated with antibody against NDUFV2 subunit, which is 
part of the NADH dehydrogenase module and hence is not present in the 
830 kDa subassembly (Fig. 1F).  
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Figure 1: BN-PAGE analysis of mitochondrial complexes and supercomplexes in MEFWT 
and MEFKO. A. The western blot analyses were performed using antibodies against CI 
subunit (NDUFA9), CV subunit (α-ATPase), CIII subunit (CORE2), CIV subunit 
(COXVA), CII subunit (SDHA) subassembly of 830 kDa is indicated with 830. B. A 
parallel gel was processed for the CI In-Gel-Activity assay. The 200 kDa band in the 
MEFKO is indicated with an arrow. C. Western blot incubation with NDUFV1 antibody 
showed in MEFKO accumulation of this subunit in the 200 kDa sub-complex, indicated with 
an arrow. D. Supercomplexes from MEFWt and MEFKO resolved by BN-PAGE were 
processed for IGA. In the MEFWt lane two bands are present: I=CI monomer; I-III=CI-
CIII2. No bands are visible in the MEF
KO lane. E. A parallel gel run followed by western 
blot was incubated with antibodies against CI-NDUFA9 and CIII-CORE2. In the MEFWt 
lane: III= CIII2; I=CI monomeric; I-III= CI-CIII2. In the MEF
KO are visible: 830=830 kDa 
CI subassembly; 830-III= supercomplexes formed by CI-830kDa and CIII2. Furthermore, a 
fully assembled CI is present in MEFKO indicated with an arrow. F. A third gel was run in 
parallel and it was processed for a second dimension. The western blots were incubated 
with antibodies against CI-NDUFV2 and CI-NDUFS3, confirming the present of holo-CI in 
the MEFKO, stabilized by CIII. 
 
158 
 
In the MEFKO, immunoreactivity for this antibody was present in the 
supercomplexes (indicated with I-III), in a sub-complex of ~200kDa 
(indicated with “a”), and in the monomeric form (indicated with “m”). 
Thus, the MEFs give a similar biochemical and molecular defect as 
previoulsy described in mouse tissues (27) and they are therefore suitable 
for further testing.  
 
Re-expression of NDUFS4 in MEFKO 
To establish that the observed defects are essentialy due to the absence of 
the NDUFS4 subunit, we expressed the accessory protein in the MEFKO 
cells using a retroviral system. BN-PAGE analysis demonstrated that re-
instertion of Wild-type NDUFS4 in MEFKO cells (R+S4) leads to a 
restoration of CI-IGA and CI stability in contrast to untreated (UT) or empty 
vector (R-S4) treated cells (Figure 2A). In a similar way, 2D BN/SDS-
PAGE analysis shows that the 830kDa (Fig. 2B, top panel) and the 200kDa 
subassemblies both shift to a fully assembled CI in NDUFS4 transduced 
MEFKO cells (Fig. 2B bottom panel).  
 
Riboflavin treatment of MEFs 
In MEFKO the absence of the NDUFS4 subunit, causes the destabilization of 
the NADH dehydrogease module, which contains the FMN group bound to 
the NDUFV1 subunit. In order to increase the stability of this module we 
hypothesized that supplementation with riboflavin, an FMN-precursor, 
might be beneficial for the MEFKO. We therefore cultured the MEFWT and 
MEFKO for one week in the presence and absence of riboflavin. 
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Figure 2. Retroviral re-expression of NDUFS4. A. WT, KO untreated MEF (UT), and KO 
treated with retrovirus with or without  NDUFS4 gene construct (R+S4 and R-S4, 
respectively) were run on BN and processed for in-gel-activity (CI-IGA) or western 
blotting using a CI antibody (CI-NDUFA9) and CII antibody (CII-SDHA). B. A parallel 
gel was processed for 2D analysis. The membranes were incubated with CI-NDUFS3 and –
NDUFV2 antibodies. I indicates fully assembled CI; 830 represents the CI subassembly 
830 kDa and “a” indicates the 200 kDa subassembly.  
 
Mitochondria from these cells were isolated and analyzed for activity and 
expression levels of the different CI-subunits and subassemblies. The 
spectrophotometric activities, demonstrated a significant increase of CI 
activity in the riboflavin treated MEFKO cells compared with the untreated 
cells (Fig. 3A). No differences in the activities of the other respiratory chain 
enzymes were observed (Fig. 3B). 
This shows that, in this case when the CI activity is severely impaired, the 
riboflavin treatment is able to improve the electron transfer from the NADH 
to ubiquinone in NDUFS4-depleted cells. To investigate whether this 
increase in activity is accompanied by an enhanced stability of the NADH-
dehydrogenase part, BN-PAGE in combination IGA and western blot-
analysis, were performed. Incubation with specific antibodies did not show 
any difference in amount of holo-CI, 830 kDa subassembly and complex II, 
III, IV and V in treated MEFWT or MEFKO cells when compared with 
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untreated ones (Fig. 4A). 
 
Figure 3. Spectrophotometric activity in riboflavin treatment. A. CI activity is normalized 
to CIV (mU/U C.IV) and expressed as percentage of the MEFWt untreated. Data are the 
mean of three independent experiment, (*p˂0,05, tTest). B. Spectrophotometric activity 
values of the other respiratory complexes are not affected by riboflavin treated in both 
MEFWt and MEFKO. 
 
Also, IGA did not show any differences for holo-CI in the treated versus 
untreated cells (Fig. 4B). However, when the western blot was incubated 
with anti-NDUFV1, that allows the detection of the NADH- dehydrogenase 
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module, a clear increase of the 200kDa module, in the treated MEFKO cells 
compared with untreated cells, was observed (Fig. 4C). The increasing 
expression levels of the NADH-dehydrogenase module is consistent with 
the enhanced expression of the NDUFV1 and NDUFV2 subunits, as shown 
on SDS-PAGE western blot (Fig. 4D).  
 
 
Figure 4: Riboflavin treatment. A. Western blot of BN-PAGE incubated with antibodies 
against CI subunit (NDUFA9), CV subunit (α-ATPase), CIII subunit (CORE2), CIV 
subunit (COXVA), CII subunit (SDHA). B. A parallel gel processed for CI IGA assay. C. 
BN-PAGE western blot incubated with CI NADH-dehydrogenase part specific antibody 
(NDUFV1), showing a 200 kDa band in the MEFKO. D. Expression levels of CI NADH 
dehydrogenase subunits NDUFV1 and NDUFV2 were analyzed on SDS-PAGE followed 
by western blot and incubated with antibody against CI subunits (NDUFV1-NDUFV2) and 
as a loading control CII subunit (SDHA).  
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Discussion 
Mitochondrial CI defects lead to dramatic disorders with poor prognosis and 
no available therapy. It is therefore vital for patients that treatments, which 
can slow down or even stop disease progression, will come into reach. In 
this study, we propose a treatment strategy based on our previous findings 
of the CI dysfunction molecular consequences caused by the absence of 
NDUFS4 subunit. This small accessory subunit is assembled late in the CI 
assembly pathway, and it was found to be crucial for the stable association 
of the NADH dehydrogenase with the hydrogenase module. In mouse 
tissues, it was shown that even in the absence of this subunit fully 
assembled CI could still exist but only when it was associated with CIII. We 
inferred that a possible treatment strategy for this CI defect could be to 
stabilize the enzyme or its intermediates. We explored the possibility to 
stabilize the NADH dehydrogenase part to increase the CI stability/activity, 
by supplementing the FMN-precursor riboflavin. The NADH 
dehydrogenase module contains the NDUFV1 subunit that it is a 
flavoprotein, containing an FMN group. Flavoproteins contain flavins, FMN 
or FAD as a prostetic group and are involved in a wide range of more than 
300 biochemical reactions like fatty acid oxidation, mitochondrial electron 
transport and tricarboxylic acid cycle. For many years, riboflavin has been 
used to treat patient with deficiency in different mitochondrial flavoenzymes 
(43). In patients with multiple Acyl-CoA dehydrogenase deficiency 
(riboflavin-responsive MADD) characterized by a reduced activity, 
riboflavin treatment is often beneficial likely due to the stabilizing effect of 
the cofactor on the affected flavin-dependent acyl-CoA dehydrogenases. 
Some CII deficient patients have been reported to benefit from riboflavin 
treatment and showed an increased CII activity and an improved clinical 
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condition (44). Nevertheless, no increase of the expression of the FAD-
containing CII subunit SDHA has been found. It was also recently reported 
that in fibroblasts of patient with mitochondrial encephalomyopaty, caused 
by the FAD containing protein AIF, riboflavin supplementation was 
associated with an improvement in the neurological condition, as well as 
correction of the respiratory chain defects (29). The idea to treat deficiency 
of the enzymes containing flavin, such as CI, with riboflavin has emerged 
already a long time ago, but reports of positive effects are scarce. In 1995 
successful treatment of a CI deficient patient was reported. However, this 
patient appeared to have a mutation in the FAD-containing assembly 
chaperone ACAD9 and the positive effect was attributed to the increased 
stability of chaperone instead of CI itself (38).  
In this study, we provide a rationale for the riboflavin treatment in CI 
deficiency cells, which might also explain why riboflavin is only effective 
in a part of the cases. In the situation of NDUFS4 deletion, a dissociation of 
the FMN-containing NADH dehydrogenase module from CI occurs and 
therefore stabilization of this module enhances its possibility to remain 
bound or to rebind again with CI. Interestingly, the binding of the NADH-
dehydrogenase module is suggested to occur late in the CI assembly 
pathway, even after the formation of supercomplexes (45). Moreover, since 
the exchange of pre-existing subunits with newly imported ones in CI has 
been reported (3) it is well possible that the NADH-dehydrogenase module 
can be replaced or rebound to the almost complete 830 kDa CI subassembly. 
The release of the NADH-dehydrogenase module has also been reported in 
patients with mutations in NDUFS6 and NDUFV1 and therefore riboflavin 
treatment might be tried in these cases as well. However, if a CI deficiency 
is caused by mutations which affect early steps in CI assembly, there will be 
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no scaffold for the NADH-dehydrogenase binding and riboflavin will likely 
not be effective in such cases. These early assembly proteins include: 
NDUF-S2, -S3, -S7, -S8, -A1, -AF1, -AF3, -AF4, -AF5, -AF6, FOXRED 
and NUBPL. This illustrates that it is unlikely to find a unique therapy to 
cure all mitochondrial CI deficiencies and mutations in different genes may 
have diverse outcomes and require different therapies–personalized 
medicine. Understanding the effects of the single mutation on CI assembly 
and biochemical consequences might give clues for therapeutic 
interventions.  
Although we observed only a partial restoration of the CI activity, this effect 
might still be sufficient to alleviate the clinical symptoms of patients. It is 
therefore of crucial importance to test this approach in the controlled 
situation of a whole organism such as the already available NDUFS4 
deficient mice. This study provides a proof of principle for a rationale for a 
CI deficiency possible therapy based on the biochemical consequences of 
this particular mutation on CI alteration. In the future therapy is likely to 
involve a combination of treatments, which will depend on the nature of the 
mutation which causes the diseases. However, this will only be possible 
after proper understanding of the molecular consequences of the mutation. 
 
Materials and methods 
Cell cultures  
Mouse embryonic fibroblasts (MEFs) were cultured in DMEM (Gibco, 
10938), 2 mM L-glutamine (Gibco), 1 mM Sodium Pyruvate (Sigma) , 
1ml/l gentamycine (Gibco), 10% FCS and 1% Pen/Strept (Gibco). 
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NDUFS4 retrovirus 
Retroviral complementation of MEF was performed as described previously 
(46).  
 
Riboflavin treatment  
Cells were cultured in DMEM (Gibco, 10938), containing 10% FCS (PAA), 
Gentamycine (Gibco), 1% Pen/Strep(Gibco), 2mM L-glutamine, 1mM 
Sodium Pyruvate (Sigma) and 1 μg/ml riboflavin (Sigma), for 1 week and 
the medium was refreshed every two days. 
The cells were harvested with trypsine and used for spectrophotometric 
activity and the BN-PAGE (see BN-PAGE cells preparation for the samples 
processing). 
 
BN-PAGE cell preparation 
The mitochondria-enriched fraction used for the BN-PAGE was performed 
as previously described (47). Briefly, five million of cells were harvested 
using trypsine and the cell pellet was suspended in ice-cold PBS 
supplemented with digitonin at a concentration of 2mg/ml. After 10 minutes 
on ice, 1 ml cold PBS was added and cells were centrifuged at 14000g at 4 
°C for 10 minutes. The pellet was washed twice with cold PBS and 
centrifuged at 14000g for 5 minutes at 4°C. The protein amount was 
measured using micro BCA protein assay kit, Pierce. 
 
1D SDS, BN-PAGE and 2DBN/SDS-PAGE 
Blue-native gels (BN-PAGE) (5-15%) were cast as described in and run 40-
80 μg of solubilized mitochondria proteins. After electrophoresis, the gels 
were further processed for In-Gel-Activity (IGA) assay, western blotting for 
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1D 10% SDS-PAGE or 1D BN-PAGE or second dimensional 10% SDS-
PAGE as described in (47). Proteins were transferred to a PROTAN®  
nitrocellulose membrane (Schleicher & Schuell). 
 
Supercomplex analysis 
The frozen mitochondria pellet isolated from cell as described in BN-PAGE 
cell preparation were solubilized in digitonin by resuspending in 30 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH=7.4, 150 mM K-
acetate, 10% (w/v) glycerol, 1 mM phenylmethanesulfonylfluoride, 1% 
(w/v) digitonin and incubated on ice for 30 min. The samples were 
centrifuged for 2 min at 600g. Before loading the sample, buffer (5% Serva 
G Blue in 750 mM 6Aminocaproic acid) was added in the ratio of 1:20 to 
the samples (26). 
On BN-PAGE (3-15% gradient gel) were loaded 80 μg proteins. Gel were 
further processed for IGA, western blotting or for second dimensional 10% 
SDS-PAGE. 
 
Immunodetection and Antibodies 
Protein immunodetection was performed using the following primary 
antibodies: B17.2L (Professor M. Tsuneoka, Kurume, Japan), SDHA (Mito 
Science), Core 2 (Invitrogen), COXVA (Mito Sciences), NDUFS4 
(Invitrogen), NDUFV1 (Sigma Aldrich), NDUFV2 (Sigma Aldrich), alpha-
ATPase (Mito Sciences), NDUFA9 (Invitrogen). Secondary antibodies used 
were; peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Invitrogen). 
The signal was generated using ECL® plus (Amersham Biosciences). 
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Spectrophotometric assay 
The complex I , II, III, IV and V activities were measured 
spectrophometrically in mitochondria isolated from frozen pellets as 
described previously (48,49) and expressed relative to milligram protein. 
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1. Introduction 
Mitochondrial complex I (CI) is the electron entry point of the oxidative 
phosphorylation system (OXPHOS) (1). It couples NADH oxidation with 
proton translocation from the mitochondrial matrix to the inter-membrane 
space, generating an electrochemical gradient across this membrane. This 
proton gradient is used by complex V to drive mitochondrial ATP synthesis.  
ATP is the free energy currency of the cell, necessary for all cellular 
processes. Thus, defects in the production of this essential compound are 
deleterious for the cellular survival. Defects in OXPHOS enzymes occur 
with an estimated incidence of 1 per 5,000 live births, and isolated CI 
deficiency (OMIM 252010) is one of those frequently encountered (2). CI 
dysfunction is associated with the pathogenesis in a broad spectrum of 
disorders ranging from inherited metabolic disorders to cancer, Parkinson’s 
disease and ageing (3-5). These disorders particularly affect organs and 
tissues with a high energy demand, such as brain, heart and skeletal muscle, 
often leading to progressive metabolic disorders with a fatal outcome. In 
these disorders the genotype-phenotype correlation is generally variable, 
since the same mutation may cause different clinical manifestations and, 
conversely, distinct mutations may result in similar clinical outcomes (2). 
CI is one of the most complex enzymes in human cells. It contains 45 
subunits and 8 prosthetic groups and has a molecular weight of almost 1 
MDa. Why do we require such a complex enzyme to catalyze the apparent 
simple chemical reaction: 
 
NADH + H+ + Q + Hin
+  => NAD+ + QH2 + 4Hout
+ 
 
This is remarkable when we take into account that in bacteria this reaction 
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only needs 14 subunits. Thus, why has mammalian CI increased its 
complexity by acquiring 31 additional subunits? Are these additional 
subunits required to regulate catalytic activity, assembly and stability of the 
enzyme or to link CI with other metabolic pathways? At present we cannot 
provide clear answers to these questions. Nevertheless, solving these issues 
will certainly provide essential clues to understand the difference in the 
clinical effects and are a prerequisite to design therapy. 
In this concluding chapter, I will illustrate the complexity of the enzyme and 
the recent progression in understanding of this complex by giving an 
historical overview of CI research. In addition, I will discuss aspects which 
are important in the light of the data presented in this thesis, focusing on a 
whole organism model, supercomplexes and possible patient therapy.  
 
1.1 Complex I: an historical overview 
Mitochondria are known for over a century and have become an important 
subject of research. They were first described as a ubiquitous elementary 
organism living inside the cell, carrying out vital function and called 
“bioplast” (6). Early in the 1900, it was recognized that these organelles 
were involved in cell respiration and they were able to perform biological 
oxidation (7-9). It was only 40 years later that it was described that 
mitochondria contain two membranes, the OXPHOS and Krebs cycle 
enzymes. A few years later it was suggested that the respiratory enzymes are 
localized in the mitochondrial inner membrane (10).  
Pioneering work of Hatefi and coworkers, in the late 1960s, led to the 
identification of the different enzymes of the OXPHOS system (11). By 
systematic extraction of large amounts of bovine heart mitochondria, they 
were able to isolate the different complexes, including CI (12). It was found 
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that CI consisted of multiple peptides, contained flavin, iron, acid labile 
sulfide and required the presence of lipids for stabilization. Later, the same 
group was able to fractionate the enzyme in three functional modules, a 
flavoprotein, a hydrogenase and a membrane part and estimated that the 
total number of CI subunits ranged from more than 10 to 25 (13). The 
completion of the sequence analysis of the mitochondrial genome led to the 
assignment of the seven mitochondrial encoded CI-subunits (14), in 1986, 
and it took another 20 years until the present number of 38 nuclear encoded 
subunits was set (15). Whether this is the final number is not clear yet.  
After more than half a century of research, the enzymatic reaction and 
composition of CI had been established. Nevertheless how this enzyme 
works, how it is made and how it plays a role in disease was still illusive. It 
was only in the last decade when answers to these questions emerged. One 
of the big questions on CI function was how the electron transfer is coupled 
to the proton translocation. Was this a substrate driven translocation like in 
CIII, a redox driven translocation like CIV, a conformational driven 
translocation like CV or was there another coupling mechanism operational? 
Answers to these questions came from high resolution elucidation of the 
structure of this complex. The structure of the Thermus thermophilius 
hydrophilic arm of the complex established the path of the electron transfer 
from NADH, via FMN through the different iron sulphur clusters, to 
ubiquinone (16). High resolution analysis of the hydrophilic membrane arm 
of Escherichia coli and the entire enzyme of T. thermophilius resolved the 
coupling mechanism (17). It became clear that the proton translocation was 
driven by conformational changes induced by the electron transfer. This 
translocation was driven by a piston (amphiphatic helix spanning almost the 
entire length of the membrane domain) operating the proton channels 
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through conformational changes. 
In 1988 the first mitochondrial DNA complex I subunit mutation associated 
with disease was described (18). This appeared to be a point mutation in the 
subunit ND4 and was associated with Leber’s hereditary optic neuropathy. 
Ten years later the first disease causing mutation in the gene encoding the 
nuclear CI subunit NDUFS4 was found (19).  
The question of how mammalian CI is assembled was only addressed in the 
last decade. What is the order of assembly of the subunits, whether 
chaperones are required and how it is regulated are questions which started 
to be answered during the last few years. The first assembly studies of the 
mammalian CI assembly pathway were done in cell lines by comparing 
subassembly profiles of patients bearing different mutations in genes 
encoding structural subunits (20-23). Another study, at this time, monitored 
subcomplex formation of newly synthesized CI subunits after complex 
depletion by blocking mtDNA translation using doxycycline (22, 24). 
Although models from these studies differed in some details, they agreed 
that CI assembly is a process in which some subunits are preassembled and 
subsequently the precomplexes are joined together to form the fully 
assembled complex. Further studies along these lines analyzed the 
incorporation of GFP-tagged NDUFS3 within intermediated subcomplexes, 
before maturation into CI (25) or monitored the assembly of newly imported 
radiolabeled nDNA-encoded subunits into isolated mitochondria (26). 
Finally, the most recent studies on CI assembly indentified five entry points 
of the mtDNA-encoded subunits by generating mouse cells Knock-Out for 
ND4, ND6 or ND5/ND6 (27). In summary, these studies pointed out that CI 
follows a modular assembly in which the distinct functional parts being the 
NADH-dehydrogenase, the hydrogenase and membrane part (see also 
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chapter 2) and that there are crucial rate limiting steps in this process.   
Beside the study of the subassembly profiles formed by the structural 
subunits, several chaperones were discovered to be involved in different 
steps of CI assembly (28). Initially, assembly chaperones were found in 
Neurospora crassa, namely CIA84 and CIA30 (29) and the first human 
chaperone was an orthologue of CIA30 named NDUFAF1 (30-32). In the 
same year, the second assembly chaperone, NDUFAF2, was described (33). 
Several approaches have been applied in order to find more CI chaperones. 
These approaches led to the discovery of new CI chaperones, such as 
NDUFAF3, NDUFAF4, ACAD9, EXCIT, C8orf38, C20orf7, Ind1 and 
MidA (31, 32, 34-36). Although the number of known CI-chaperones is 
rapidly increasing their molecular mechanism in the CI assembly process is 
still unclear.  
A heavily debated issue of the complicated assembly pathway was the 
organization of the respiratory complexes in the mitochondrial inner 
membrane. Initially, it was suggested that the OXPHOS complexes are 
organized in rigid supramolecular structure, the “solid state” model (37). 
Conversely, in 1986 this theory was questioned by Hackenbrock who 
proposed a new theory for the OXPHOS organization, the “random 
collision” model. He suggested that the complexes are individually 
dispersed in the mitochondrial inner membrane and functionally connected 
by the random collision of small electron carriers (cytochrome c and 
ubiquinone) (38). However, in the early 2000s Schägger and coworkers 
published a breakthrough article in which they demonstrated the existence 
of supercomplexes and introduced the concept of “respirosome” to define 
the supramolecular organization of the respiratory chain complexes (39). 
This idea is now widely accepted and suggests that CI physiologically 
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interacts with a dimer of CIII and different copies of CIV to form a structure 
that may represent the “real respiratory unit” (39). Further evidence for this 
concept came from the group of Enriquez who demonstrated the ability of 
these supercomplexes (CI+CIII+CIV) to respire by using Clarke-type 
oxygen electron (40). The same authors suggested also the presence of 
supercomplexes containing, besides CI+CIII+CIV, also CII and CV and 
proposed that supercomplexes are a highly dynamic organization, the so 
called “plasticity” model (40). 
After 70 years since the OXPHOS discovery and 50 years since CI isolation, 
we now know that CI has an “L-shaped” structure, 45 subunits, a molecular 
size of 980 kDa and that it physically interacts with other respiratory 
complexes, but we are far from fully understanding the function of its 
accessory subunits, and which and how many chaperones are involved in its 
assembly pathway, its role in different metabolic pathways and the role of 
the supercomplexes.  
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Table 1. Historical table of principal discoveries in mitochondria and complex I. 
1890 Description of “bioplast, a cytoplasmic structure of  
ubiquitous occurrence resembling bacteria and 
functioning 
 as “elementary organism” 
(6) 
1948-
1951 
Mitochondria contain the enzymes of the citric acid cycle 
and oxidative phosphorylation 
(41) 
1955 Respiratory complexes are present in a well organized 
supramolecular structure, “solid state” model 
(37) 
1961 Isolation of complex I from bovine heart (11) 
1986 Identification of all mitochondrial encoded complex I 
subunits  
(14) 
1986 Respiratory complexes are individually dispersed in the 
mitochondrial membrane, “random collision” model 
(38) 
1988 First disease associated mitochondrial complex I subunit 
mutation 
(18) 
1989 First study on complex I assembly in Neurospora Crassa (42)  
1998 First disease causing mutation in nuclear encoded 
complex I subunit 
(19) 
1998 Discovery of two chaperones of complex I in Neurospora 
crassa 
(29) 
2001-
2003 
First study on complex I assembly using patient cell lines (20,23) 
 
2004 Study on complex I assembly following in time the 
releasing of the mitochondrial translation blocked by 
doxycycline 
(22) 
2005 Description of the first assembly factor for complex I, 
NDUFAF1 
(31) 
2005 First disease causing mutation in complex I assembly 
factor 
(33) 
2006 ”Final” number of 45 complex I subunits established (15) 
2006 Crystal structure of hydrophilic domain of complex I 
from Thermus thermophilus 
(16) 
2007 Study on complex I assembly using BN-PAGE and 
radioactivity labeling of some subunits 
(26) 
2007 Study on complex I assembly using an inducible cell lines 
expressing monomeric Green Fluorescent Protein (GFP) 
(25) 
2010 First complex I mouse model, resembling the human 
pathology 
(43) 
2008 Respiratory complexes are an highly dynamic 
organization, “Plasticity” model 
(44) 
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2008-
2009 
New complex I assembly chaperones: C20orf7, C8orf38, 
NDUFAF3 and NDUFAF4. 
(34,36,45,46)  
2010 Study of the incorporation of the mitochondrially encoded 
structural subunits in complex I assembly 
(27) 
2010 Structural basis for conformational coupling between 
electron transfer and proton translocation in complex I 
(47) 
2010 Discovery of complex I assembly chaperones: FOXRED1 
and NUBPL 
(48) 
2011 Structure of complex I membrane domain in Escherichia 
coli  
(17) 
2011 Description of ACAD9 as a complex I assembly 
chaperones 
(35) 
2012 Complex I assembly is assisted by complex III (49, 50) 
18
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2. NDUFS4 deficient mice, a model for complex I deficiency  
At present, the most suitable system to study the molecular mechanism of 
CI disorders are the generation of mouse models which resemble the human 
pathology. The first mouse model for CI deficiency was the harlequin 
mouse. This mouse had a CI deficiency caused by mutations in apoptosis 
inducing factor (AIF). Although the phenotype of this mouse was 
comparable with the clinical effects found in isolated CI deficiencies, later 
studies in patients with AIF mutations clearly indicated that CI was certainly 
not the only enzyme affected by these mutations (51). This result therefore 
raised the question whether the CI deficiency was a secondary consequence 
of this mutation, making it questionable whether the phenotypes observed 
were solely caused by CI deficiency. A better defined way to study isolated 
CI deficiencies would be to knock-out a CI subunit known to be associated 
with disease. However, knocking-out an essential subunit of CI would likely 
result in an embryonic lethal phenotype and this indeed appear to be the 
case for NDUFS1 subunit knock-out (Zeviani personal communication). 
Nevertheless, the group of Palmiter succeeded to make a viable CI deficient 
mouse by disrupting NDUFS4 subunit (43). This is an accessory CI subunit 
and different mutations in its gene have been reported (52-62). The 
availability of this mouse model provided an excellent tool to evaluate the 
effects of CI isolated deficiency on organism level, since the mice 
phenotype expression resembles very much the human situation. In human, 
mutations in NDUFS4 were the first nuclear encoded subunit defects to be 
found (63). All mutations in NDUFS4 result in fatal early onset 
mitochondrial disease, often associated with Leigh or Leigh like syndromes 
(52, 53, 55-62, 64).  
Using this mouse to investigate CI deficiency has given several important 
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insights allowing better understanding of the molecular consequences 
leading to the observed pathogenicity. First, we observed that functional CI 
could still be made explaining the viability of the mice. Second, the 
complex is unstable but supercomplex organization, stabilize CI also in the 
pathological condition. Third, in the mutated mice the electron influx, 
namely the NADH dehydrogenase module, was more easily disconnected to 
the rest of the enzyme. Fourth, we observed a CI decrease in all tissues, but 
differences in residual activity were observed. Finally, stabilization of the 
electron influx part, by addition of cofactor FMN, can provide stability to 
the assembled complex and increases its activity, thereby providing a 
rationale for therapy.  
 
2.1 Tissue specific pathology of NDUFS4 mice 
The systemic NDUFS4 KO mouse displayed a predominant neurological 
phenotype (43). This was further substantiated by the fact that a brain 
specific KO mouse very closely resembles the phenotype of the systemic 
KO mouse (54) whereas a heart KO mouse showed no progression to heart 
failure and was clinically normal up to at least one year of age (65). This 
means that either the CI-defect is different in distinctive tissues or that the 
consequences of CI deficiency are different in the diverse tissues.    
Is the CI defect different in tissues? In our studies we observed that the CI 
deficiency was present in all studied tissues, but the residual activities were 
different. We found 44% residual CI activity in heart, around 25% residual 
activity in muscle, brain and kidney and 10-15% in pancreas, liver and lung. 
The relative high residual activity of CI in heart compared with the lower 
activity in brain seems consistent with the findings showed by other authors 
(54, 65). In addition, the relatively higher amount of the 200 kDa electron 
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influx part in heart might suggest that possibly CI might be less instable in 
heart compared with other tissues including brain. 
Are the cellular consequences of CI-deficiency different in tissues? In this 
context, one could consider reactive oxygen species (ROS) production 
which could cause cell death specifically in neuronal cells 
(neurodegeneration). CI is the major source of ROS production in 
mitochondria (66, 67). There are two possible sites in which the O2 is 
reduced to superoxide (O2
-): 1) the NDUFV1 subunit, belonging to the 
NADH dehydrogenase module, 2) and the CoQ-binding site (68, 69). ROS 
production is important in cell signalling in physiological condition. 
However, under pathological situation, when the ROS production becomes 
too high, they can damage mtDNA, proteins, lipids and in this way activate 
the apoptosis pathway (70, 71). Increased ROS production was observed in 
NDUFS4-patient fibroblasts (72) and in mouse embryonic fibroblasts from 
the NDUFS4-KO mouse (73). Moreover, in the olfactory bulb tissue of the 
brain KO mice, an increased protein oxidation, likely caused by ROS 
overproduction, was observed (54). In this context, the disconnection of the 
NADH dehydrogenase module from the rest of the enzyme in NDUFS4 
patients and NDUFS4-KO mice, can be interpreted in two ways: on one 
hand, the loose NADH dehydrogenase part could produce ROS, since it is 
capable to show in-gel-activity; on other hand, it could be a way to prevent 
the ROS overproduction, by disconnecting the electron influx in the 
OXPHOS system. Interestingly, also in patient cell lines bearing mutations 
in NDUFV1, NDUFS1 and NDUFS6 genes and in cybrids harboring 
mutations in complex IV, release of the NADH dehydrogenase part was 
observed, suggesting that this could be a common mechanism to prevent 
damage due to ROS overproduction (50, 74-76). Although this might be an 
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attractive hypothesis, more research is required to elucidate the exact role of 
the release of this electron influx part.  
 
2.2 Supercomplexes 
A part the initial controversial discussion about the organization of the 
OXPHOS complexes in the mitochondrial inner membrane, it is now widely 
accepted that they are associated in a supramolecular organization, called 
supercomplexes. It was suggested that the supercomplex is a more efficient 
organization since they may reduce the diffusion distance of the substrates, 
improve the electron transfer, and decrease ROS formation. However, it is 
now clear that crucial role of the supercomplexes is the structural 
stabilization of CI. In fact, mutations causing a CIII or CIV deficiency, as a 
secondary effect cause CI structural destabilization (40, 77-79). 
Interestingly, patient cell lines with CIII decreased activity but no 
disturbance in assembly, did not show any secondary CI deficiency (40). 
Another further confirmation about the structural role of the supercomplexes 
came from the study on tissues of NDUFS4 KO mice (chapter IV). Analysis 
of the supercomplex organization, by using mild extraction, in different 
mouse tissues, showed that a part of CI is stabilized by CIII, also in the 
absence of NDUFS4 (chapter V and chapter VI). Moreover, a sub-
supercomplex (CI)830kDa-CIII was present, showing that the supercomplex 
can be formed even if the CI assembly process is not finished (33). Thus, it 
can be also hypothesized that CIII assists CI during the late stage of the 
assembly process. This hypothesis was put forward by recent study on the 
biosynthesis of the supercomplexes by blocking mtDNA translation using 
doxycycline. The authors proposed a multistep model for mitochondrial 
supercomplex assembly, in which the holo-CI is formed after the association 
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of CIII and CIV to the CI-830kDa subcomplexes, lacking just the NADH-
dehydrogenase module (55). This pre-supercomplexes, formed by 
(CI)830kDa-CIII, was also described by different other authors, and it is not 
clear if it constitutes an assembly step or a breakdown product (26, 33, 50). 
Pulse-chase experiment that analyzed the time course incorporation of the 
13 mtDNA-encoded proteins into respiratory chain complexes and 
supercomplexes suggested that the latter originates by the direct association 
of single pre-fully assembled complexes (47). In conclusion, we can say that 
although the concept of supercomplexes is accepted, questions on their 
dynamics, their assembly and their physiological role remain to be further 
elucidated.  
 
2.3 Complex I disorder treatment 
There is currently no effective treatment for mitochondrial disorders. The 
still frequently used classical interventions with vitamins or co-factors are 
only beneficial in some rare mitochondrial disease conditions, such as 
defects in coenzyme Q biosynthesis (80, 81). Different strategies are being 
developed in order to cure different mutations leading to CI mutations, such 
as gene therapy (replacement or repair), controlled regulation of specific 
transcriptional regulators, metabolic manipulation (ROS scavenging, 
normalization of Δψ) and, in the case of CI deficiency of mtDNA origin, 
alteration of the balance between wild-type and mutated mtDNA (e.g. by 
exercise training, ketogenic diet), or complementation with allotopic 
expression of the mitochondrial genes, by transferring a wild-type version of 
the mitochondrial mutated gene to the nucleus. The effect of some of these 
interventions has already been explored in humans, while others are still at 
the level of single-cell research. However, it is unlikely to find a unique 
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therapy to cure all mitochondrial CI deficiencies. Mutations in different 
genes may have diverse outcomes and they need different therapies. 
Understanding the effects of the single mutation on CI assembly and 
biochemical consequences might give clues for therapeutic interventions. 
Among the different vitamins used to cure patients with mitochondrial 
disorder, riboflavin was extensively used, showing in some cases a clinical 
improvement. Riboflavin is a precursor of the FAD and FMN, which are the 
cofactors of many enzymes, such as CI, CII, AIF, and ACAD9. Recent 
studies used riboflavin to treat patients harboring mutations in ACAD9, AIF 
and CII, improving the clinical phenotype (51, 82, 83). However, despite the 
increase of the CII enzymatic activity, no increased expression level of the 
fully assembled CII and the subunit containing FAD cofactors were found, 
neither were the expression levels of AIF and ACAD9, both containing 
FAD cofactors, studied. The authors suggested that the administration of the 
vitamin may stabilize the protein contain the FAD cofactors, but no 
biochemical studies have been performed. 
The role of the accessory CI subunit NDUFS4 is to allow the stable 
connection between the NADH dehydrogenase module and the rest of the 
complex. The NDUFV1 subunit, belonging to the NADH dehydrogenase 
module, contains the flavin mononucleotide (FMN) group. The analysis of 
the level expressions of the subunits present in NADH dehydrogenase 
module (NDUFV1 and NDUFV2) in MEF KO cells compared with control 
cells, showed a decrease in the expression levels of both subunits meaning 
that in the KO cells these subunits are more rapidly degraded since, they are 
not stably connected to CI. Based on this data, the increased 
amount/stability of these subunits, after increasing the amount of the 
available cofactors, and consequently of the NADH dehydrogenase part may 
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increase the CI activity and holo-enzyme stability. This theory was 
empirically confirmed, indicating that this might be a suitable therapy for CI 
deficiency caused by an instable FMN containing NADH dehydrogenase 
part (chapter IV and V). However, in cases where the molecular defect is 
not in this module and affects assembly at an earlier stage, riboflavin 
supplementation is unlikely to work. In the future, probably personalized 
medicine should be applied and therapy is likely to depend on the nature of 
the mutation.  
 
3. Future perspectives 
This thesis illustrates that the CI assembly process is a complicated 
mechanism in which many structural or chaperone proteins and other 
respiratory complexes are involved. The study of the assembly process in 
mouse models or cell knock-out for a structural subunit (NDUFS4), not only 
increases our knowledge of the assembly process but gives us the 
opportunity to design therapy for patients. However, still many questions to 
be answer remain unsolved, such as: how is the exact CI assembly process, 
and what is the exact role of the chaperones and which other chaperones are 
involved in CI assembly, what is the exact biosynthesis pathway of the 
supercomplexes assembly and how the alteration of this supramolecular 
structure can affect CI or CIII-CIV? Answer these questions is a conditio 
sine qua non is impossible to find suitable therapies for disorders caused by 
CI deficiency or by its partners in supercomplexes organization.  
 
 
 
 
193 
 
Reference List 
 
 1.  Brandt,U. (2006) Energy converting NADH:quinone oxidoreductase 
(complex I). Annu Rev Biochem, 75,69-92. 
 2.  Koene,S., Rodenburg,R.J., van der Knaap,M.S., Willemsen,M.A., 
Sperl,W., Laugel,V., Ostergaard,E., Tarnopolsky,M., Martin,M.A., 
Nesbitt,V., et al. (2012) Natural disease course and genotype-
phenotype correlations in Complex I deficiency caused by nuclear 
gene defects: what we learned from 130 cases. J Inherit Metab Dis, 
35,737-47. 
 3.  Nagrath,D., Caneba,C., Karedath,T., Bellance,N. (2011) 
Metabolomics for mitochondrial and cancer studies. Biochim 
Biophys Acta, 1807,650-63. 
 4.  Schapira,A.H. (2011) Mitochondrial pathology in Parkinson's 
disease. Mt Sinai J Med, 78,872-81. 
 5.  Mammucari,C., Rizzuto,R. (2010) Signaling pathways in 
mitochondrial dysfunction and aging. Mech Ageing Dev, 131,536-
43. 
 6.  Altmann,R. (1890) Veit, Leipzig. 
 7.  Wieland,G.R. (1922) DEVONIAN PLANTS. Science, 55,427-28. 
 8.  Battelli,F., Stern L (1912) Ergeb Physiol, 15, 196-268. 
 9.  Warburg,O. (1913) Arch Gesamte Physiol, 154,599-617. 
 10.  Lehninger,A.L., Smith,S.W. (1949) Efficiency of phosphorylation 
coupled to electron transport between dihydrodiphosphopyridine 
nucleotide and oxygen. J Biol Chem, 181,415-29. 
 11.  Hatefi,Y., Haavik,A.G., Jurtshuk,P. (1960) Studies on the electron 
transport system. 32. Reduction of coenzyme Q by DPNH. Biochem 
Biophys Res Commun, 3,281-6. 
 12.  Hatefi,Y., Galante,Y.M., Stiggall,D.L., Ragan,C.I. (1979) Proteins, 
194 
 
polypeptides, prosthetic groups, and enzymic properties of 
complexes I, II, III, IV, and V of the mitochondrial oxidative 
phosphorylation system. Methods Enzymol, 56,577-602. 
 13.  Ragan,C.I., Widger,W.R., King,T.E. (1974) Pyridine nucleotide 
transhydrogenase activity of soluble cardiac NADH dehydrogenase 
and particulate NADH-ubiquinone reductase. Biochem Biophys Res 
Commun, 60,894-900. 
 14.  Chomyn,A., Cleeter,M.W., Ragan,C.I., Riley,M., Doolittle,R.F., 
Attardi,G. (1986) URF6, last unidentified reading frame of human 
mtDNA, codes for an NADH dehydrogenase subunit. Science, 
234,614-8. 
 15.  Carroll,J., Fearnley,I.M., Skehel,J.M., Shannon,R.J., Hirst,J., 
Walker,J.E. (2006) Bovine complex I is a complex of 45 different 
subunits. J Biol Chem, 281,32724-7. 
 16.  Sazanov,L.A., Hinchliffe,P. (2006) Structure of the hydrophilic 
domain of respiratory complex I from Thermus thermophilus. 
Science, 311,1430-6. 
 17.  Efremov,R.G., Baradaran,R., Sazanov,L.A. (2010) The architecture 
of respiratory complex I. Nature, 465,441-5. 
 18.  Wallace,D.C., Singh,G., Lott,M.T., Hodge,J.A., Schurr,T.G., 
Lezza,A.M., Elsas,L.J., Nikoskelainen,E.K. (1988) Mitochondrial 
DNA mutation associated with Leber's hereditary optic neuropathy. 
Science, 242,1427-30. 
 19.  van den Heuvel,L., Ruitenbeek,W., Smeets,R., Gelman-Kohan,Z., 
Elpeleg,O., Loeffen,J., Trijbels,F., Mariman,E., de,B.D., Smeitink,J. 
(1998) Demonstration of a new pathogenic mutation in human 
complex I deficiency: a 5-bp duplication in the nuclear gene 
encoding the 18-kD (AQDQ) subunit. Am J Hum Genet, 62,262-8. 
 20.  Triepels,R.H., Hanson,B.J., van den Heuvel,L.P., Sundell,L., 
Marusich,M.F., Smeitink,J.A., Capaldi,R.A. (2001) Human complex 
I defects can be resolved by monoclonal antibody analysis into 
distinct subunit assembly patterns. J Biol Chem, 276, 8892-7. 
195 
 
 21.  Ugalde,C., Janssen,R.J., van den Heuvel,L.P., Smeitink,J.A., 
Nijtmans,L.G. (2004) Differences in assembly or stability of 
complex I and other mitochondrial OXPHOS complexes in inherited 
complex I deficiency. Hum Mol Genet, 13,659-67. 
 22.  Ugalde,C., Vogel,R., Huijbens,R., Van Den Heuvel,B., Smeitink,J., 
Nijtmans,L. (2004) Human mitochondrial complex I assembles 
through the combination of evolutionary conserved modules: a 
framework to interpret complex I deficiencies. Hum Mol Genet, 
13,2461-72. 
 23.  Antonicka,H., Ogilvie,I., Taivassalo,T., Anitori,R.P., Haller,R.G., 
Vissing,J., Kennaway,N.G., Shoubridge,E.A. (2003) Identification 
and characterization of a common set of complex I assembly 
intermediates in mitochondria from patients with complex I 
deficiency. J Biol Chem, 278,43081-8. 
 24.  Loeffen,J.L., Smeitink,J.A., Trijbels,J.M., Janssen,A.J., 
Triepels,R.H., Sengers,R.C., van den Heuvel,L.P. (2000) Isolated 
complex I deficiency in children: clinical, biochemical and genetic 
aspects. Hum Mutat, 15,123-34. 
 25.  Vogel,R.O., Dieteren,C.E., van den Heuvel,L.P., Willems,P.H., 
Smeitink,J.A., Koopman,W.J., Nijtmans,L.G. (2007) Identification 
of mitochondrial complex I assembly intermediates by tracing 
tagged NDUFS3 demonstrates the entry point of mitochondrial 
subunits. J Biol Chem, 282,7582-90. 
 26.  Lazarou,M., McKenzie,M., Ohtake,A., Thorburn,D.R., Ryan,M.T. 
(2007) Analysis of the assembly profiles for mitochondrial- and 
nuclear-DNA-encoded subunits into complex I. Mol Cell Biol, 
27,4228-37. 
 27.  Perales-Clemente,E., Fernandez-Vizarra,E., Acin-Perez,R., 
Movilla,N., Bayona-Bafaluy,M.P., Moreno-Loshuertos,R., Perez-
Martos,A., Fernandez-Silva,P., Enriquez,J.A. (2010) Five entry 
points of the mitochondrially encoded subunits in mammalian 
complex I assembly. Mol Cell Biol, 30,3038-47. 
 28.  Nouws,J., Nijtmans,L.G., Smeitink,J.A., Vogel,R.O. (2012) 
196 
 
Assembly factors as a new class of disease genes for mitochondrial 
complex I deficiency: cause, pathology and treatment options. Brain, 
135,12-22. 
 29.  Kuffner,R., Rohr,A., Schmiede,A., Krull,C., Schulte,U. (1998) 
Involvement of two novel chaperones in the assembly of 
mitochondrial NADH:Ubiquinone oxidoreductase (complex I). J 
Mol Biol, 283,409-17. 
 30.  Janssen,R., Smeitink,J., Smeets,R., van den Heuvel,L. (2002) CIA30 
complex I assembly factor: a candidate for human complex I 
deficiency? Hum Genet, 110,264-70. 
 31.  Vogel,R.O., Janssen,R.J., Ugalde,C., Grovenstein,M., Huijbens,R.J., 
Visch,H.J., van den Heuvel,L.P., Willems,P.H., Zeviani,M., 
Smeitink,J.A., Nijtmans,L.G. (2005) Human mitochondrial complex 
I assembly is mediated by NDUFAF1. FEBS J, 272,5317-26. 
 32.  Dunning,C.J., McKenzie,M., Sugiana,C., Lazarou,M., Silke,J., 
Connelly,A., Fletcher,J.M., Kirby,D.M., Thorburn,D.R., Ryan,M.T. 
(2007) Human CIA30 is involved in the early assembly of 
mitochondrial complex I and mutations in its gene cause disease. 
EMBO J, 26,3227-37. 
 33.  Ogilvie,I., Kennaway,N.G., Shoubridge,E.A. (2005) A molecular 
chaperone for mitochondrial complex I assembly is mutated in a 
progressive encephalopathy. J Clin Invest, 115,2784-92. 
 34.  Sugiana,C., Pagliarini,D.J., McKenzie,M., Kirby,D.M., Salemi,R., 
bu-Amero,K.K., Dahl,H.H., Hutchison,W.M., Vascotto,K.A., 
Smith,S.M., et al. (2008) Mutation of C20orf7 disrupts complex I 
assembly and causes lethal neonatal mitochondrial disease. Am J 
Hum Genet, 83,468-78. 
 35.  Nouws,J., Nijtmans,L., Houten,S.M., van den Heuvel,B.M., 
Huynen,M., Venselaar,H., Hoefs,S., Gloerich,J., Kronick,J., 
Hutchin,T., et al. (2010) Acyl-CoA dehydrogenase 9 is required for 
the biogenesis of oxidative phosphorylation complex I. Cell Metab, 
12,283-94. 
 36.  Saada,A., Vogel,R.O., Hoefs,S.J., van den Brand,M.A., 
197 
 
Wessels,H.J., Willems,P.H., Venselaar,H., Shaag,A., Barghuti,F., 
Reish,O., et al. (2009) Mutations in NDUFAF3 (C3ORF60), 
encoding an NDUFAF4 (C6ORF66)-interacting complex I assembly 
protein, cause fatal neonatal mitochondrial disease. Am J Hum 
Genet, 84,718-27. 
 37.  Chance,B., Williams,G.R. (1955) Respiratory enzymes in oxidative 
phosphorylation. IV. The respiratory chain. J Biol Chem, 217,429-
38. 
 38.  Hackenbrock,C.R., Chazotte,B., Gupte,S.S. (1986) The random 
collision model and a critical assessment of diffusion and collision in 
mitochondrial electron transport. J Bioenerg Biomembr, 18,331-68. 
 39.  Schagger,H. (2001) Respiratory chain supercomplexes. IUBMB 
Life, 52,119-28. 
 40.  Acin-Perez,R., Bayona-Bafaluy,M.P., Fernandez-Silva,P., Moreno-
Loshuertos,R., Perez-Martos,A., Bruno,C., Moraes,C.T., 
Enriquez,J.A. (2004) Respiratory complex III is required to maintain 
complex I in mammalian mitochondria. Mol Cell, 13,805-15. 
 41.  Kennedy,E.P., Lehininger,A.L. (1949) Oxidation of fatty acids and 
tricarboxylic acid cycle intermediates by isolated rat liver 
mitochondria. J Biol Chem, 179,957-72. 
 42.  Friedrich,T., Hofhaus,G., Ise,W., Nehls,U., Schmitz,B., Weiss,H. 
(1989) A small isoform of NADH:ubiquinone oxidoreductase 
(complex I) without mitochondrially encoded subunits is made in 
chloramphenicol-treated Neurospora crassa. Eur J Biochem, 
180,173-80.  
 43.  Kruse,S.E., Watt,W.C., Marcinek,D.J., Kapur,R.P., 
Schenkman,K.A., Palmiter,R.D. (2008) Mice with mitochondrial 
complex I deficiency develop a fatal encephalomyopathy. Cell 
Metab, 7,312-20. 
 44.  Acin-Perez,R., Fernandez-Silva,P., Peleato,M.L., Perez-Martos,A., 
Enriquez,J.A. (2008) Respiratory active mitochondrial 
supercomplexes. Mol Cell, 32,529-39. 
198 
 
 45.  Pagliarini,D.J., Calvo,S.E., Chang,B., Sheth,S.A., Vafai,S.B., 
Ong,S.E., Walford,G.A., Sugiana,C., Boneh,A., Chen,W.K., et al. 
(2008) A mitochondrial protein compendium elucidates complex I 
disease biology. Cell, 134,112-23. 
 46.  Saada,A., Edvardson,S., Rapoport,M., Shaag,A., Amry,K., Miller,C., 
Lorberboum-Galski,H., Elpeleg,O. (2008) C6ORF66 is an assembly 
factor of mitochondrial complex I. Am J Hum Genet, 82,32-8. 
 47.  Hunte,C., Zickermann,V., Brandt,U. (2010) Functional modules and 
structural basis of conformational coupling in mitochondrial 
complex I. Science, 329,448-51. 
 48.  Calvo,S.E., Mootha,V.K. (2010) The mitochondrial proteome and 
human disease. Annu Rev Genomics Hum Genet, 11,25-44.  
 49.  Moreno-Lastres,D., Fontanesi,F., Garcia-Consuegra,I., Martin,M.A., 
Arenas,J., Barrientos,A., Ugalde,C. (2012) Mitochondrial complex I 
plays an essential role in human respirasome assembly. Cell Metab, 
15,324-35. 
 50.  Hornig-Do,H.T., Tatsuta,T., Buckermann,A., Bust,M., Kollberg,G., 
Rotig,A., Hellmich,M., Nijtmans,L., Wiesner,R.J. (2012) Nonsense 
mutations in the COX1 subunit impair the stability of respiratory 
chain complexes rather than their assembly. EMBO J, 31,1293-307. 
 51.  Ghezzi,D., Sevrioukova,I., Invernizzi,F., Lamperti,C., Mora,M., 
D'Adamo,P., Novara,F., Zuffardi,O., Uziel,G., Zeviani,M. (2010) 
Severe X-linked mitochondrial encephalomyopathy associated with 
a mutation in apoptosis-inducing factor. Am J Hum Genet, 86,639-
49. 
 52.  Budde,S.M., van den Heuvel,L.P., Smeets,R.J., Skladal,D., 
Mayr,J.A., Boelen,C., Petruzzella,V., Papa,S., Smeitink,J.A. (2003) 
Clinical heterogeneity in patients with mutations in the NDUFS4 
gene of mitochondrial complex I. J Inherit Metab Dis, 26,813-5. 
 53.  Budde,S.M., van den Heuvel,L.P., Janssen,A.J., Smeets,R.J., 
Buskens,C.A., DeMeirleir,L., Van,C.R., Baethmann,M., Voit,T., 
Trijbels,J.M., Smeitink,J.A. (2000) Combined enzymatic complex I 
and III deficiency associated with mutations in the nuclear encoded 
199 
 
NDUFS4 gene. Biochem Biophys Res Commun, 275,63-8. 
 54.  Quintana,A., Kruse,S.E., Kapur,R.P., Sanz,E., Palmiter,R.D. (2010) 
Complex I deficiency due to loss of Ndufs4 in the brain results in 
progressive encephalopathy resembling Leigh syndrome. Proc Natl 
Acad Sci USA, 107,10996-1001. 
 55.  Assouline,Z., Jambou,M., Rio,M., Bole-Feysot,C., de,L.P., 
Barnerias,C., Desguerre,I., Bonnemains,C., Guillermet,C., Steffan,J., 
et al. (2012) A constant and similar assembly defect of 
mitochondrial respiratory chain complex I allows rapid identification 
of NDUFS4 mutations in patients with Leigh syndrome. Biochim 
Biophys Acta, 1822,1062-9. 
 56.  Iuso,A., Scacco,S., Piccoli,C., Bellomo,F., Petruzzella,V., 
Trentadue,R., Minuto,M., Ripoli,M., Capitanio,N., Zeviani,M., 
Papa,S. (2006) Dysfunctions of cellular oxidative metabolism in 
patients with mutations in the NDUFS1 and NDUFS4 genes of 
complex I. J Biol Chem, 281,10374-80. 
 57.  Budde,S.M., van den Heuvel,L.P., Smeitink,J.A. (2002) The human 
complex I NDUFS4 subunit: from gene structure to function and 
pathology. Mitochondrion, 2,109-15. 
 58.  Papa,S., Scacco,S., Sardanelli,A.M., Vergari,R., Papa,F., Budde,S., 
van den Heuvel,L., Smeitink,J. (2001) Mutation in the NDUFS4 
gene of complex I abolishes cAMP-dependent activation of the 
complex in a child with fatal neurological syndrome. FEBS Lett, 
489,259-62. 
 59.  Petruzzella,V., Panelli,D., Torraco,A., Stella,A., Papa,S. (2005) 
Mutations in the NDUFS4 gene of mitochondrial complex I alter 
stability of the splice variants. FEBS Lett, 579,3770-6. 
 60.  Petruzzella,V., Vergari,R., Puzziferri,I., Boffoli,D., Lamantea,E., 
Zeviani,M., Papa,S. (2001) A nonsense mutation in the NDUFS4 
gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes 
assembly and activity of the complex in a patient with Leigh-like 
syndrome. Hum Mol Genet, 10,529-35. 
 61.  Anderson,S.L., Chung,W.K., Frezzo,J., Papp,J.C., Ekstein,J., 
200 
 
Dimauro,S., Rubin,B.Y. (2008) A novel mutation in NDUFS4 
causes Leigh syndrome in an Ashkenazi Jewish family. J Inherit 
Metab Dis, Suppl 2:S461-7. 
 62.  Scacco,S., Petruzzella,V., Budde,S., Vergari,R., Tamborra,R., 
Panelli,D., van den Heuvel,L.P., Smeitink,J.A., Papa,S. (2003) 
Pathological mutations of the human NDUFS4 gene of the 18-kDa 
(AQDQ) subunit of complex I affect the expression of the protein 
and the assembly and function of the complex. J Biol Chem, 
278,44161-7. 
 63.  Loeffen,J., Smeitink,J., Triepels,R., Smeets,R., Schuelke,M., 
Sengers,R., Trijbels,F., Hamel,B., Mullaart,R., van den Heuvel,L. 
(1998) The first nuclear-encoded complex I mutation in a patient 
with Leigh syndrome. Am J Hum Genet, 63,1598-608. 
 64.  Petruzzella,V., Papa,S. (2002) Mutations in human nuclear genes 
encoding for subunits of mitochondrial respiratory complex I: the 
NDUFS4 gene. Gene, 286,149-54. 
 65.  Sterky,F.H., Hoffman,A.F., Milenkovic,D., Bao,B., Paganelli,A., 
Edgar,D., Wibom,R., Lupica,C.R., Olson,L., Larsson,N.G. (2012) 
Altered dopamine metabolism and increased vulnerability to MPTP 
in mice with partial deficiency of mitochondrial complex I in 
dopamine neurons. Hum Mol Genet, 21,1078-89. 
 66.  Adam-Vizi,V., Chinopoulos,C. (2006) Bioenergetics and the 
formation of mitochondrial reactive oxygen species. Trends 
Pharmacol Sci, 27,639-45. 
 67.  Murphy,M.P. (2009) How mitochondria produce reactive oxygen 
species. Biochem J, 417,1-13. 
 68.  Hirst,J., King,M.S., Pryde,K.R. (2008) The production of reactive 
oxygen species by complex I. Biochem Soc Trans, 36,976-80. 
 69.  Kussmaul,L., Hirst,J. (2006) The mechanism of superoxide 
production by NADH:ubiquinone oxidoreductase (complex I) from 
bovine heart mitochondria. Proc Natl Acad Sci USA, 103,7607-12. 
 70.  Smeitink,J.A., Zeviani,M., Turnbull,D.M., Jacobs,H.T. (2006) 
201 
 
Mitochondrial medicine: a metabolic perspective on the pathology of 
oxidative phosphorylation disorders. Cell Metab, 3,9-13. 
 71.  Balaban,R.S., Nemoto,S., Finkel,T. (2005) Mitochondria, oxidants, 
and aging. Cell, 120,483-95. 
 72.  Distelmaier,F., Koopman,W.J., van den Heuvel,L.P., 
Rodenburg,R.J., Mayatepek,E., Willems,P.H., Smeitink,J.A. (2009) 
Mitochondrial complex I deficiency: from organelle dysfunction to 
clinical disease. Brain, 132,833-42. 
 73.  Valsecchi,F., Monge,C., Forkink,M., de Groof,A.J., Benard,G., 
Rossignol,R., Swarts,H.G., van Emst-de Vries SE, Rodenburg,R.J., 
Calvaruso,M.A., et al. (2012) Metabolic consequences of NDUFS4 
gene deletion in immortalized mouse embryonic fibroblasts. 
Biochim Biophys Acta, 1817,1925-36. 
 74.  Hoefs,S.J., Skjeldal,O.H., Rodenburg,R.J., Nedregaard,B., van 
Kaauwen,E.P., Spiekerkotter,U., von Kleist-Retzow,J.C., 
Smeitink,J.A., Nijtmans,L.G., van den Heuvel,L.P. (2010) Novel 
mutations in the NDUFS1 gene cause low residual activities in 
human complex I deficiencies. Mol Genet Metab, 100,251-6. 
 75.  Moran,M., Rivera,H., Sanchez-Arago,M., Blazquez,A., Merinero,B., 
Ugalde,C., Arenas,J., Cuezva,J.M., Martin,M.A. (2010) 
Mitochondrial bioenergetics and dynamics interplay in complex I-
deficient fibroblasts. Biochim Biophys Acta, 1802,443-53. 
 76.  Kirby,D.M., Salemi,R., Sugiana,C., Ohtake,A., Parry,L., Bell,K.M., 
Kirk,E.P., Boneh,A., Taylor,R.W., Dahl,H.H., et al. (2004) NDUFS6 
mutations are a novel cause of lethal neonatal mitochondrial 
complex I deficiency. J Clin Invest, 114,837-45. 
 77.  Li,Y., D'Aurelio,M., Deng,J.H., Park,J.S., Manfredi,G., Hu,P., Lu,J., 
Bai,Y. (2007) An assembled complex IV maintains the stability and 
activity of complex I in mammalian mitochondria. J Biol Chem, 
282,17557-62. 
 78.  Diaz,F., Fukui,H., Garcia,S., Moraes,C.T. (2006) Cytochrome c 
oxidase is required for the assembly/stability of respiratory complex 
I in mouse fibroblasts. Mol Cell Biol, 26,4872-81. 
202 
 
 79.  Seelert,H., Dani,D.N., Dante,S., Hauss,T., Krause,F., Schafer,E., 
Frenzel,M., Poetsch,A., Rexroth,S., Schwassmann,H.J., et al. (2009) 
From protons to OXPHOS supercomplexes and Alzheimer's disease: 
structure-dynamics-function relationships of energy-transducing 
membranes. Biochim Biophys Acta, 1787,657-71. 
 80.  Koene,S., Smeitink,J. (2009) Mitochondrial medicine: entering the 
era of treatment. J Intern Med, 265,193-209. 
 81.  Koene,S., Smeitink,J. (2011) Mitochondrial medicine. J Inherit 
Metab Dis, 34,247-8. 
 82.  Gerards,M., van den Bosch,B.J., Danhauser,K., Serre,V., van,W.M., 
Wanders,R.J., Nicolaes,G.A., Sluiter,W., Schoonderwoerd,K., 
Scholte,H.R., et al. (2011) Riboflavin-responsive oxidative 
phosphorylation complex I deficiency caused by defective ACAD9: 
new function for an old gene. Brain, 134,210-9. 
 83.  Bugiani,M., Lamantea,E., Invernizzi,F., Moroni,I., Bizzi,A., 
Zeviani,M., Uziel,G. (2006) Effects of riboflavin in children with 
complex II deficiency. Brain Dev, 28,576-81. 
  
 
 
 
 
 
 
 
 
 
 
203 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
204 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
205 
 
Chapter VIII 
 
 
Summary 
 
 
Samenvatting 
 
 
Sommario 
 
 
 
 
 
 
 
206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
207 
 
Summary 
Mitochondria are organelles which are present in every cell of our body. An 
important function of these organelles is to supply cells with a usable type 
of energy in the form of ATP. This is done by a process called oxidative 
phosporylation (OXPHOS). The topic of this thesis, complex I (CI) is a 
crucial component of this OXPHOS system and it catalyses the first step in 
this process. Dysfunction of this enzyme has severe cellular consequences, 
leading to devastating metabolic disorders for which no treatment is 
available. 
 
CI is an intricate enzyme. It contains many polypeptide subunits and 
cofactors and being the entry point of electrons in the OXPHOS system it is 
a crucial component in the metabolic regulation of the cell. It regulates, 
amongst others, the ratio of substrates, the redox balance, ATP production 
and reactive oxygen species generation. The complexity of this enzyme is 
illustrated by the fact that it gives rise to many different clinical phenotypes 
and that the number of mutations found in proteins affecting its function has 
exponentially increased over the last decade.  
 
To understand how mutations lead to CI deficiency and how this is related 
to disease phenotypes, it is important to comprehend how this enzyme is 
made. The aim of this thesis was to further elucidate how the biogenesis of 
CI takes place and how this is affected in patients with a CI deficiency. 
Better understanding of this process is also a requirement for proper 
diagnosis and to be able to make a first step in the development of therapy. 
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Chapter I of this thesis provides a necessary introduction on energy 
metabolism in mitochondria by OXPHOS and how CI plays a role in this 
process. I give a brief overview on the types of CI-disorders and provide a 
background of the biochemical consequences of CI deficiency. 
 
In Chapter II we focus on the biogenesis of human CI. We address the 
intrinsic proteins, subunits, of CI in detail and summarize their possible 
function and topology in the complex. CI is evolutionary conserved and 
simpler forms of CI exist in prokaryotes and lower eukaryotes. To better 
understand the assembly of CI in human cells, we addressed how this 
complex is made in lower organisms, like Escherichia coli and Neurospora 
Crassa. By integrating data reported from these organisms with our present 
knowledge on mammalian CI assembly, we propose an updated CI 
assembly scheme. In this scheme we included where subunits are 
incorporated and assembly factors come into play. We put forward the idea 
that CI-assembly involves the preassembly of the different functional 
modules, which are subsequently joined into a functional complex.   
 
An essential method to study CI assembly is one and two dimensional blue 
native electrophoresis (BN-PAGE), which is discussed in Chapter III. This 
technique not only separates the native respiratory complexes, but also 
allows detection of assembly intermediates and breakdown products. In this 
chapter we provide a hands-on description of the procedure including 
pitfalls and points of care. We also provide real life examples of patient 
samples and provide guidelines for the interpretation of blue native data in 
the context of OXPHOS assembly.  
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Chapter IV describes the discovery of a novel mutation in the 
mitochondrial DNA causing mitochondrial encephalomyelopathy with lactic 
acidosis and stroke-like episodes. The initial biochemical diagnosis of this 
patient was difficult because enzyme measurements of a muscle biopsy 
revealed an isolated complex IV deficiency, whereas in the patients 
fibroblasts there was a decrease of CI and CIV. These deficiencies were 
consistent with an assembly defect of these complexes as measured by BN-
PAGE. Mitochondrial translation analysis revealed a severe defect in this 
patient which was consistent with a mutation in the gene encoding the 
mitochondrial tRNAHis.  However, the final prove came from an experiment 
in which we replaced the mitochondrial DNA in a control cell with the 
mitochondrial DNA from this patient. Because the resulting cells showed 
the same defects as the patient fibroblasts we could establish that the 
mitochondrial DNA alteration was indeed the disease causing mutation.  
The central part of this thesis is the study of mouse model lacking the CI 
subunit NDUFS4 (KO-mouse). This mouse model has a similar clinical 
phenotype as the patients harboring mutation in this subunit, and for this 
reason is a very useful model to study the molecular consequences of CI 
deficiency and specifically how it affects the different tissues. In Chapter V 
we analyzed CI in a number of tissues from these KO-mice and compared 
these with wild type mice (WT-mice). In all studied KO-tissues a similar CI 
assembly defect was observed.  The stability of the CI was severely 
hampered in the KO-tissues and the complex falls apart into an 830kDa and 
200kDa subcomplex. Further analysis led to the conclusion that the absence 
of CI-subunit NDUFS4 destabilizes the connection of the electron influx 
part, the NADH dehydrogenase module, and the rest of the enzyme. 
Paradoxically, analyzed mouse tissues retain CI spectrophotometric activity, 
210 
 
despite the fact that the entry point of the electrons (NADH dehydrogenase 
part) and the site of ubiquinone reduction (hydrogenase part) seemed  
physically not connected. This apparent contradiction was explained by 
studying the supercomplex organization in these NDUFS4 KO-tissues, 
which showed that part of CI still was fully-assembled, but only when it 
interacted with complex III.  
 
Based on the data obtained in chapter V, we hypothesize that a possible 
therapeutic intervention may be to stabilize CI by increasing the amount or 
of the NADH dehydrogenase. This hypothesis was verified in Chapter VI. 
Since the NADH dehydrogenase part contains the cofactor flavin 
mononucleotide (FNM), we reasoned that increasing this factor might 
stabilize this subassembly and subsequently enhance CI function. A strategy 
which has been successfully applied in the past for other FMN containing 
enzymes. We therefore isolated embryonic fibroblast (MEF) from wild type 
and knock-out mice and supplied these cells with riboflavin, a precursor of 
FMN. After one week of treatment the cells were harvested and analyzed. 
Excitingly the data demonstrated a significant increase of CI-activity in the 
riboflavin treated KO-MEFs compared with the untreated KO-MEFs. This 
increased activity was consistent with increased levels of the NADH 
dehydrogenase module and its subunits NDUFV1 and NDUFV2. These data 
suggest that the increased riboflavin amount has a stabilizing effect on this 
NADH dehydrogenase module, which in turn can increase the CI activity in 
these NDUFS4 deficient mice. This prove-of-principle provides a promising 
concept for further testing in the whole mice.    
 
The general discussion in Chapter VII, describes the significance of the 
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work of this thesis in the context of the moving field of mitochondrial CI-
disorders. To illustrate the recent progression of this subject, I give a short 
historical overview of how past research has led to our current 
understanding of CI assembly. In addition, in this chapter we also address 
several important aspects in which the conceptual advances of this study 
have to be placed. One aspect is the use of transgenetic mouse models to 
study CI-disease. The use of whole organism models is essential to answer 
the questions of phenotype/genotype correlations. Studying differences in 
disease expression in different tissues is vital to understand how a disease 
evolves. Illustrative for this is the fact that disruption of CI subunit 
NDUFS4, which has the same molecular function in all tissues, hardly gives 
a defect in heart whereas it gives a severe phenotype in brain. Another 
aspect is the supramolecular organization of OXPHOS complexes. In this 
study we showed that this is essential for the stabilization of CI in a disease 
condition. In this context, CIII may be even considered as a CI chaperone as 
it might be connected with the CI assembly intermediates, before that the 
assembly of the whole complex is finished. The aspect of CI-treatment to 
cure patients with these devastating diseases is the most important goal. Our 
studies have shown the value of studying the process of CI assembly and 
how this knowledge helps to understand the pathogenesis of disease and 
provides rationales for therapy.  
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Samenvatting 
Mitochondriën zijn organellen die aanwezig zijn in iedere cel van ons 
lichaam. Een belangrijke functie van deze organellen is energie om te zetten 
in een voor de cel bruikbare vorm middels een proces dat oxidatieve 
fosforylering heet (OXFOS). Een essentiële component van dit OXFOS 
systeem is complex I (CI), dat de eerste stap in dit proces katalyseert. Slecht 
functioneren van dit eiwit heeft vervelende consequenties voor de cel en is 
de oorzaak van ernstige stofwisselings ziekten, die gekenmerkt worden door 
een grote diversiteit in klinische verschijningen met veelal slechte 
vooruitzichten. 
 
Complex I is een ingewikkeld enzym. Het bevat veel subeenheden en 
cofactoren. Omdat de ingang vormt voor elektronen in het OXFOS systeem, 
is het een cruciale component in de metabole regulatie van de cel. Het 
reguleert onder andere de verhouding van substraten, de redox balans, ATP 
productie en de aanmaak vrije zuurstof radicalen. De complexiteit van dit 
eiwit wordt geïllustreerd door het feit dat het oorzaak is van vele 
verschillende soorten ziekten en dat het aantal mutaties dat gevonden is in 
eiwitten die de functie van het enzym aantasten de laatste tien jaar 
exponentieel toegenomen zijn.  
 
Om te begrijpen hoe mutaties leiden tot een complex I defect en hoe dit leidt 
tot bepaalde ziektebeelden, is het belangrijk om te begrijpen hoe dit eiwit 
wordt gemaakt. Het doel van dit proefschrift was om verder uit te zoeken 
hoe de biogenese van CI plaatsvindt en hoe dit aangedaan is in patiënten 
met een CI deficiëntie. Beter begrip van dit proces is een voorwaarde voor 
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een betere diagnostiek en om een begin te maken met het ontwikkelen van 
therapie. 
 
Hoofdstuk I van dit proefschrift geeft een noodzakelijke inleiding in het 
energie metabolisme in mitochondriën door OXFOS en hoe complex I in dit 
proces betrokken is. Ik geef een kort overzicht in de soorten van complex I 
ziekten en een achtergrond in de biochemische consequenties van CI 
deficiëntie.  
 
In hoofdstuk II gaan we meer gericht in op de biogenese van CI. We 
behandelen de subeenheden waaruit complex I is opgebouwd in meer detail, 
gaan in op hun mogelijke functie in het complex en waar ze in het complex 
ze mogelijk zitten. CI is een evolutionair geconserveerd enzym en er bestaan 
simpelere vormen van CI in prokaryoten en lagere eukaryoten. Om een beter 
begrip te krijgen van de assemblage van complex I in humane cellen, kijken 
we eerst hoe dit complex gemaakt wordt in lagere organismen zoals 
Escherichia coli en Neurospora Crassa. Door de resultaten van deze 
organismen te integreren met onze huidige kennis van zoogdier complex I 
stellen we een geactualiseerd schema voor complex I assemblage voor. Dit 
schema laat zien waar de subeenheden ingebouwd worden en waar 
assemblage factoren een rol spelen. We poneren het idee dat eerst de 
functionele CI-modules assembleerd worden alvorens deze verder aan 
elkaar gezet worden om zodoende een werkend complex te krijgen. 
 
Een essentiële methode om CI assemblage te bestuderen wordt besproken in 
hoofdstuk III, te weten één- en twee dimensionale blue native 
electrophorese (BN-PAGE). Deze techniek is niet alleen geschikt om de 
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natieve OXFOS complexen the scheiden, maar maakt het ook mogelijk 
assemblage intermediairen aan te tonen. In dit hoofdstuk geven we een 
werkprotocol van de techniek waarbij wijzen op aandachtspunten en 
mogelijke valkuilen. We geven ook een aantal praktijk voorbeelden hoe 
deze techniek te gebruiken voor de analyse van patiënten monsters en geven 
richtlijnen voor de interpretatie van uitkomsten in de context van OXFOS 
assemblage. 
 
In hoofdstuk IV beschrijven we de ontdekking van een nieuwe mutatie in 
het mitochondrieel DNA, te weten m12146 A>G in het mt-tRNAHis,  die 
mitochondriele encephalomyelopathie met lactaat acidose en beroertes 
(MELAS) veroorzaakt. De initiële biochemische diagnose van deze patiënt 
was moeilijk omdat de enzym metingen van een spierbiopt een geïsoleerde 
complex IV (CIV) deficiëntie te zien gaf terwijl in de fibroblasten er een 
afname van zowel CI en CIV was. Deze deficiënties waren consistent met 
een assemblage defect voor deze complexen gemeten met BN-PAGE. 
Analyse van mitochondriële translatie producten gaf te zien dat er een 
ernstig defect was in deze patiënt, wat in overeenstemming was met de 
gevonden mutatie in het mitochondriële gen dat codeert voor de transfer 
RNA voor histidine. Het uiteindelijke bewijs werd geleverd door een 
experiment waarbij we het mitochondriële DNA van een controle cel 
vervingen met het mtDNA van de patiënt. Omdat de zo gevormde cellen 
hetzelfde defect te zien gaven als de originele fibroblasten van de patiënt 
konden we bevestigen dat de mtDNA mutatie inderdaad de oorzaak van de 
ziekte was.  
 
Het centrale gedeelte van dit proefschrift is de studie van een muizen model 
216 
 
waarbij een complex I subeenheid ontbrak, namelijk NDUFS4. Dit 
muizenmodel heeft een vergelijkbaar klinisch beeld als patiënten met 
mutaties in dezelfde subunit. Om deze reden is dit een erg bruikbaar model 
voor de studie naar de moleculaire consequenties van mutaties in deze 
subeenheid en het testen van mogelijke therapieën. In hoofdstuk V hebben 
we verschillende weefsels van deze muis bestudeerd en vonden dat alle 
weefsels een vergelijkbaar CI assemblage defect te zien gaven. De stabiliteit 
van CI is afgenomen door de afwezigheid van de NDUFS4 subeenheid en 
het complex valt uiteen onderdelen met een moleculair gewicht van 830 
kDa en 200kDa. Verdere analyse toont aan dat de afwezigheid van NDUFS4 
de verbinding tussen het NADH dehydrogenase gedeelte en de rest van het 
eiwit destabiliseert. Het is tegenstrijdig dat de muizenweefsels nog CI 
spectrofotometrische activiteit hebben ondanks het feit dat de ingang voor 
elektronen (het NADH dehydrogenase gedeelte) en het gedeelte waar 
ubiquinon gereduceerd wordt (het hydrogenase gedeelte) fysiek niet aan 
elkaar gekoppeld zitten. Deze ogenschijnlijke tegenstrijdigheid kon 
verklaard worden toen we de supercomplex organisatie in deze muizen 
bestudeerden. Dit liet zien dat een gedeelte volledig geassembleerd CI 
aanwezig was, maar alleen als het vast zat met complex III.. 
 
Gebaseerd op de resultaten van hoofdstuk V hypothetiseren we dat een 
mogelijke therapie eruit zou kunnen bestaan om complex I te stabiliseren 
door de hoeveelheid van het NADH dehydrogenase gedeelte te vergroten. 
Deze hypothese werd getest in hoofdstuk VI. Omdat het NADH 
dehydrogenase gedeelte een cofactor bevat, te weten flavin mononucleotide 
(FMN), bedachten we dat door de hoeveelheid van deze factor te verhogen 
we dit subcomplex zouden kunnen stabiliseren en zo de complex I functie 
217 
 
verbeteren. Deze strategie is al vaker met succes toegepast voor andere 
FMN bevattende eiwitten. We hebben daarom embryonale fibroblasten van 
wild type en knock out muizen geïsoleerd. Na een week riboflavine, een 
precursor van FMN, behandeling van deze cellen werden ze geoogst en 
geanalyseerd. De data lieten zien dat er een toename van CI activiteit optrad 
in de behandelde knock out cellen vergeleken met onbehandelde cellen. 
Deze toename van activiteit was consistent met de toegenomen niveaus van 
de NADH dehydrogenase module en zijn subeenheden NDUFV1 en 
NDUFV2. Deze data suggereren dat de toegenomen hoeveelheid riboflavine 
een stabiliserend effect heeft op de NADH dehydrogenase module, wat op 
zijn beurt weer leidt tot een toename van CI activiteit in deze NDUFS4-
deficiente muizen. Deze bevindingen zijn een veel belovend concept voor 
verder onderzoek in deze muizen. 
 
De algemene discussie in hoofdstuk VII beschrijft de betekenis van het 
onderzoek van dit proefschrift in de context van het snel voortschrijdende 
veld van mitochondriële CI-ziekten. Om de recentelijk vooruitgang van dit 
relatief oude onderwerp te illustreren geef ik een kort historisch overzicht 
over hoe CI onderzoek geleidt heeft tot het huidige begrip van dit 
onderwerp. Verder zal ik in dit hoofdstuk belangrijke aspecten behandelen 
die een wetenschappelijke context schetsen waarin de conceptuele 
vooruitgang van deze studie geplaatst kan worden. Een van deze aspecten is 
het gebruik van transgene muizen om CI gerelateerde ziekten te bestuderen. 
Het gebruik van een diermodel is belangrijk om vragen te kunnen 
beantwoorden over genotype-fenotype correlaties. Door te onderzoeken hoe 
verschillende weefsels worden aangetast, kunnen we beter begrijpen hoe de 
ziekte zich ontwikkeld. Een goed voorbeeld is het feit dat de disruptie van 
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de CI subeenheid NDUFS4, dat een vergelijkbaar biochemisch defect in alle 
weefsels geeft, nauwelijks tot ziekte leidt als het afwezig is in het hart 
terwijl het een ernstige afwijking geeft als het afwezig is in de hersenen. Een 
ander belangrijk aspect is de supermoleculaire organisatie van de OXFOS 
complexen. In deze studie laten we zien dat dit is essentieel voor de 
stabilisatie van CI in een ziekte conditie. Het aspect om tot een genezing te 
komen van deze ernstige ziekten is natuurlijk het uiteindelijke doel van dit 
onderzoek. Deze studie het belang zien van het bestuderen van het 
assemblage proces en hoe deze kennis kan helpen om het ziekteverloop te 
begrijpen en aanwijzigingen geeft voor de ontwikkeling van therapie.  
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Sommario 
I mitocondri sono organelli presenti in ogni cellula del nostro corpo. La loro 
funzione è di fornire alle cellule una fonte di energia utilizzabile, e cioè 
ATP. Tale processo di trasformazione avviene tramite il sistema della 
fosforilazione ossidativa.  
Questa tesi tratta principalmente del complesso I (CI), uno dei componenti 
del sistema della fosforilazione ossidativa. Il CI è il punto d’inizio del 
sistema di fosforilazione ossidativa, e interviene anche in altri processi 
cellulari. È quindi facile immaginare come disfunzioni in tal enzima abbiano 
gravissime conseguenze sul metabolismo cellulare, che si portano a severe 
malattie metaboliche con esiti fatali. Mutazioni che colpiscono il CI 
insorgono solitamente in giovane età, molte volte anche pochi mesi dopo la 
nascita, e portano inesorabilmente a una morte altrettanto prematura, 
talvolta entro i primi anni di vita. Finora tutte le terapie sono palliative atte 
solo ad alleviare i sintomi più che a curare realmente la malattia. 
 
Lo scopo di questa tesi è di favorire la comprensione del CI e delle 
alterazioni del suo assemblaggio in condizioni patologiche. Lo studio di 
questi processi è alla base di un’appropriata diagnosi per sviluppare una 
corretta ed efficace terapia. 
 
Il Capitolo I di questa tesi fornisce un’introduzione sui mitocondri e sul CI. 
È quindi presentata una breve panoramica sui diversi tipi di disturbi legati al 
CI e sulle conseguenze biochimiche dovute alla sua disfunzione. 
  
Nel Capitolo II ci concentriamo sulla biogenesi del CI umano. Analizziamo 
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i suoi componenti strutturali, la loro funzione e localizzazione all’interno 
dell’enzima. Il CI umano si evolve da un enzima più piccolo e semplice 
presente negli organismi batterici. Per comprendere meglio l'assemblaggio 
di CI nelle cellule umane, abbiamo, quindi, analizzato come tale complesso 
si assembla in tali organismi inferiori, cioè in Escherichia coli e in 
Neurospora crassa.  
Integrando i dati ottenuti in tali organismi con le nostre attuali conoscenze 
sull’assemblaggio del CI nei mammiferi, è proposta una versione aggiornata 
del processo di assemblaggio. In questo schema è incluso anche il possibile 
ruolo dei chaperoni, in altre parole di quelle proteine fondamentali durante il 
processo di assemblaggio ma non presenti nel CI intero. Si suggerisce 
quindi che l’assemblaggio del CI avviene tramite la formazione di tre 
diversi sub-complessi che sono in seguito unite insieme a formare il CI 
intero.  
Una tecnica indispensabile per lo studio dell’assemblaggio del CI è 
l’elettroforesi blu nativa bidimensionale (2D BN/SDS-PAGE), che viene 
descritta nel Capitolo III. Questa tecnica, non solo separa i complessi 
respiratori nativi, ma consente anche di seguire la formazione 
dell’assemblaggio, dei suoi prodotti intermedi e di degradazione. In questo 
capitolo sono illustrati anche degli esempi nell’applicazione pratica di tale 
tecnica e il metodo per l’interpretazione dei dati. 
 
Nella Capitolo IV si riporta una nuova mutazione nel DNA mitocondriale 
che causa un encefalo miopatia con acidosi lattica ed episodi di tipo 
ischemico. La diagnosi del paziente oggetto dello studio era difficile poiché 
le analisi biochimiche sulla biopsia muscolare avevano rivelato una carenza 
enzimatica del complesso IV, mentre nei fibroblasti isolati dal medesimo 
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soggetto era presente una diminuzione dell’attività del CI e CIV. L’analisi 
della traduzione mitocondriale rivelava un difetto nelle cellule del paziente, 
coerente con la mutazione nel tRNAHis mitocondriale.  
La dimostrazione che le cause biochimiche sono dovute alla mutazione nel 
DNA mitocondriale, proviene dalla creazione di cibridi trasnmitocondriali, 
in altre parole dalla fusione tra la cellula di paziente enucleata con una 
cellula contenente un nucleo normale ma privo di DNA mitocondriale . Tali 
cellule, chiamate cibridi, mostrano lo stesso difetto biochimico indicando 
quindi che la causa del difetto è la mutazione mitocondriale  
 
La parte centrale di questa tesi affronta lo studio del modello murino privo 
della subunità CI NDUFS4 (KO-mouse). Tale modello murino mostra un 
fenotipo clinico simile a quello descritto nei pazienti con mutazioni nel gene 
codificante per la medesima proteina. Pertanto, tale modello è fondamentale, 
non solo per lo studio delle conseguenze biochimiche causate dall’assenza 
di questa proteina, ma anche per valutare l’efficacia di possibili terapie.  
Nel Capitolo V viene analizzato il difetto biochimico del CI nei diversi 
tessuti del KO-mouse che sono comparati con quelli dei topi sani (WT-
mouse). Il CI nei diversi tessuti di KO-mouse è influenzato dall’assenza 
della subunità NDUFS4 causando la rottura dell’enzima in due pezzi: il 
sotto-complesso di 830kDa e uno di 200kDa. Ulteriori analisi hanno 
mostrato che il CI, anche in assenza della NDUFS4, può stabilizzarsi 
quando interagisce con il complesso III (CIII). Tale scoperta spiegherebbe 
perché anche in assenza di un presunto CI intero, è misurabile l’attività 
spettrofotometrica dell’enzima. Sulla base dei dati ottenuti nel capitolo V, si 
ipotizza che un eventuale intervento terapeutico potrebbe indurre la 
stabilizzazione del CI aumentando la quantità della NADH-deidrogenasi, 
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sub-complesso di 200kDa. Questa ipotesi è stata verificata nel Capitolo VI. 
Poiché la parte NADH-deidrogenasi contiene il cofattore flavin-
mononucleotide (FNM), ne è stato dedotto che aumentando la presenza di 
tale fattore si può stabilizzare questo sottocomplesso e conseguentemente 
migliorare la funzione del CI. Il precursore del gruppo FMN (riboflavina o 
vitamina B2) è stato prescritto nel trattamento per la cura di varie malattie 
mitocondriali, ed è stato riscontrato un effetto positivo sul decorso clinico, 
anche se attualmente non vi sono studi volti alla comprensione dell’azione 
molecolare di tale vitamina. Al fine di valutare qual è il suo effetto 
molecolare e studiarne gli effetti biochimici, abbiamo isolato fibroblasti 
embrionali (MEF) da topi di controllo e KO. Le cellule Wt e KO sono state 
coltivate in presenza di riboflavina. Dopo una settimana di trattamento le 
cellule sono state analizzate. I dati ottenuti dimostrano un significativo 
aumento dell’attività del CI nelle cellule KO trattate con la riboflavina 
rispetto alle cellule KO non trattate. L’aumento dell’attività 
spettrofotometrica è coerente con gli aumentati livelli di espressione del 
modulo NADH-deidrogenasi e dei suoi componenti proteici, NDUFV1 e 
NDUFV2. Questi dati suggeriscono che il trattamento con la riboflavina ha 
un effetto diretto sulla stabilizzazione del modulo NADH deidrogenasi, che 
a sua volta, aumenta l'attività del CI in cellule KO. Tali dati incoraggiano un 
possibile test in vivo degli effetti della riboflavina in questo modello murino. 
 
La discussione generale nel Capitolo VII, descrive il significato del lavoro 
di questa tesi in un contesto di studio sulle mutazioni nel CI più ampio. 
Viene data una breve panoramica storica su come la ricerca negli ultimi 
dodici anni ha fatto passi da giganti nello studio del CI. Inoltre, in questo 
capitolo viene illustrata l’importanza dell’utilizzo dei topi transgenici per lo 
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studio delle malattie mitocondriali, per analizzare le differenze 
nell'espressione fenotipica nei diversi tessuti. Infatti, è fondamentale capire 
come una malattia evolve. Nel mio studio, l’assenza della subunità 
NDUFS4 del CI, determina lo stesso danno molecolare in tutti i tessuti, 
provoca un difetto nel cuore che è meno grave se paragonato alle pesanti 
conseguenze che ha invece nel cervello o nel muscolo. Un altro aspetto 
descritto nel capitolo VII è l'organizzazione sovramolecolare dei complessi 
del sistema della fosforilazione ossidativa. Nel mio studio ho dimostrato che 
l’esistenza e la formazione dei supercomplessi sono essenziale soprattutto in 
una condizione patologica. In tale contesto, il CIII può essere considerato 
come un chaperone del CI, poiché interviene a stabilizzare il CI anche 
quando il processo di assemblaggio non è terminato o è danneggiato. Lo 
studio finale sulla possibile terapia rappresenta il valore aggiunto della mia 
tesi, mostrando come solo una conoscenza profonda e sapiente costituisce 
l’unico mezzo per lo sviluppo di terapie adeguate.  
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